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CORONARY HEART DISEASE IN DIABETES 
 
Coronary heart disease (CHD) is a major complication of diabetes mellitus, 
representing the cause of death in more than half of all patients with this disease 1. This 
relationship is true in both diabetes mellitus type 1 (insulin-dependent) and type 2 
(insulin-independent). The presence of diabetes dramatically reduces survival after 
myocardial infarction, both in the short-term (hospital) and in the long-term 2-8. The 
long-term mortality rate (3-5 years) after acute myocardial infarction has been reported 
to be 2-3 times higher in individuals with diabetes as compared with non-diabetics 9-13. 
The mortality rate of diabetic patients after coronary artery bypass grafting (CABG) is 
about twice that of non-diabetic patients during both the early and late phases after the 
operation 14. Using techniques to estimate infarct size, like myocardial enzyme release 
or QRS score, diabetic patients were found to have infarct sizes similar to or even 
smaller than those of non-diabetics. Despite this observation, mortality is twice as high 
among diabetic patients 15-17.  
There is a significant association between the degree of metabolic control, as indicated 
by levels of glycosylated hemoglobin (HbA1c) and hyperlipidemia, and the prevalence 
of cardiovascular disease 18-26. However, recently the large-scale United Kingdom 
Prospective Diabetes Study only showed a significant correlation between intensive 
blood-glucose control and microvascular complications and not macrovascular 
complications 27. Hypertension is also a major predictor of cardiovascular disease in 
diabetes 28. In fact, the coexistence of diabetes and hypertension increases the risk of 
left ventricular hypertrophy and cardiac failure more than either disease alone 29-33. 
 
 
MANAGEMENT OF TYPE 2 DIABETES 
 
About 80-90% of the diabetic population has type 2 diabetes. The prevalence of type 2 
diabetes in most countries is at least 2% 34, and the incidence is rising as a result of 
increasing obesity, an ageing population and decreasing physical activity 35. Diet and 
exercise remain the cornerstone of the management of type 2 diabetes with the aim of 
maintaining ideal body weight and reversing the potentially damaging metabolic 
consequences of the disease. However, the ability of patients to maintain lower weight 
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and metabolic benefits for prolonged periods is limited and pharmacological therapy is 
often necessary 36.  
Sulfonylurea (SU) derivatives, e.g. glibenclamide, have represented the backbone of 
oral therapy in type 2 diabetes for over 40 years 37, 38. Besides the SU derivatives, the 
biguanide metformin has also been used frequently over the last decades. SU 
derivatives are often used in non-obese patients, while metformin is primarily given to 
obese patients. Other oral blood glucose lowering agents are alpha-glucosidase 
inhibitors, e.g. acarbose, and thiazolidinediones, e.g. rosiglitazone.  
It is common for many type 2 diabetic patients to progress from treatment by diet alone 
to monotherapy with an oral blood glucose lowering agent, then to a combination of 
two, and sometimes three, oral agents, before eventually switching to subcutaneous 
insulin 39.  
In the subsequent paragraphs, the different oral blood glucose lowering agents and 
insulin are discussed in more detail. Because this thesis focuses primarily on 
cardiovascular effects of sulfonylurea derivatives, special emphasis is given to the 
paragraph Sulfonylurea derivatives. 
 
 
SULFONYLUREA DERIVATIVES 
 
Mechanism of action 
Although SU derivatives have represented the backbone of oral blood glucose lowering 
therapy in type 2 diabetes patients, their mechanism of action was only resolved 
recently 40. In figure 1.1, the mechanism of SU derivatives, e.g. glibenclamide, is 
depicted. In healthy individuals, insulin is released from the pancreatic β-cells due to an 
increase in intracellular glucose levels. This increase in intracellular glucose levels 
raises the intracellular ATP level, which results in closure of the so-called                
ATP-sensitive K+ (KATP) channels. This depolarizes the plasma membrane of β-cells. 
This in turn results in an increase in Ca2+ influx, largely through activation of voltage-
gated Ca2+ channels. Subsequently, this rise in intracellular Ca2+ levels triggers 
exocytosis of insulin granules, thereby stimulating the release of insulin 41-44. In patients 
with type 2 diabetes, pancreatic β-cells are not able to produce sufficient insulin to 
lower blood glucose levels. SU derivatives are able to stimulate insulin secretion by 
binding to the sulfonylurea receptor SUR1, which is located on the KATP channel, and 
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thereby it closes these channels. This blocking effect initiates the insulin secretion as 
described above 40, 45.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Mechanisms of insulin secretion and the actions of SU derivatives on the pancreatic β-cell. 
 
Similar KATP  channels are also located in the cardiovascular system, both in vascular 
smooth muscle (VSM) and in myocardial cells 45, 46. It has been shown that the KATP 
channel consists of an inward-rectifying (IR) K+ channel pore and a sulfonylurea (SUR) 
receptor. The KATP  channel is an octameric 4:4 complex, four Kir 6.2 protein subunits 
and four SUR subunits 47. In the pancreatic β-cells the KATP channels are a complex of 
the Kir 6.2 together with the SUR1 receptor subtype, while in myocardial cells the       
Kir 6.2 forms a complex with the SUR2a, and in VSM cells Kir 6.2 forms a complex with 
the SUR2b 48-50.  
It has been reported that SU derivatives are more specific for the SUR1 receptor as 
compared with the SUR2a and SUR2b 51, 52. In addition, differences in specificity are 
reported between SU derivatives 52. In table 1.1, the properties of the KATP channels in 
the pancreas, VSM and the myocardium are shown. Interestingly, the newly developed 
SU derivative glimepiride has been reported to be more specific for the SUR1 as 
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compared with the conventional sulfonylurea derivative glibenclamide, and therefore it 
is proposed that glimepiride should have less cardiovascular effects than glibenclamide 
53. Although recently, it has been shown in excised membrane patches that glimepiride 
blocks recombinant KATP channels, of the three subtypes, with similar efficacy 54. 
 
Table 1: Properties of KATP channels in pancreas, heart, and vascular smooth muscle (VSM) 
 Pancreas Heart VSM 
 
Sulfonylurea receptor 
Activation by ATP 
 
SUR1 
Yes 
 
SUR2a 
Yes 
 
SUR2b 
No 
IC50 for ATP 15-40 µmol.L-1 20-100 µmol.L-1 29 µmol.L-1 
    
IC50 for Glib 5 nmol.L-1 6-9 nmol.L-1 20-100 nmol.L-1 
IC50 for Tolb 
Potency of KCOs 
3-20 µmol.L-1 
D > P > C 
80-380 µmol.L-1 
P = C >> D (=0)  
350 µmol.L-1 
P = C > D 
    
Glib = glibenclamide (KATP channel blocker); Tolb = tolbutamide (KATP channel blocker);  
D = diazoxide (KATP channel opener); P = pinacidil (KATP channel opener - KCO); C = cromakalim (KATP channel 
opener). Adapted from Yokoshiki et al. 52. 
 
Cardiovascular effects of SU derivatives  Experimental animal studies 
Depolarization of the arterial smooth muscle cells by glibenclamide has been reported 
in various arterial smooth muscle tissues, including coronary arteries 55-58. Application 
of glibenclamide to the coronary artery of anesthetized dogs increased coronary 
resistance and reduced coronary blood flow 59, 60, suggesting that functional KATP 
channels are present under physiological conditions 61-63. In addition, it has been found 
that glibenclamide is able to attenuate the reactive hyperemia following a period of 
ischemia in isolated hearts 64-66. So, this suggests that in coronary VSM tissue, KATP 
channels may be acting as an important background K+ conductance, which helps to 
regulate vascular tone.  
During a period of myocardial ischemia, cardiac KATP channels, located at the 
sarcolemmal membrane, open due to the fall in intracellular ATP levels and the change 
in ATP/ADP ratio. The resulting hyperpolarization of the myocardial cell membrane 
attenuates the Ca2+ influx, through the voltage-gated Ca2+ channels. This results in 
energy preservation and therefore myocardial KATP channels are involved in the 
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endogenous protective mechanism against an ischemic insult 45, 67, 68. This mechanism is 
also depicted in figure 1.2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Mechanisms occurring after opening of KATP channels during a period of ischemia in the 
myocardial cell.  
 
Besides sarcolemmal KATP channels, KATP channels have also been located on the 
mitochondrial membrane. Until now, no consensus has been reached on how exactly 
this opening of mitochondrial KATP channels results in protection of post-ischemic 
cardiac function. It has been shown that the mitochondrial membrane potential is 
dissipated, which in turn decreases the driving force for Ca2+ influx through the Ca2+ 
uniporter. The resulting prevention of mitochondrial Ca2+ overload protects the hearts 
against ischemia-induced injury 69, 70. Another possibility may be that the opening of 
mitochondrial KATP channels increases the mitochondrial matrix volume and changes 
energetics. This would result in inhibition of ATP wastage 71, 72.   
There have been a number of studies involving the effect of glibenclamide on the 
outcome of an ischemic insult. Although the majority of these studies suggest 
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aggravation of ischemic injury, there are also several studies suggesting attenuation of 
ischemic injury. It has been shown conclusively that glibenclamide increases infarct 
size after a period of ischemia, both in a situation of a single ischemic insult 73-75 and in 
a situation of ischemic preconditioning 74, 76-78, where a brief period of ischemia lessens 
the amount of myocardial damage produced by a subsequent prolonged ischemia. It is 
thought that the mechanism by which glibenclamide aggravates the development of 
infarcted tissue is based on counteracting the endogenous mechanism by opening of 
sarcolemmal KATP channels as is shown in figure 1.3 and by blocking mitochondrial 
KATP channels. By blocking the sarcolemmal KATP channels, there is an increase in Ca2+ 
influx, and subsequently energy use is increased during ischemia, resulting in more 
tissue being infarcted. By blocking of mitochondrial KATP channels, the protective 
mechanisms, as described above, can be attenuated and therefore this can be detrimental 
to the heart.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Interaction of SU derivatives with KATP channels during ischemia in the myocardial cell.  
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Recently, it has been shown that glibenclamide abolished the infarct-limiting effect of 
ischemic preconditioning by blocking mitochondrial KATP channels, while glimepiride, 
the newer SU derivative, did not abolish this beneficial effect of ischemic 
preconditioning 79. This indicates that glimepiride selectively blocks sarcolemmal and 
not mitochondrial KATP channels, while glibenclamide blocks both. Furthermore, it has 
been shown that glibenclamide but not glimepiride may further precipitate left 
ventricular dilatation after myocardial infarction 73. 
Concerning the effects of glibenclamide on post-ischemic cardiac function, studies are 
much less consistent. Evidence exists that after a situation of myocardial ischemia, 
glibenclamide is deleterious to cardiac function 80, 81. This deleterious effect can be 
explained by the counteracting of the endogenous protective mechanism of opening of 
cardiac KATP channels. However, other studies showed improved post-ischemic cardiac 
function 82-84. There are a number of possible explanations for this protective effect. It 
may be that the increases in   Ca2+ influx during ischemia due to the depolarization of 
the myocardial membrane is beneficial, especially in situations of myocardial stunning 
(reversible ischemic injury), due to the positive inotropic effect of Ca2+ during 
reperfusion. Glibenclamide has been shown to have effects not directly related to 
blocking of myocardial KATP channels 82, 84. Glibenclamide may attenuate ischemia-
induced acidosis indicating an inhibitory effect of glibenclamide on anaerobic 
glycolysis during ischemia 82, 85. On the other hand, ATP preservation during ischemia 
by glibenclamide has been reported to explain the protective effect of glibenclamide on 
post-ischemic function 84.  
Besides the effect of glibenclamide on post-ischemic mechanical function of the heart, 
its blocking effect on KATP channels can be antiarrhythmic. Since intracellular K+ loss 
and its subsequent accumulation in the extracellular fluid during ischemia are 
implicated in the development of malignant ventricular arrhythmias, drugs which 
prevent ischemia-induced shortening of the action potential duration and reduce K+ 
outflow, like KATP channel blockers, are potentially antiarrhythmic 68, 86, 87. This 
hypothesis is supported by the majority of the experimental studies, demonstrating that 
glibenclamide protects against ventricular arrhythmias in various models of 
ischemia/reperfusion in rats 88-91, rabbits 92, and in dogs 93, 94. Interestingly, glimepiride 
seems to be more potent in preventing ventricular fibrillation in anesthetized rats than 
glibenclamide 95. However, recently it has been shown in conscious sheep that 
glibenclamide was proarrhythmic during reperfusion 96. 
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Cardiovascular effects of SU derivatives  Experimental human studies  
Whereas in different experimental animal models SU derivatives have been shown to 
interfere with coronary vascular smooth muscle relaxation, there are few data in man. It 
was shown the maximal coronary flow reserve and metabolic coronary vasodilation 
were comparable in diabetic patients assigned to insulin treatment or SU derivative 
treatment 97. However, on the day of the experiment, blood glucose lowering agents 
were withheld, probably resulting in serum levels too low to elicit any effect. Although 
no vasoactive effect of SU derivatives on the coronary circulation in humans has been 
shown, it has been shown in healthy individuals that the vasodilatory effect of diazoxide 
in the forearm was significantly reduced by concomitant infusion of a therapeutic 
glibenclamide concentration 98. Interestingly, in that study treatment with a therapeutic 
concentration of glimepiride did not reduce the diazoxide-induced vasodilation. In a 
recent study, infusion of glibenclamide did not change baseline forearm blood flow but 
significantly decreased the reactive hyperemia following arterial occlusion in healthy 
subjects 99. In another study, it was found that a therapeutic concentration of 
glibenclamide (oral ingestion) significantly decreased baseline flow and peak reactive 
flow after arterial occlusion of the human calf 100. These findings may have implications 
for type 2 diabetes patients with coronary disease treated with SU derivatives. However, 
it should be emphasized that these studies dealt with healthy subjects and only acute 
treatment was investigated. In accordance with this, it has been shown recently that the 
vasodilating response to forearm ischemia was similar in type 2 diabetes patients treated 
with diet alone or with glibenclamide or glimepiride at equipotent glucose lowering 
doses 101. 
There is some evidence that the human myocardium is sensitive to therapeutic levels of 
glibenclamide. It was shown that glibenclamide can prevent ischemic preconditioning 
in vivo 102-104 and in vitro (using right atrial trabeculae) 105. Therefore, the use of 
glibenclamide might have deleterious effects in patients with repetitive myocardial 
ischemia treated with this agent.  
In various experimental models of acute ischemia, pre-treatment with SU derivatives 
proved antiarrhythmic during myocardial ischemia 92. Clinical data seem to corroborate 
these results. In type 2 diabetes patients treated with glibenclamide, decreases in 
ventricular premature beats 106-108, decreases in incidence of ventricular tachycardias 85, 
106, 107, and decreases in incidence of ventricular fibrillation 109 have been reported. 
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Cardiovascular effects of SU derivatives  Epidemiological studies 
In the 1970s, the first large-scale randomized trial in type 2 diabetes, the University 
Group Diabetes Program (UGDP), followed 1000 patients assigned different therapies 
for about 5.5 years. In this trial it was reported that patients treated with the first 
generation SU derivative tolbutamide had an increased cardiovascular risk and a higher 
incidence of cardiovascular mortality 110. However, shortly after its appearance this 
report was extensively criticized on methodological and statistical grounds 111-113. Seven 
other epidemiological studies in the 1970s were contradictory and not conclusive either 
114. Later, in a retrospective study, it was found that type 2 diabetes patients treated with 
insulin had a significantly lower mortality rate from acute myocardial infarction as 
compared with type 2 diabetes patients treated with oral blood glucose lowering agents 
115. In another study, SU derivative treatment did not influence hospital outcome in 
terms of cardiovascular morbidity and mortality 116. The second large-scale randomized 
trial in type 2 diabetes, the United Kingdom Prospective Diabetes Study (UKPDS), 
which was completed only recently, followed around 3900 patients assigned to either 
conventional treatment or intensive treatment (both treatments including SU derivatives 
and insulin) for about 15 years. In this trial, it was concluded that there were no 
differences in the rates of myocardial infarction or diabetes-related death between 
patients assigned to SU derivative or insulin therapy 27. However, because the UKPDS 
intended to compare conventional treatment (fasting plasma glucose levels                    
<15 mmol.L-1) with intensive treatment (fasting plasma glucose level < 6 mmol.L-1), 
some methodological questions arose concerning the conclusion that SU derivatives did 
not have any adverse cardiovascular effect as compared with insulin 117. The 
maintenance of blood glucose as close to the normal range as possible required a 
stepwise addition of blood glucose lowering agents when the glycemic goals were not 
met. Therefore substantial therapeutic overlap between comparison groups occurred, 
obscuring the outcome concerning adverse cardiovascular effects of SU derivatives. 
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BIGUANIDES 
 
Mechanisms of action 
Biguanides, e.g. metformin, are widely used in the treatment of type 2 diabetes 118, 119.             
In vivo, the capacity of metformin to decrease blood-glucose levels does not result from 
an increase in insulin secretion 120. Major effects of the drug in humans are to decrease 
hepatic glucose output, and to increase both glycolytic lactate production by the 
intestine and insulin-dependent peripheral glucose utilization 119, 121. The latter process 
is associated with increased plasma membrane expression of glucose-transporter 
isoforms GLUT1 and GLUT4 122-125. Although these effects are clearly described, the 
exact mechanism of action remains uncertain.  
Recently, two studies showed that metformin inhibits complex I of the mitochondrial 
respiratory chain in isolated hepatocytes 126, 127.  The decrease in ATP/ADP ratio in the 
liver due to complex I inhibition, inhibits gluconeogenesis by inhibiting pyruvate               
carboxylase 128, 129. In addition to an inhibition of pyruvate carboxylase, a stimulation of 
pyruvate kinase flux will occur because of the increased phosphoeneolpyruvate 
concentrations 128, 129, an effect confirmed directly by others 130. Together, these two 
effects will lead to an inhibition of gluconeogenesis. Inhibition of complex I can also 
account for the direct inhibition of fatty acid oxidation, that occurs following metformin 
treatment 119, 121. In many cells, modest inhibition of the respiratory chain upregulates 
the expression of glucose transporters and glycolytic enzymes 131, 132, thus the increases 
in GLUT1 and GLUT4 expression and the subsequent increased peripheral glucose 
utilization may be explained also by inhibition of complex I. Finally, the stimulation of 
glycolytic lactate production can also be explained by inhibition of mitochondrial 
respiration. Therefore, the inhibition of complex I of the mitochondrial respiratory 
chain may certainly be the primary locus of action of metformin 126, 127. 
 
Cardiovascular effects of biguanides 
In insulin-resistant rats, metformin improved the acethylcholine-induced relaxation of 
mesenteric arteries. Therefore, metformin may improve the endothelium-derived 
vasodilation 133. It has been shown that metformin improves cardiac function in isolated 
streptozocin-diabetic rat hearts under conditions of increasing preloads 134.  To our 
knowledge, no effects of metformin on post-ischemic cardiac function have been 
described yet.  
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It has been found that in humans with type 2 diabetes, metformin improves endothelial 
function 135. In patients with peripheral atherosclerosis arterial flow was significantly 
increased after a standardized ischemia after three and six months 136. 
In the recent United Kingdom Prospective Diabetes (UKPDS) Study, metformin was 
the only oral blood glucose lowering agent which reduces the amount of macrovascular 
complications in patients with type 2 diabetes 27. This beneficial effect of metformin on 
macrovascular complications has been confirmed in two meta-analyses of five and 
eleven randomized studies 137, 138. On the other hand, it has been shown recently in a 
population-based observational study that there is an increased mortality in patients 
with type 2 diabetes using sulfonylurea derivatives in combination with metformin as 
compared with sulfonylurea derivatives only 139. 
 
 
INSULIN 
 
Mechanisms of action 
When oral treatment with anti-hyperglycemic agents is no longer sufficient to reduce 
blood glucose levels, the treatment of type 2 diabetes progresses to insulin injections 39. 
In the section SU derivatives, the mechanism by which insulin secretion from the 
pancreatic β-cell is described in detail. Below, the mechanisms of insulin action on cells 
is described. The binding of insulin to the subunit of its receptor causes 
autophosphorylation by ATP of an intracellular β-subunit receptor site that generates 
tyrosine kinase activity. The receptor tyrosine kinase then phosphorylates an insulin 
receptor substrate or substrates. The latter begins a cascade of serine and threonine 
phosphorylations, which activate or deactivate target enzymes of glucose metabolism. 
Docking of other regulatory proteins to the insulin receptor substrate initiates other 
cascades that stimulate or repress gene transcription via insulin response elements 
(IREs) in DNA molecules. Glucose transporters are moved to the plasma membrane 
and facilitate glucose entry. Also independently, amino acids, K+, Mg2+ and phosphate 
entry into the cell are facilitated. Mitogenic proteins are activated that increase 
transcription factors required to stimulate gene expression concerned with cell      
growth 140.  
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Cardiovascular effects of insulin 
Although it has been clearly demonstrated that insulin acts as a vasoactive peptide in 
the peripheral vasculature, causing significant vasodilation 141-145, it is not known 
whether insulin is an important mediator in the regulation of the coronary blood flow in 
health and disease. Barrett et al. showed that coronary blood flow did not change after 
administration of physiological insulin concentrations 146. On the other hand, applying 
supraphysiological concentrations of insulin in neonatal lambs resulted in increases in 
coronary blood flow 147-149, however blood-glucose levels were allowed to fall. In 
another study using blood glucose lowering hyperinsulinemia the increases in coronary 
blood flow were significantly more pronounced as compared with euglycemic 
hyperinsulinemia 150. Therefore, the role of blood glucose level is very important in 
interpreting these results.  
In humans, increases 151, 152 as well as no changes 153, 154 in coronary blood flow due to 
insulin administration were observed both in coronary artery disease patients and in 
healthy subjects. Furthermore, it has been shown that insulin therapy improves 
endothelium-dependent and independent vasodilation in type 2 diabetic patients 155. 
Since their introduction in 1965 by Sodi-Pollares, glucose-insulin-potassium (GIK) 
solutions have been used to protect against ischemia-induced damage 156. In these 
studies, the GIK solutions have supraphysiological insulin concentrations and long 
ischemic incidents leading to a situation of myocardial infarction are imposed 156-158. 
Although, much research has focused on the beneficial effect of GIK solutions, much 
less has looked at the effects of physiological insulin concentrations on post-ischemic 
cardiac function. Recently, a study was performed in isolated working rat hearts, which 
showed that using a post-prandial concentration of insulin post-ischemic cardiac 
function was improved 159. However, in this study insulin was only administered after 
the ischemic insult.  
On the contrary it has been shown in several studies that hyperinsulinemia is a predictor 
of coronary heart disease in patients with type 2 diabetes 160, 161 and in non-diabetic               
subjects 162-164. Recently, it has been shown that hyperinsulinemia is not a risk factor in 
patients with unstable angina pectoris as compared with healthy subjects 139. 
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ISOLATED HEART MODEL  
 
There has been a variety of methods described to study the cardiovascular system 
during recent decades, from isolated animal cells to intact humans. To study the effects 
of myocardial ischemia however, research in humans is restricted, because of ethical 
reasons. One of the most used methods to study myocardial ischemia/reperfusion injury 
is the isolated heart model. Other possibilities include anesthetized open-chest dogs and 
cellular experiments.  
 
Potential pitfalls 
An isolated heart experiment can be performed with various species. The rat is mostly 
used in ischemia/reperfusion studies, although, for example, a rabbit heart can also be 
used. It should however be noted that rabbit hearts are generally more vulnerable to 
ischemia than rat hearts.  
Recently, due to the development of genetic knockout mice, the mouse has gained 
popularity as the species of choice in isolated heart experiments. However, the mouse 
heart is very small and therefore difficult to isolate and to perform experiments with.  
Besides the choice of species, it is very important to notice differences in perfusion 
fluids in isolated heart models. Frequently used is the so-called Krebs-Henseleit buffer, 
which is a crystalloid buffer, including electrolytes, bicarbonate and glucose. Although 
most studies use this Krebs-Henseleit buffer or comparable buffers, it has been argued 
that hearts perfused with these buffers do have hypoxic areas due to inadequate tissue 
oxygenation 165. To improve this inadequate tissue oxygenation, erythrocytes can be 
added. By this means, the oxygen capacity is greatly improved, resulting in much lower 
coronary blood flows in these hearts, and therefore, no hypoxic areas are present 
anymore 165. Besides addition of erythrocytes, proteins can be added to the perfusion 
fluid. By doing this, the hearts develop significantly less edema throughout an 
experiment 166. Furthermore, it has been shown that hearts perfused with erythrocyte- 
and protein-enriched buffers have higher levels of high-energy phosphates, indicating 
that using these additions is far more physiological 166.     
Another point of importance is the way the hearts are perfused. Mostly used are the 
Langendorff 167 and working heart preparations 168. The Langendorff and working heart 
preparations differ in that the Langendorff heart does not pump fluid; thus only a single 
cannulation is required and coronary perfusion is achieved by retrograde flow in the 
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aorta. In the working or ejecting heart the left atrium and aorta are cannulated, the 
hearts are supplied with a fluid at a filling pressure (preload) and the left ventricle ejects 
against a fixed afterload. Because of the relative simplicity, the Langendorff preparation 
is far more often used in ischemia/reperfusion studies, however the working heart 
preparation more resembles the in vivo situation and is therefore more clinically 
relevant than the Langendorff preparation 168-170.  
 
The model used in this thesis 
Although much research has been done studying cardiovascular effects of SU 
derivatives, there is still much controversy, as is described above. In this thesis, we 
investigated the cardiovascular effects of SU derivatives and compared these effects 
with other blood glucose lowering drugs. We used an isolated, erythrocyte perfused, 
working rat heart model. This model has a number of advantages compared with the 
standard isolated crystalloid perfused Langendorff model, which are especially 
important concerning the present research topic.  
First, a working heart preparation is used, which is more clinically relevant. It has a 
higher workload and therefore the ATP usage is higher. Because intracellular ATP 
levels determine the open-state probability of myocardial KATP channels, the use of a 
working heart preparation is important. Second, erythrocytes were added to the 
perfusate, which will result in an improved tissue oxygenation. Without addition of 
erythrocytes, hypoxic areas may develop, which subsequently results in opening of 
myocardial KATP channels. Therefore, erythrocytes are an important addition to the 
perfusate. Third, endogenous adenosine is quickly taken up by erythrocytes. During 
ischemia, due to breakdown of ATP, endogenous adenosine levels rise. As a result of 
this, differences can be expected between erythrocyte and crystalloid perfused models 
with respect to prevailing adenosine levels. Because it has been shown that adenosine 
receptors in the myocardium may be linked to KATP channels, this furthermore improves 
the usefulness of this model to determine the cardiovascular effects of SU derivatives. 
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MAGNETIC RESONANCE SPECTROSCOPY  
 
Principle 
The phenomenon of magnetic resonance spectroscopy (MRS) depends upon the 
property of certain nuclei (with an odd number of protons and neutrons) to exhibit a net 
nuclear spin. Such nuclei include 1H, 31P, 13C, and 23Na. The spin of a nucleus creates a 
tiny magnetic field, or magnetic moment. Under normal conditions, the orientations of 
the magnetic moments are random. However, when such nuclei are placed in a constant 
magnetic field, B0, their magnetic moments tend to align the axis of the field. Some of 
the magnetic moments become aligned parallel to the B0 field, and some antiparallel. 
The energy state of the nucleons differs between the parallel and antiparallel 
orientations.  
If the sample (e.g. an isolated heart) is irradiated with radio-frequency (rf) energy while 
in the B0 field, some of the nuclei in the lower energy state will absorb energy and rise 
to the higher energy level. As the rf energy is absorbed, the direction of the net 
magnetic moment is tipped away from the direction of the B0 field. When the rf 
radiation is turned off, the nuclei will resonate as they return to their initial distribution 
of orientations, emitting rf energy. The emitted rf energy is called a free induction 
decay (FID). In a given magnetic field, each nucleus has a characteristic resonant 
frequency. 
The B0 field experienced by an individual nucleus is modified by its local chemical 
environment, since surrounding electrons may act as magnetic shields.  The alteration 
of resonance frequency due to this magnetic shielding is called chemical shift. The 
chemical shift allows discrimination of the MRS signals from nuclei of the same 
species located in different chemical environments. Thus, phosphorus nuclei contained 
in inorganic phosphate (Pi), phosphocreatine (PCr), and the three phosphates of ATP 
will all have different chemical shifts. The FID obtained from a biological sample (e.g. 
isolated heart) is a signal in the time domain consisting of superimposed resonances 
from several chemical compounds (e.g. Pi, PCr, and ATP). To determine the 
contributions to the FID from each compound, the component of the signal at each 
chemical shift must be separated. To do so, the time-domain signal is processed by 
Fourier transformation, the result of which is a frequency-domain signal with peaks at 
specific frequencies corresponding to the chemical shift of each compound. This is 
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called the magnetic resonance spectrum. The quantity of a metabolite that is detected by 
MRS is related to the area under its spectral peak 171. 
 
Different nuclei 
1H spectroscopy forms the basis of magnetic resonance imaging (MRI), as hydrogen is 
present in large quantities in tissue, and produces large magnetic resonance signals, that 
is it has a high sensitivity, and most hydrogen is 1H, in other words, it has a high natural 
abundance. 13C is useful for studying reactions involving cell respiration, such as the 
production and burning of glucose, but its natural abundance is only 1%, and its 
sensitivity is only around 1.6% of that of hydrogen. 19F occurs in the body at very low 
concentrations, so tracers including 19F can be easily detected: compounds exist which 
can be used to detect Ca2+ concentration (5F-BAPTA) and oxygen partial pressure 
(perfluor-crown-ether). 31P has a high abundance, reasonable sensitivity (6.6% relative 
to 1H), and its compounds are present at millimolar concentrations in tissue with a high 
metabolic rate, such as brain and muscle.  
 
The isolated heart and 31P MRS 
31P MRS has a long history of use in measuring myocardial phosphates 172, 173, having 
the great advantage that dynamic metabolic status and intracellular pH can be 
continuously, immediately and non-invasively assessed. Biochemical methods require 
either biopsy or freeze-clamped tissue samples, and histological methods need tissue 
sections. Isolated hearts can be used in combination with 31P MRS providing the above-
described advantages in combination with ischemia/reperfusion injury.  
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AIM OF THE THESIS 
 
Although much research has been performed, there is still no conclusive answer as to 
whether SU derivatives have detrimental or beneficial effects on post-ischemic cardiac 
function. Most importantly this is due to the different models used to study these kind 
of effects, as is described above. Especially, the number of studies using therapeutic 
concentrations of these drugs is limited. Moreover, our model has specific 
characteristics, which makes the model superior to address the topic of this thesis. 
Therefore, the aim of this thesis was to determine the hemodynamic and metabolic 
effects of therapeutic concentrations of SU derivatives. Furthermore, these effects were 
compared with other blood glucose lowering agents, i.e. the biguanide metformin and 
insulin.  
 
 
THESIS OUTLINE 
 
To study the hemodynamic and metabolic effects of the blood glucose lowering agents, 
the isolated, erythrocyte perfused, working rat heart model was used in combination 
with 31P MRS. Using this complex setup a clinically relevant situation was approached 
as closely as possible, as is described above. In figure 1.4, a schematic presentation of 
the perfusion system is shown. The work described in this thesis can be divided in the 
following chapters.  
 
Chapter 2 describes the functional and metabolic differences between the working 
heart preparation and the Langendorff preparation, to assess whether the working heart 
is more susceptible to ischemic damage than the Langendorff preparation.  
 
In Chapter 3 dose-response relationships for the classical SU derivative 
glibenclamide and the newly developed glimepiride were determined to study the 
effects on coronary blood flow and ischemia-induced cardiac functional loss, including 
the use of therapeutic concentrations of both drugs.  
In Chapter 4, we determined whether the glibenclamide-induced improvements of 
post-ischemic function can be ascribed to KATP channel blockade or not. This was tested 
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using two KATP channel opening drugs, pinacidil (sarcolemmal and mitochondrial KATP 
channels) and diazoxide (mitochondrial KATP channels).   
In Chapter 5, we determined the involvement of KATP channels in the adenosine- and 
dipyridamole-induced cardiac hemodynamic effects. This was tested using adenosine, 
dipyridamole and glibenclamide. 
In Chapter 6, we tested whether the improvements of glibenclamide on post-ischemic 
cardiac function can be related to intracellular ATP measurements using 31P MRS.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: Schematic of the perfusion system. RP = roller pump; PL = preload; AL = afterload; AF = 
aortic flow; WK = windkessel; VP = venous pressure (preload); AP = arterial pressure (afterload).  
 
In Chapter 7, we determined whether the biguanide metformin affects post-ischemic 
cardiac function and in this way contributes to the reduction in macrovascular 
complications observed in patient groups using this drug.  
In Chapter 8, we determined the effects of pre- and postprandial concentrations of 
insulin on coronary blood flow and post-ischemic cardiac function.  
 
Finally, the results observed in all studies are discussed in the Summary and 
Conclusions. 
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ABSTRACT 
 
The isolated rat heart is widely used for the assessment of ischemia-induced changes in 
functional and metabolic parameters and can be studied either as a Langendorff or as a 
working heart preparation. We hypothesized that the working heart is more vulnerable 
to ischemia than the Langendorff preparation, and therefore of more clinical relevance. 
Using an erythrocyte- and protein-enriched perfusate and employing 31P magnetic 
resonance spectroscopy, we compared these preparations on their vulnerability to 
ischemic injury. In total four groups were studied: a Langendorff and a working heart 
preparation for hemodynamic monitoring; and a Langendorff and a working heart 
preparation for metabolic monitoring. There were no significant changes in coronary 
blood flow between both preparations, neither at baseline or post-ischemically. In 
addition, relative pre-ischemic ATP and phosphocreatine (PCr) levels were similar in 
both preparations. However, the 12 min global ischemia-induced cardiac functional loss 
was significantly lower in the Langendorff versus working heart preparation (5.1 ± 1.8 
versus 20.7 ± 2.7 %, P=0.0003). During ischemia, the intracellular pH dropped more 
severely in the working heart versus Langendorff preparation (final pH: 6.43 ± 0.06 
versus 6.62 ± 0.09, P=0.04). The recovery of high-energy phosphates after ischemia, 
however, was similar between both groups. We conclude that the functional recovery to 
ischemia is less in the working heart preparation as compared with the Langendorff 
preparation, without significant changes in the recovery of high-energy phosphate 
levels.   
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INTRODUCTION 
 
The isolated mammalian heart has been extensively used to study myocardial 
ischemia/reperfusion injury. The effects of therapeutic interventions can be assessed 
more easily and directly than in vivo. The isolated rat heart is most convenient for this 
purpose, either perfused according to Langendorff 167 or as a working preparation 168, 174. 
Both preparations have made a great contribution to the understanding of myocardial 
ischemia/reperfusion injury. 
The Langendorff and working heart preparations differ in that the Langendorff 
preparation does not perform external work, in other words, it does not pump fluid. 
Coronary perfusion is achieved by cannulation and retrograde perfusion of the aorta 167. 
In the working heart both the left atrium and aorta are cannulated, and the heart 
performs external work, in other words, the left atrium receives perfusate with a certain 
preload (usually between 10 and 15 mmHg) and the left ventricle ejects the perfusate 
against a fixed afterload (usually between 75 and 100 mmHg) 168, 174.  
The difference in vulnerability to ischemic injury between the Langendorff and the 
working preparation has not been examined in much detail. It has been shown that the 
responsiveness to ischemia is similar for Langendorff and working preparations of the 
rat, however these hearts were perfused using a crystalloid buffer only 170. Smolens et 
al. on the other hand showed that the Langendorff perfused heart does not accurately 
predict the ability of the heart to support a physiological workload, also perfusing the 
hearts using crystalloid buffer only 169. Furthermore, it has been shown that the changes 
in left ventricular volume are much larger in the working heart than in the Langendorff 
preparation.175 indicating a higher workload in these hearts. 
Because of the limited knowledge about the vulnerability to ischemia of erythrocyte-
enriched crystalloid perfused isolated heart, perfused either as a Langendorff or as a 
working heart preparation, the present study was performed. Using an erythrocyte- and 
protein-enriched crystalloid perfusate, we studied the effects of a moderate ischemic 
interval (12 min at normothermia) on cardiac function and metabolic status of the heart 
continuously using both the Langendorff and the working heart preparation and 
employing 31phosphorus magnetic resonance spectroscopy to assess high-energy 
phosphates and intracellular pH.  
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MATERIALS & METHODS 
 
Experimental groups 
In total 26 animals were used in four experimental groups. Two groups (n=8 per group) 
were used to test hemodynamic readings, a Langendorff preparation and a working 
heart preparation. In addition, two separate groups (n=5 per group) were used to study 
high-energy phosphate profiles (again a Langendorff preparation and a working heart 
preparation). The hemodynamic data presented in the results section are only from the 
first two groups. 
 
Animal model 
A detailed description of the perfusion set-up has been published elsewhere 174, also 
using magnetic resonance spectroscopy 176. Briefly, a male Wistar rat (400g nominal 
weight, 4-6 months old) was anesthetized with diethyl ether, the heart excised via 
thoracotomy and placed in ice-cold buffer. The aorta was cannulated and Langendorff 
perfusion with buffer was started within 8-10 min after heart removal. For the working 
heart groups the left atrium was cannulated and after checking for leaks the system was 
switched to working configuration with erythrocyte suspension. Fluid columns were 
used to maintain the preload pressure at 15 mmHg and the afterload pressure at         
100 mmHg.  
For the Langendorff heart groups, only the aorta was cannulated and a fluid-filled latex 
balloon was placed in the left ventricle, filled with saline to result in an end-diastolic 
pressure of 10 mmHg. Then the setup was switched to the buffer perfusate with 
erythrocyte suspension. A fluid column was used to maintain the afterload pressure at 
100 mmHg. The buffer (using 95% O2 and 5% CO2) and erythrocyte suspension      
(18% O2, 8% CO2 and the rest N2) were equilibrated using membrane oxygenators. The 
composition of the buffer solution was as follows: NaCl 118, CaCl2 3.0, KCl 4.7, 
NaHCO3 25, MgSO4 1.2, KH2PO4 1.2, Na2EDTA 0.5, Glucose 11.1 mmol.L-1 For the 
erythrocyte suspension albumin was added to the same buffer solution to 1.5% followed 
by adding washed bovine erythrocytes to a hematocrit of 0.25. The free Ca2+ 
concentration in this composition was measured as 1.6 mmol.L-1. The temperature of 
the heart and perfusate were maintained throughout the experiment at normothermia of 
a rat (38 ± 1 oC). In the magnet the temperature of the heart (in air) was maintained 
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using a humidified system and temperature was measured inside the heart with 
Luxtron® fibre-optic probes 177. 
 
Experimental protocol  
After an equilibrium period of approximately 15 min, baseline cardiac performance was 
assessed for 8 min. Then, the working hearts groups were switched to Langendorff 
mode for 10 min and the Langendorff preparations remained in Langendorff mode (pre-
ischemic period), followed by 12 min of normothermic global ischemia by clamping the 
aortic line. Thereafter reperfusion was initiated in Langendorff mode for a period of 20 
min in all groups (post-ischemic period). Finally, cardiac performance was assessed in 
the same way as before. Erythrocyte suspension perfusate was used throughout.  
For the working heart preparation cardiac performance was assessed by measuring 
cardiac output (aortic blood flow + coronary blood flow against constant pressure). 
Aortic blood flow was measured using an ultrasound flow probe (Transonic Systems 
Inc., Ithaca, NY, USA) and coronary blood flow was measured by collecting and 
weighing the perfusate dripping off the heart. The coronary blood flow data collected 
during the pre-ischemic, post-ischemic and recovery periods were normalized to the 
baseline coronary blood flow data. Functional loss was calculated by dividing the 
reduction in left ventricular output (aortic flow + coronary blood flow) in the recovery 
period by the left ventricular output in the baseline period.  
For the Langendorff preparation, cardiac performance was assessed by measuring the 
change in left ventricular developed pressure (∆LVDP = left ventricular systolic 
pressure  end-diastolic pressure (EDP)). ∆LVDP was measured using a latex balloon 
in the left ventricle filled with physiological salt to an EDP of 10 mmHg. Coronary 
blood flow was measured in the same way as described above.  Functional loss was 
calculated by dividing the reduction in ∆LVDP in the recovery period by the ∆LVDP in 
the baseline period.  
 
Magnetic Resonance Spectroscopy 
Magnetic resonance spectroscopy experiments were performed using a 7.0 T magnet 
(Magnex Scientific, Abingdon, England) interfaced to a S.M.I.S. spectrometer (Surrey 
Medical Imaging Systems, Surrey, England) operating at 300.22 MHz for 1H and at          
121.53 MHz for 31P. The horizontal magnet is equipped with a 150 mT/m shielded 
gradient set and has a free bore size of 120 mm. A solenoid coil was used with a 
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diameter of 20 mm. Field inhomogeneity was adjusted by shimming on the water (1H) 
signal from the sample yielding line widths of 50-70 Hz. 31P magnetic resonance 
spectra were acquired using a simple pulse and acquire sequence with a hard 90 o RF 
pulse (=60 µs) and a repetition time of 4 s. The pulse sequence also generated trigger 
pulses to slightly over-pace the heart such that acquisition immediately preceded a 
pacing pulse to minimize movement artifacts. 32 free induction decays (FIDs) were 
acquired and averaged resulting in a time resolution of 2 min, which gave an adequate 
signal-to-noise ratio for frequency domain analysis. The sweep width was 10 kHz and 
512 data points were collected. The spectra obtained during the 8 min baseline and 
recovery periods (4 time points per period, 128 FIDs total) were averaged. Also the 10 
min pre-ischemic period spectra (5 time points, 160 FIDs total), and the last 14 min of 
the post-ischemic period (7 time points, 224 FIDs total) were averaged. During 
ischemia and the first 6 min of reperfusion, 2 min spectra (32 FIDs) were used. 
Signals in 31P magnetic resonance spectra were quantitated by iterative fitting of the 
time-domain signal with the variable projection method (VARPRO) and with 
appropriate prior knowledge for the ATP-multiplets using MRUI software (version 
99.7).178, 179 Peak areas were obtained by fitting the spectral lines to Gaussian line 
shapes. All peaks were analyzed relatively to an external reference of methylene 
diphosphonic acid (resonating at 16 ppm), which was positioned adjacent to the heart in 
the coil. The ATP content was determined from the β-ATP intensity. Its baseline value 
was used as a reference for the phosphocreatine (PCr) and Pi levels. The chemical shift 
of the PCr-peak was set to 0 ppm and the pH was calculated from the shift between PCr 
and inorganic phosphate (Pi) as described previously 180. 
 
Statistical analysis 
The hemodynamic results are presented as mean ± standard error of the mean (SEM). 
Differences in coronary blood flow and cardiac functional loss were statistically tested 
using Students t test. Differences in metabolic profiles were tested in different sections 
during the experiment. These sections are: baseline period (8 min  1 time point), pre-
ischemic period (10 min  1 time point), ischemic period (12 min  6 time points), post-
ischemic period (20 min  4 time points) and recovery period (8 min  1 time point). 
The baseline, pre-ischemic and recovery period differences were statistically tested for 
intergroup differences using Students t test. The ischemic and reperfusion periods were 
statistically tested using repeated measures analysis of variance, followed by a 
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Students t test with Bonferroni correction for intergroup differences. Statistical 
analysis was performed using SPSS (version 8.0.0, SPSS inc., USA). Differences were 
considered to be statistically significant at P-values lower than 0.05.  
 
 
RESULTS 
 
Hemodynamic readings 
Fig. 2.1 shows a graphical representation of the coronary blood flow before and after 
ischemia (baseline, pre-ischemic, post-ischemic and recovery periods) for the 
Langendorff and the working heart preparations.  
Figure 2.1: Graphical representation of the coronary blood flow throughout the whole experimental 
protocol (baseline, pre-ischemic, post-ischemic and recovery periods) of the Langendorff (closed triangles) 
and the working heart preparations (open circles). Results are presented as mean ± standard error of the 
mean (SEM). 
 
There was no difference observed in baseline coronary blood flow between the 
Langendorff and working heart preparation (Table 2.1). Furthermore, no significant 
differences were observed for the pre-ischemic, post-ischemic and recovery period 
coronary blood flow values between the Langendorff and working heart preparations 
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(Table 2.1). Only, the peak of the post-ischemic reactive hyperemia was reached at the 
3rd min in the Langendorff preparation, one min earlier than in the working heart 
preparation. Although there were no differences in coronary blood flow, there was 
indeed a difference in post-ischemic cardiac function.  
 
Table 2.1: Hemodynamic readings of the Langendorff and working heart preparations at baseline, pre-
ischemic, post-ischemic and recovery periods. End diastolic pressure (EDP), Left ventricular developed 
pressure (LVDP), Aortic flow and Coronary flow are shown. Results are presented as mean ± standard 
error of the mean (SEM). 
 EDP (mmHg) LVDP (mmHg) Aortic flow 
(mL.min-1) 
Coronary flow 
(mL.min-1) 
 
Working (n=8) 
    
Baseline   58.4 ± 3.1 9.1 ± 0.4 
Pre-ischemic    8.9 ± 0.6 
Post-ischemic    9.4 ± 0.8 
Recovery   42.1 ± 2.8 10.3 ± 0.7 
 
Langendorff (n=8)     
Baseline 10 ± 1 126 ± 6  8.6 ± 1.2 
Pre-ischemic 9 ± 1 121 ± 8  9.3 ± 1.4 
Post-ischemic 12 ± 2 108 ± 5  10.1 ± 1.4 
Recovery 11 ± 2 119 ± 6  10.0 ± 1.4 
     
 
After the 12 min global ischemic incident, the Langendorff preparation showed 
significantly less cardiac functional loss as compared with the working heart 
preparation (5.1 ± 1.8 versus 20.7 ± 2.7 %, P=0.0003) (Fig. 2.2).  
 
Metabolic readings 
During the 10 min pre-ischemic period, no significant differences in relative ATP and 
PCr levels were observed between the working heart and Langendorff preparation (Fig. 
2.3B&C). The calculated ATP:PCr ratios were also comparable (working: 0.66 ± 0.07                     
versus 0.59 ± 0.08 for Langendorff). The relative Pi levels were significantly higher 
during the baseline and pre-ischemic period in the working heart preparation as 
compared with the Langendorff preparation (0.76 ± 0.24 (baseline) and 0.97 ± 0.27 
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(pre-ischemic) versus 0.16 ± 0.10 (p=0.05) and 0.17 ± 0.11 (P=0.03), respectively)     
(Fig. 2.3A). The calculated intracellular pH was not significantly different between 
groups during the baseline and the pre-ischemic periods (Fig. 2.3D).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: Box-plot graphs of percentage of post-ischemic functional loss in the working heart and the 
Langendorff preparation are shown. ***=P<0.001 versus working heart preparation.  
 
During the ischemic period, the decline in relative PCr and ATP content were not 
different between both groups (Fig. 2.3B&C). Also, the rise in relative Pi levels to the 
maximum level at the end of the 12 min ischemic incident was not significantly 
different. During ischemia the drop in intracellular pH was significantly more severe in 
the working heart preparation compared with the Langendorff preparation (P=0.04), 
with a final pH after 12 min ischemia of 6.43 ± 0.06 versus 6.62 ± 0.09, respectively  
(Fig. 2.3D).  
During reperfusion (post-ischemic period  from 30th  50th min in Fig 2.3) the relative 
PCr levels tended to be consistently higher in the working heart preparation compared 
with the Langendorff preparation (P=0.11) (Fig. 2.3B). Intracellular ATP levels during 
the post-ischemic period tended to be higher in the working heart preparation compared 
with the Langendorff preparation (P=0.08) (Fig. 2.3C). Pi levels were significantly 
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Working                 Langendorff
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whole experimental protocol
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higher post-ischemically in the working heart preparation compared with the 
Langendorff preparation (p=0.003), for individual points after 4 (0.50 ± 0.09 versus 
0.13 ± 0.06, p=0.05) and 20 min of reperfusion (0.99 ± 0.14 versus 0.21 ± 0.15, P=0.02) 
(Fig. 2.3A). As tested with repeated measurements ANOVA, no significantly different 
intracellular pH levels were observed during the post-ischemic period between groups 
(P=0.41). However, using Students t test with Bonferroni correction, the intracellular 
pH was significantly higher after 4 and 6 min of reperfusion in the working heart 
preparation (4 min: 7.22 ± 0.05 versus 6.94 ± 0.06, P=0.03; 6 min: 7.25 ± 0.03 versus 
7.00 ± 0.04, P=0.004) (Fig. 2.3D). 
During the recovery period, no statistically significant differences between groups were 
observed for intracellular ATP, PCr and intracellular pH levels (Fig. 2.3C&D). The 
intracellular Pi level tended to be higher in the working heart preparation compared 
with the Langendorff preparation (1.15 ± 0.20 versus 0.49 ± 0.22, P=0.06).  
Comparing the recovery period with the baseline period, no differences were observed 
comparing intracellular pH and Pi levels. However, the recovery period PCr level was 
significantly lower for the Langendorff preparation compared with baseline period               
(1.28 ± 0.20 versus 1.84 ± 0.26, P=0.05). This was not the case for the working heart 
preparation (Fig. 2.3B). In addition, the recovery period ATP level was significantly 
lower for the Langendorff preparation compared with baseline period (0.52 ± 0.10 
versus 1.00, P=0.008). The recovery period ATP level tended to be lower in the 
working heart preparation compared with baseline period (0.74 ± 0.13 versus 1.00, 
P=0.11) (Fig. 2.3C). 
 
 
DISCUSSION 
 
The present study showed that the working heart preparation had a significantly higher 
cardiac functional loss than the Langendorff preparation after the 12 min global 
ischemic insult. These observations do not seem to be related to changes in intracellular 
levels of ATP, PCr or pH. This indicates that there is a discrepancy between the amount 
of cardiac functional loss and the recovery of high-energy phosphate levels comparing 
these preparations in our model. 
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Isolated rat heart in cardiovascular research 
The isolated rat heart has been used for decades in a huge number of studies that have 
revealed many aspects of cardiac metabolism, pharmacology and electrophysiology. 
Thus, it has contributed importantly to the understanding of the metabolism and 
function of the human heart. The effect of ischemia and reperfusion on rat hearts is 
possibly the most used intervention in studying hemodynamic and metabolic changes. 
Varieties of Langendorff and working heart preparations have been described, 
apparently with some avoidable limitations. Firstly, most isolated hearts are perfused 
with crystalloid buffer, to provide oxygen and metabolic supplies to the heart. However, 
it has been shown previously that perfusing hearts with crystalloid buffer, without the 
presence of an oxygen carrier (e.g. hemoglobin) results in higher coronary blood flow 
levels (near maximal vasodilation); in fact, hearts are at the brink of being hypoxic 
during normal baseline situations 165. This is illustrated by the 3-fold decrease in 
coronary blood flow levels after switching from crystalloid perfused buffer to 
erythrocyte-enriched crystalloid buffer in our setup 165. Therefore interpretation of 
ischemia-induced and vasoactive effects is much more difficult because baseline 
registrations are not completely free of hypoxia. In addition, it has been shown that 
erythrocyte-perfused hearts do have significantly higher high-energy phosphate levels 
than crystalloid-perfused hearts 166. A second point of importance is the lack of protein 
in crystalloid perfused hearts. The presence of protein is needed to avoid edema 166. 
 
Langendorff versus working heart preparation 
It has been reported previously that a working heart has a higher workload than a 
Langendorff preparation 169, 175 and in addition to this the oxygen requirement is several 
times greater in the working heart preparation 168, 181-183. Therefore, it would be expected 
that the working heart would need more coronary blood flow to supply the heart with 
metabolites and oxygen. In the present study, there were no indications that the 
coronary blood flow levels were higher in the working heart preparation compared with 
the Langendorff preparation. There was only a slight tendency that the peak coronary 
blood flow level could be higher in the working heart preparation. Although the 
possibly higher workload in the working heart preparations were not clearly visible in 
differences in coronary blood flow, the Pi level was significantly higher in this group 
indeed indicating a higher workload. Therefore, these results indicate that in our model 
using erythrocytes and protein-enriched buffer perfusate, the logically increased 
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demand of metabolites and oxygen in the working heart preparation can be easily 
provided without need of extra coronary blood flow as compared with the Langendorff 
preparation.  
Because of the lower workload in Langendorff prepared hearts, it was also expected 
that these hearts could withstand ischemic damage more easily than working hearts. 
This seems to be correct because the cardiac functional loss was significantly less in the 
Langendorff versus working heart preparation. We assessed this in terms of the relative 
loss of LVDP in the Langendorff preparation and the relative loss of cardiac output at 
constant pressure in the working heart preparation. These indices of cardiac functional 
loss have been shown to be representative for this purpose 170. The lower loss of cardiac 
function can be explained by less intense contractions, thereby using less energy 
because of the smaller workload in the Langendorff preparation. In this way, post-
ischemic heart function is better preserved during ischemia. However, both groups had 
similar ATP:PCr ratios at baseline, which are in close agreement with ATP:PCr ratios 
measured in vivo in rat hearts suggesting that the hearts in both groups were not 
substantially metabolically compromised 172. Furthermore, in the present study there 
were no indications that switching the hearts from the working state to the 
Langendorff state in the working heart preparation resulted in higher pre-ischemic 
ATP and PCr levels. This would suggest that no extra energy is used in the working 
state compared with the Langendorff state. It has been shown that with increasing 
workloads the relative amounts of ATP and PCr remained constant 184. In addition, 
intracellular pH was similar after switching between states. The only indication of a 
higher workload in the working hearts is the higher Pi levels as stated above.  
During ischemia, no significant differences were observed in PCr and ATP depletion 
and Pi build-up between both groups.  This seems logical because the ischemic insult 
was completely the same in both groups. This was also found previously 170. However, 
intracellular pH dropped more quickly and more severely in the working heart 
preparation, which has been associated with more contractile failure 185 and therefore, 
the more severe ischemia-induced intracellular acidosis in the working heart preparation 
indicates a higher degree of damage. This higher degree of damage is in close 
agreement with the observed higher cardiac functional loss in the present study.  
During reperfusion the time to peak of coronary blood flow was one minute earlier in 
the Langendorff preparation compared with the working heart preparation. It is 
previously shown, that time to peak coronary blood flow correlates with post-ischemic 
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recovery 186 and therefore the earlier time to peak coronary blood flow in the 
Langendorff preparation indicates a better recovery of post-ischemic function. 
Intracellular pH levels recovered significantly better in the working heart preparation 
compared with the Langendorff preparation in the post-ischemic period. In accordance 
with this, PCr and ATP levels tended to do the same. These findings can hardly be 
linked to the lower cardiac functional loss observed in the working heart preparation. 
Various groups including ours showed that the recovery of high-energy phosphates is 
correlated with cardiac functional recovery 176, 187-189. Other groups, however, failed to 
find a correlation between high-energy phosphates and cardiac functional recovery 190, 
191. 
 
Conclusion 
The present study shows that the amount of tissue perfusion and high-energy phosphate 
levels during normoxia and ischemia are comparable in the Langendorff and working 
heart preparations. Furthermore, the working heart preparation was more vulnerable to 
the ischemic insult as compared with the Langendorff preparation, as is indicated by the 
higher amount of cardiac functional loss and the more severe ischemia-induced 
acidosis. For studying cardiac functional effects after short ischemic intervals, like 
stunning, the working heart is more suitable because of the higher amount of functional 
loss compared with the Langendorff preparation. 
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ABSTRACT 
 
This study determined whether sulfonylurea derivatives affect cardiac function prior to 
and after a mild ischemic incident (stunning). This was investigated using an isolated, 
erythrocyte perfused, working rat heart model. In total eleven groups were studied: five 
increasing (clinically relevant) concentrations of the classical glibenclamide (range 
0.0054 µmol.L-1), five increasing concentrations of the newly developed glimepiride                     
(range 0.0050.8 µmol.L-1), and one control group. Pre-ischemically, glibenclamide and 
glimepiride reduced coronary blood flow concentration dependently to 55.2 ± 4.5 and          
58.5 ±.5.5% respectively (P<0.001). Twenty min after a 12-min ischemic incident, 
these reductions of flow were even more pronounced (to 38.3 ± 6.7 and 45.8 ± 5.8%, 
P<0.001). This shows that both sulfonylureas reduce coronary blood flow at 
concentrations slightly higher than therapeutic ones. In the control group, the ischemic 
incident significantly lowered cardiac function by 22.2 ± 2.9%. In the therapeutic range, 
glimepiride, but not glibenclamide, significantly reduced this ischemia-induced cardiac 
functional loss to 4.9 ± 1.2% (P<0.01). Therefore, we suggest that both sulfonylureas 
and in particular glimepiride can be used safely in patients with type 2 diabetes 
mellitus, as long as the coronary vascular system is not compromised. Because of the 
obvious vasoconstrictor response to sulfonylurea derivatives, these drugs must be used 
with caution in patients with a reduced coronary reserve. 
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INTRODUCTION 
 
Sulfonylurea derivatives are still the cornerstone of the treatment of type 2 diabetes 
mellitus 37, 38. These drugs exert their blood glucose lowering effect by stimulating 
insulin secretion in the pancreatic β-cell 37, 38. Although this mechanism of action has 
been known for decades, the molecular target for sulfonylurea derivatives was 
discovered only recently 40. Sulfonylurea derivatives are able to bind to a specific 
sulfonylurea receptor (SUR1), which is a principal component of the so-called         
ATP-sensitive K+ channel (KATP channel). By blocking K+ efflux, sulfonylurea 
derivatives depolarize the plasma membrane, which triggers the opening of voltage-
dependent Ca2+ channels. The subsequent influx of Ca2+ ultimately results in insulin 
release 40, 45. 
Functional KATP channels have also been identified in the cardiovascular system 45. The 
sulfonylurea receptors in myocardial and in vascular smooth muscle cells are slightly 
different from the pancreatic SUR1, and have been characterized as SUR2a and SUR2b 
respectively 48-50. Although classical drugs such as tolbutamide and glibenclamide have 
a much higher affinity at SUR1 than at SUR2a and SUR2b 52, it is still unknown whether 
therapeutic concentrations of these drugs affect the function of the cardiovascular 
system. Theoretically, blockade of the cardiovascular KATP channel may interfere with 
endogenous cardioprotective mechanisms, especially during states of ischemia, when 
reduced levels of intracellular ATP trigger the opening of KATP channels 45, 67, 68. High 
concentrations of sulfonylurea derivatives have been shown to block several beneficial 
or detrimental ischemia-induced phenomena, including coronary vasodilation 65, 66, 
arrhythmias 84, 94, 95, ischemic preconditioning 78, 102, loss of cardiac function 80, 82-84 and 
myocardial stunning 192.  
Many different models and protocols have been used to study the effects of 
sulfonylureas on cardiac hemodynamics. The primary model used to study 
hemodynamics before and after ischemia is an isolated heart model. In general, these 
isolated hearts are perfused with crystalloid oxygenated buffers. Due to the lower 
oxygen capacity of these buffers (lack of hemoglobin), the coronary blood flow in these 
models is much higher than in the in vivo situation, in fact there is near maximal 
vasodilation. Therefore vasodilator responses and the effects of sulfonylureas on 
coronary blood flow are difficult to determine in these models    165, 166. Furthermore, 
most groups have used a Langendorff perfused heart 167 instead of a working heart    
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set-up 168. This can also be a source of difficulty in interpreting the clinical relevance of 
results. Another important point in interpreting results is to consider whether infarct 
size or functional recovery is measured. Also, the differences between reversible 
ischemic damage (e.g. stunning) and irreversible ischemic damage (infarct) have to be 
taken into account. 
Therefore, we used an isolated working rat heart model. To the modified Krebs-
Henseleit buffer we added bovine erythrocytes and albumin. The use of erythrocytes 
makes the coronary blood flow more like that in vivo, so results are better interpretable. 
The use of albumin gives a better view of the pharmacological effects of sulfonylureas 
in rat hearts as drug-protein interaction occurs and thus extrapolation to the in vivo 
situation in patients treated with these drugs is improved.  
The objective of the present study was to address the myocardial safety of therapeutic 
concentrations of sulfonylurea derivatives in this novel and useful model of myocardial 
ischemia. We investigated two sulfonylurea derivatives,  glibenclamide, because this is 
the most widely used classical representative of this class of drugs, and glimepiride, 
because this sulfonylurea derivative has been shown to be more selective for the SUR1 
receptor 53, 98. Finally, drugs were used over a large concentration range, including 
therapeutic concentrations. 
 
 
MATERIALS AND METHODS 
 
Reagent and experimental groups  
Glibenclamide was purchased from Sigma-Aldrich Chemie B.V., Zwijndrecht, The 
Netherlands. Glimepiride was kindly provided by Hoechst Marion Roussel, The 
Netherlands. In total 50 animals were used in 11 experimental groups: vehicle (n=8); 
and increasing concentrations of glibenclamide: 0.005, 0.05, 0.25, 1 and 4 µmol.L-1 
(n=3 to 5) and glimepiride 0.005, 0.05, 0.15, 0.25 and 0.8 µmol.L-1 (n=3 to 5). 
Concentrated drug solutions were infused into the system by a syringe with a computer-
controlled pump (1:10). The vehicle composition in the syringe was as follows:              
1 mmol.L-1 NaOH, 0.4% dimethylsulfoxide (DMSO), 0.8% NaCl and 1.5% bovine 
serum albumin (fraction V, ICN Biomedicals B.V., Zoetermeer, The Netherlands). The 
drug concentrations were free non-protein bound concentrations (measured by high-
performance liquid chromatography (HPLC) analysis following equilibrium          
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analysis 193). Both sulfonylurea derivatives were highly bound to protein (97.5 %), and 
therefore we used the free unbound concentrations. For example, a free concentration 
of 4 µmol.L-1 glibenclamide was achieved by applying a total concentration of            
160 µmol.L-1 glibenclamide. For glimepiride, 0.8 µmol.L-1 was the highest achievable 
unbound concentration without crystallization. 
 
Animal Model 
A more detailed description of the perfusion set-up has already been published 
elsewhere 174. Briefly, a male Wistar rat (400 g nominal weight; 4-6 months old) was 
anesthetized with diethyl ether, and the heart was excised by thoracotomy and placed in 
ice-cold buffer. The aorta was cannulated and Langendorff perfusion with buffer was 
started within 8-10 min after heart removal. Subsequently, the left atrium was 
cannulated, pacing-wires were attached and the hearts were paced at around 360 bpm 
(delay time = 1 ms, voltage = 5 V). After checking for leaks, the system was switched 
to the working configuration with an erythrocyte suspension. Fluid columns were used 
to maintain the preload pressure at 2 kPa and the afterload pressure at 13 kPa. The 
buffer (95% O2 and 5% CO2) and erythrocyte suspension (18% O2, 8% CO2 and the rest 
N2) were equilibrated using membrane oxygenators. The composition of the modified 
Krebs-Henseleit buffer solution was as follows: NaCl 118, CaCl2 3.0, KCl 4.7, 
NaHCO3 25, MgSO4 1.2, KH2PO4 1.2, NaEDTA 0.5, glucose 11.1 mmol.L-1. The 
erythrocyte suspension was prepared by washing heparinized bovine blood three times 
with physiological saline. For the erythrocyte suspension, albumin was added to the 
same buffer solution to 1.5% followed by addition of erythrocytes to give a hematocrit 
of 0.25. The free Ca2+ concentration in this suspension was 1.6 mmol.L-1 as determined 
by blood gas analysis. The temperature of the heart and perfusate was maintained 
throughout the experiment at normothermia of a rat (38 oC).  
 
Experimental protocol & statistical analysis 
After an equilibrium period of approximately 15 min, baseline cardiac performance was 
assessed for 8 min with a preload pressure of 2 kPa, holding the afterload pressure 
constant at 13 kPa (baseline period). Next, drug was infused for 10 min in Langendorff 
mode at a constant pressure of 13 kPa (pre-ischemic period), followed by 12 min of 
normothermic global ischemia, achieved by clamping the aortic line. Thereafter 
reperfusion was initiated in Langendorff mode for 20 min, again with infusion of drug 
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(post-ischemic period). Then the set-up was switched back to working mode. Finally, 
cardiac performance was assessed for the second time in the same way as before 
(recovery period). In Fig. 3.1 a graphical representation of the coronary blood flow 
during the whole protocol is shown, illustrating the protocol used. Cardiac performance 
was assessed by measuring cardiac output (aortic blood flow + coronary blood flow 
against constant pressure). All the data presented in the results section are based on the 
following data points in the different periods unless otherwise stated: baseline period  
8th min, pre-ischemic period  10th min, post-ischemic period  20th min and recovery 
period  1st min. Aortic blood flow was measured using an ultrasound flow probe 
(Transonic Systems Inc., Ithaca, NY, USA) and coronary blood flow was measured by 
collecting and weighing the perfusate dripping off the heart. The coronary blood flow 
data collected during the pre-ischemic, post-ischemic and recovery periods were 
normalized to the baseline coronary blood flow data. Functional loss was calculated by 
dividing the reduction in left ventricular output (aortic flow + coronary blood flow) in 
the recovery period by the left ventricular output in the baseline period. The flow debt 
repayment post-ischemically is expressed as the total summed coronary blood flow 
during the 20-min post-ischemic period relative to the coronary blood flow during the 
last minute (8th min) of the baseline period (If coronary blood flow had remained a 
constant 100% throughout the 20-min post-ischemic period, this total would be 2000). 
The results are presented as means ± standard error of the mean (SEM). Differences in 
coronary blood flow and cardiac functional loss were statistically tested using one-way 
analysis of variance (ANOVA) followed by a Bonferroni comparison test. The 
Bonferroni comparison test was only performed when the one-way ANOVA was 
significant. One-site competition curve fitting was done to determine the concentration-
response relationships of the coronary blood flow effects. Differences in EC50 were 
tested using the Welch corrected        t-test. Statistical analysis was performed using 
Instat (version 3.00, Graphpad Software Inc. San Diego, USA). Curve fitting was 
performed using Prism (version 2, Graphpad Software Inc.). For the curve fitting an r2-
value higher than 0.95 was considered reliable. Differences were considered to be 
statistically significant at P values lower than 0.05.  
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RESULTS 
 
Fig. 3.1 shows a graphical representation of the baseline coronary blood flow, and of 
the effects of vehicle and of both sulfonylurea derivatives (4 µmol.L-1 glibenclamide 
and 0.8 µmol.L-1 glimepiride) on coronary blood flow before and after ischemia 
(baseline, pre-ischemic, post-ischemic and recovery periods).  
Figure 3.1: Coronary blood flow tracings throughout the whole experimental protocol (baseline, pre-
ischemic, post-ischemic and recovery periods) for vehicle (open circles), 4 µmol.L-1 glibenclamide 
(open squares) and 0.8 µmol.L-1 glimepiride (closed triangles). 
 
The absolute data on coronary blood flow as well as the data on aortic blood flow after 
administration of vehicle or drugs during the baseline and recovery periods are 
summarized in table 3.1. Both glibenclamide and glimepiride reduced coronary blood 
flow concentration dependently during the pre-ischemic period (Table 3.2). This 
concentration-dependent vasoconstrictor effect of glibenclamide and glimepiride was 
even more pronounced in the post-ischemic period as compared with the pre-ischemic 
period (Glibenclamide: Emax post-ischemically 38.3 ± 6.7 % versus pre-ischemically 
55.2 ± 4.5 %  P<0.01; Glimepiride: Emax post-ischemically 45.8 ± 5.8 % versus pre-
ischemically 58.5 ± 5.5 %  P<0.05).  
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Table 3.1: Effects of vehicle, glibenclamide (Glib) and glimepiride (Glim) on cardiac hemodynamics at 
baseline and recovery periods. Absolute aortic blood flow and absolute coronary blood flow are shown. 
Data are presented as means ± standard error of the mean (SEM).  
 
 
Aortic blood flow 
(mL.min-1 ± SEM) 
Coronary blood flow 
(mL.min-1 ± SEM) 
 Baseline Recovery Baseline Recovery 
 
Vehicle (n=8) 
 
 
58.3 ± 3.1 
 
42.0 ± 2.7 
 
9.1 ± 0.4 
 
10.3 ± 0.7 
0.005 µmol.L-1 Glib (n=5) 60.8 ± 3.9 44.6 ± 5.9 10.5 ± 1.9 12.8 ± 2.0 
0.05 µmol.L-1 Glib (n=5) 58.8 ± 3.4 46.8± 5.9 10.4 ± 1.9 11.5 ± 1.8 
0.25 µmol.L-1 Glib (n=3) 60.3 ± 12.2 47.0 ± 11.0 7.8 ± 0.8 9.1 ± 1.3 
1 µmol.L-1 Glib (n=3) 67.7 ± 4.3 62.7 ± 6.8 8.5 ± 0.3 7.2 ± 1.2 
4 µmol.L-1 Glib (n=5) 
 
62.8 ± 4.0 
 
61.4 ± 4.1 8.7 ± 0.8 
 
7.1 ± 0.8 
0.005 µmol.L-1 Glim (n=5) 69.2 ± 2.0 62.4 ± 3.4 9.0 ± 1.3 11.9 ± 1.4 
0.05 µmol.L-1 Glim (n=5) 66.2 ± 2.0 62.2 ± 2.6 8.9 ± 0.6 9.3 ± 0.5 
0.15 µmol.L-1 Glim (n=3) 69.7 ± 1.2 57.3 ± 3.7 7.6 ± 0.4 9.3 ± 0.4 
0.25 µmol.L-1 Glim (n=3) 68.7 ± 1.9 51.3 ± 4.6 9.2 ± 0.6 8.6 ± 0.7 
0.8 µmol.L-1 Glim (n=5) 72.4 ± 2.6 60.0 ± 3.7 9.7 ± 1.6 8.4 ± 1.7 
 
 
One-site competition curve-fitted concentration-response relationships are shown in 
Fig. 3.2 for both drugs during the pre- versus the postischemic period. For all four 
curves, the r2 values were above 0.95, indicating reliable curve fits. Pre-ischemically, 
the calculated log EC50 values were not significantly different between both 
sulfonylurea derivatives: 6.6 ± 0.3 (0.28 µmol.L-1) and  -6.8 ± 0.5 (0.17 µmol.L-1)  for 
glibenclamide and glimepiride, respectively (P=0.70). Post-ischemically, a small 
tendency towards lower EC50 values was observed: -6.9 ± 0.1 (0.13 µmol.L-1) and 7.3 
± 0.2 (0.05 µmol.L-1) for glibenclamide (P=0.38) and glimepiride (P=0.29), 
respectively. Furthermore, the post-ischemic EC50 value tended to be higher for 
glibenclamide than for glimepiride (P=0.12). The flow debt repayment was 
significantly reduced for the two highest concentrations of both sulfonylurea derivatives 
(Table 3.3).  
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In the vehicle group, 12 min of global ischemia induced a calculated loss of cardiac 
function of 22.2 ± 2.9 % (Fig. 3.3). The highest concentration of glibenclamide 
significantly reduced this ischemia-induced loss of function (4.3 ± 1.2 % compared with 
22.2 ± 2.5 %, P<0.01). At therapeutic concentrations of glibenclamide, no protective 
effect was observed. In contrast, low concentrations of glimepiride (0.005 and              
0.05 µmol.L-1) significantly reduced the ischemia-induced loss of cardiac function       
(5.0 ± 1.4 % and 4.9 ± 1.2 % versus 22.2 ± 2.9 %, P<0.01).  
 
 
DISCUSSION 
 
This study clearly shows that both glibenclamide and glimepiride were able to 
significantly reduce the loss of cardiac function induced by 12 min of global ischemia.  
It should however be noted that glimepiride was cardioprotective at therapeutic  
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Figure 3.2: One-site competition
curve fitting for normalized coronary
blood flow effects induced by
pre/post-ischemic glibenclamide (A)
and glimepiride (B) treatment. The
dotted lines and squares represent the
pre-ischemic curves, while the solid
lines and triangles represent the post-
ischemic curves. The rectangled areas
represent the therapeutic concentration
range of the sulfonylurea derivatives.
Results are presented as means ±
standard error of the mean (SEM).  
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Table 3.2: Effects of vehicle, glibenclamide (Glib) and glimepiride (Glim) on cardiac hemodynamics at 
the end of pre-ischemic and post-ischemic periods. Coronary blood flow data are shown normalized to 
baseline level (8th min of baseline period). Data are presented as means ± standard error of the mean 
(SEM). *=P<0.05, **=P<0.01, ***=P<0.001. 
 Normalized coronary blood flow (%± SEM) 
 Pre-ischemic Post-ischemic 
 
Vehicle (n=8) 
 
97.4 ± 3.1 
 
103.0 ± 6.6 
 
0.005 µmol.L-1 Glib (n=5)  87.9 ± 5.9 100.5 ± 8.2 
0.05 µmol.L-1 Glib (n=5)  78.7 ± 3.1 * 84.3 ± 6.9 
0.25 µmol.L-1 Glib (n=3)  74.5 ± 2.2 * 56.7 ± 10.1 ** 
1 µmol.L-1 Glib (n=3) 63.0 ± 7.4 *** 36.4 ± 2.2 *** 
4 µmol.L-1 Glib (n=5) 
 
55.2 ± 4.5 *** 
 
38.3 ± 6.7 *** 
0.005 µmol.L-1 Glim (n=5) 97.1 ± 8.5 101.0 ± 9.3 
0.05 µmol.L-1 Glim (n=5) 86.4 ± 4.5 74.3 ± 6.7 
0.15 µmol.L-1 Glim (n=3) 70.0 ± 7.8 ** 58.5 ± 13.0 ** 
0.25 µmol.L-1 Glim (n=3) 80.8 ± 2.6 61.0 ± 4.3 ** 
0.8 µmol.L-1 Glim (n=5) 58.5 ± 5.5 *** 45.8 ± 5.8 *** 
 
 
concentrations, while for glibenclamide this protection was only present at much higher 
concentrations. Furthermore, this study shows that both sulfonylurea derivatives 
slightly reduce coronary blood flow at therapeutic concentrations. Since the majority of 
publications on this issue concern supratherapeutic concentrations of sulfonylurea 
derivatives, we think that our observations on glibenclamide and glimepiride in the 
therapeutic range are of special importance. 
 
Clinical relevance 
The effects of sulfonylurea derivatives on post-ischemic cardiac function are difficult to 
determine in a clinically relevant fashion. It is impossible to study these mechanisms in 
humans, so animal research is still necessary. Up to now, most studies of the cardiac 
effects of sulfonylurea derivatives have used concentrations that are much higher than 
the therapeutic range 59, 60, 65, 80, 82-84. In the majority of these studies, isolated perfused 
animal hearts were used. These models do have some avoidable limitations. First of all,  
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 Flow debt repayment 
(a.u.± SEM) 
 
Vehicle (n=8) 
 
3220 ± 192 
 
0.005 µmol.L-1 Glib (n=5)  3649 ± 416 
0.05 µmol.L-1 Glib (n=5)  2996 ± 322 
0.25 µmol.L-1 Glib (n=3)  2461 ± 137 
1 µmol.L-1 Glib (n=3) 1833 ± 149 * 
4 µmol.L-1 Glib (n=5) 1592 ± 135 *** 
 
0.005 µmol.L-1 Glim (n=5) 3391 ± 327 
0.05 µmol.L-1 Glim (n=5) 3111 ± 129 
0.15 µmol.L-1 Glim (n=3) 2452 ± 238  
0.25 µmol.L-1 Glim (n=3) 2045 ± 131 * 
0.8 µmol.L-1 Glim (n=5) 2146 ± 266 ** 
 
 
Figure 3.3: Percent post-ischemic functional loss after vehicle (white bar), glibenclamide (light gray 
bars) or glimepiride (dark gray bars) treatment. The rectangled areas represent the therapeutic range of 
the sulfonylurea derivatives. Results are presented as means ± standard error of the mean (SEM), 
**=P<0.01 versus vehicle.  
 
 
0
5
10
15
20
25
30
Vehicle 0.005 0.05 0.25 1 4 0.005 0.05 0.15 0.25 0.8
  Glibenclamide (µmol.L-1)                                      Glimepiride (µmol.L-1)
** ** **
Cardiac functional loss (%) 
Table 3.3: Effects of vehicle,
glibenclamide (Glib) and
glimepiride (Glim) on the flow
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blood flow during the  post-
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most isolated hearts are perfused with crystalloid buffer, to provide oxygen and 
metabolites to the heart. However, it has been shown previously that perfusing hearts 
with crystalloid buffer, without the presence of an oxygen carrier (e.g. hemoglobin), 
results in higher coronary blood flow levels (near maximal vasodilation); in fact, hearts 
are at the brink of being hypoxic during normal baseline situations 165. This is illustrated 
by the 3-fold decline in coronary blood flow levels after switching from crystalloid 
perfusion buffer to erythrocyte-enriched crystalloid buffer in our set-up 165. Therefore 
interpretation of ischemia-induced and vasoactive effects is much more difficult 
because baseline registrations are not completely free of ischemia. A second point of 
importance is the lack of protein in crystalloid-perfused hearts. The presence of protein 
is needed to avoid edema, and also reflects the in vivo condition of patients treated with 
sulfonylurea derivatives more precisely than protein-free perfusion fluid. Sulfonylureas 
are highly protein-bound drugs (>98%), and the dynamic equilibrium between the 
bound and the active non-bound fractions of the drugs also occurs in our model. Also, 
the isolated heart model mostly used is the so-called Langendorff heart set-up instead of 
the preferable working heart set-up. Because in the working heart set-up the heart 
actually performs external work, this model is one step further in the direction of 
clinical relevance than the Langendorff heart set-up.  
Because of the reduced clinical relevance of the previous studies, we performed the 
present study with therapeutic concentrations of sulfonylurea derivatives using an 
isolated working rat heart set-up. In this set-up, the heart was perfused with a crystalloid 
buffer, enriched with erythrocytes and protein to improve the clinical relevance of 
observations on coronary blood flow and on functional recovery effects post-
ischemically.  
 
Hemodynamic effects  
Coronary blood flow 
The observed dose-dependent decrease in coronary blood flow after glibenclamide and 
glimepiride treatment during normoxia is consistent with previous observations in open-
chest dogs 59, 60. These observations suggest that the ion flux across KATP channels in 
vascular smooth muscle cells of coronary arteries contributes to baseline coronary 
vascular tone. Although the maximal decrease observed during the highest 
concentrations of glibenclamide and glimepiride was impressive, there was only slight 
vasoconstriction at therapeutic concentrations. Interestingly, the vasoconstrictor effect 
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of the drugs was more pronounced in the post-ischemic period. This agrees with the 
view that the open-state probability of KATP channels is higher during and after 
ischemia than under resting conditions 45, 67. This may explain the conflicting effects in 
animal models which are continuously hypoxic. Consistent with the observations of 
Aversano et al. in anesthetized open-chest dogs, we found a decrease in the flow debt 
repayment with the highest concentrations of both sulfonylurea derivatives 66. The 
ischemic incident tended to decrease the calculated EC50values, suggesting that the 
affinity for the sulfonylurea receptor is higher after ischemia.  
Interpretation of the clinical relevance of the vasoconstrictor response to both 
sulfonylurea derivatives on the coronary circulation is difficult, because in the present 
study healthy rats were used instead of diabetic rats. Since diabetes impairs regional 
blood flow and many of these patients have coronary artery disease, the importance of 
the vasoconstrictor effect of the sulfonylurea derivatives may be underestimated in the 
present study.  
 
Cardiac function 
A high concentration of glibenclamide was found to reduce the ischemia-induced loss 
of cardiac function; however, therapeutic concentrations of this drug did not affect the 
cardiac performance. In contrast, low concentrations of glimepiride were also able to 
reduce the ischemia-induced loss of function. Apparently, these effects were not related 
to the effects on coronary blood flow. This was consistent with previous observations in 
isolated hearts 82-84. 
Other groups showed a detrimental effect on cardiac function post-ischemically in 
isolated hearts and isolated ventricular myocytes in the presence of sulfonylureas 80, 192, 
194. It is believed that this effect is potentiated by depolarization of the myocardial 
membrane followed by increased Ca2+ influx, thereby prolonging the ischemia-induced 
shortening of the action potential and increasing energy utilization, and in this way 
damaging the heart.  
It is important to notice the difference between those ischemic insults that induce 
infarction, resulting in necrosis of myocardial tissue, and those that do not (e.g. 
stunning). This is important because sulfonylurea derivatives prevent the ischemia-
induced reduction in action potential duration. As a result of a longer action potential 
duration, more Ca2+ would enter the cell and could thereby maintain contractile force in 
a situation of myocardial stunning. However, in a situation of myocardial infarction the 
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increased force development may use ATP at a faster rate and could thereby accelarate 
the ischemic injury. 
An explanation for the improvement could be that sulfonylureas metabolically preserve 
high-energy phosphate compounds 84. By preserving in particular intracellular ATP 
levels, hearts would be less energy depleted after ischemia, and therefore they might 
recover better. In addition, the involvement of lactate may be important in the observed 
reduction in functional loss, which has been shown in isolated rat hearts 82 and in 
isolated ventricular myocytes 195. Sulfonylureas may attenuate ischemia-induced 
intracellular lactate accumulation, implying an inhibitory effect on glycolysis and 
possibly glycogenolysis 82. This may be protective to the ischemic heart.  
 
Differences in sulfonylurea derivatives 
In clinical practice, type 2 diabetic patients placed on glibenclamide treatment are 
treated with oral doses about 2-3 times higher than those of glimepiride (15 mg per day 
versus 6 mg per day maximally). These oral doses result in plasma concentrations of 
about 0.9 µmol.L-1  and 1.5 µmol.L-1  for glibenclamide and glimepiride, respectively. 
Because sulfonylurea derivatives bind highly to protein (more than 98 %), the resultant 
non-bound concentrations are about 0.02 and 0.04 µmol.L-1 for glibenclamide and 
glimepiride, respectively. Because these concentrations are peak plasma levels, we 
included two clinically relevant concentrations for both sulfonylurea derivatives in our 
experiments: 0.005 and 0.05 µmol.L-1 (protein unbound).  
Glimepiride, the newer sulfonylurea derivative, has been reported to be more specific 
than glibenclamide for the SUR1 receptor in the pancreatic β cell 53, 98. Geisen et al. 
found that a three-fold higher concentration of glimepiride is needed to close 
cardiovascular KATP channels to the same extent as glibenclamide 53. It has also been 
shown that glimepiride does not inhibit the protection induced by ischemic 
preconditioning, while glibenclamide abolishes the protection, which also supports the 
concept that glimepiride has fewer cardiovascular effects 98. The present study, 
however, showed similar effects of glibenclamide and glimepiride on coronary blood 
flow both under normoxia and post-ischemia conditions. Therefore, there are no 
indications in this study that the specificity of glimepiride is different from the 
specificity of glibenclamide concerning vascular KATP channels or in particular the 
SUR2b receptor. Interestingly, but hard to explain, glimepiride reduced the ischemia-
induced functional loss at therapeutic concentrations, while glibenclamide did not. 
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These observations cannot be explained by specific effects on KATP channels because at 
higher glimepiride concentrations the reduced functional loss disappeared. Therefore, 
other mechanisms must be responsible for this effect. One possibility may be that 
sulfonylurea derivatives affect metabolic processes, especially during ischemia 82, 84, 195.  
 
Conclusion 
Our observations show clearly that glibenclamide and glimepiride both reduce coronary 
blood flow at concentrations that are slightly higher than therapeutic ones. In the 
therapeutic range, the cardiac functional loss induced by 12 min of normothermic 
global ischemia was significantly reduced by glimepiride, while this reduction did not 
occur with glibenclamide. Therefore, this study suggests that both sulfonylureas, and in 
particular glimepiride, can be used safely in patients with type 2 diabetes mellitus, as 
long as the coronary vascular system is not compromised. Because of the obvious 
vasoconstrictor response to sulfonylureas, these drugs must be used with caution in 
patients with a reduced coronary reserve.  
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ABSTRACT 
 
Glibenclamide preserves post-ischemic myocardial function in the isolated, erythrocyte 
perfused, working rat heart model. This study addresses the possible involvement of           
KATP channels in the beneficial action of glibenclamide We hypothesized that if 
glibenclamide improved post-ischemic cardiac function by blocking of KATP channels, 
opening of these KATP channels should result in the opposite, namely detrimental effects 
on post-ischemic heart function. 
Post-ischemic functional loss and coronary blood flow were recorded during treatment 
with glibenclamide (GLIB; 4 µmol.L-1; n=5), the KATP channel openers pinacidil 
(PINA; 1 µmol.L-1; n=5) and diazoxide (DZX; 30 µmol.L-1; n=5), the combination of 
GLIB with PINA (n=5) and GLIB with DZX (n=5), and vehicle (n=8). 
Both PINA and DZX significantly increased coronary blood flow 2-3 fold, which was 
abolished by GLIB pre- and postischemically. This confirms that under both flow 
conditions GLIB significantly blocks KATP channels in the coronary vasculature. The 12 
min global ischemic incident resulted in a cardiac functional loss of 22.2 ± 2.9 % during 
vehicle. GLIB reduced the cardiac functional loss to 4.3 ± 1.2 % (P<0.01). 
Interestingly, both PINA and DZX reduced the cardiac functional loss to 4.0 ± 1.5 % 
(P<0.01) and 2.9 ± 1.4 % (P<0.001), respectively. The combination PINA+GLIB 
resulted in additional protection compared with the individual components (0.6 ± 0.1 
versus 4.0 ± 1.5 %, P<0.05). Thus, in contrast to its effect on coronary vascular tone, 
the GLIB-induced improvement of post-ischemic cardiac function is not mediated 
through blockade of the KATP channel. Alternative mechanisms may be operative, such 
as uncoupling of mitochondrial respiratory chain, and thereby preconditioning the 
hearts against stunning.  
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INTRODUCTION 
 
Sulfonylurea derivatives are still the corner-stone in the treatment of diabetes mellitus 
type 2. By closing the ATP-sensitive K+ (KATP) channels in the pancreatic β cells, 
depolarization of the cell membrane triggers the opening of voltage-gated Ca2+ 
channels. The resulting influx of Ca2+ leads ultimately to the excretion of insulin 37, 38.  
Similar KATP channels exist in the cardiovascular system 45. During ischemia, 
myocardial KATP channels open due to a fall in intracellular ATP levels, thereby 
hyperpolarizing the membrane. This will result in less Ca2+ influx, reduced contractions 
and thereby energy saving 45, 67, 68.  
Opening of KATP channels delays ischemic cell death by preconditioning the hearts, 
which is prevented by the sulfonylurea derivative glibenclamide 74-78. In contrast, we 
and others have shown that, depending on the conditions, glibenclamide can preserve 
myocardial function 82-84, 196. This improved cardiac function may be due to the positive 
inotropic effects of increased intracellular Ca2+, resulting from blockade of KATP 
channels.  
Although myocardial KATP channel blocking may be involved in the observed 
protection of post-ischemic heart function, other mechanisms can also be active. It has 
been described that glibenclamide may attenuate the ischemia-induced intracellular 
acidosis, and thereby protect hearts against ischemia 82. Another possibility may be that 
glibenclamide uncouples mitochondrial oxidative phosphorylation 197, 198. It has been 
shown that uncoupling mitochondria with dinitrophenol (DNP) is protective against 
ischemia 199 and therefore the cardioprotection by glibenclamide can also be a result of 
uncoupling which is not related to its action on KATP channels. 
We hypothesized that if glibenclamide preserves post-ischemic myocardial function via      
KATP channels, its action should be reversed by KATP openers. On the other hand, if a 
mechanism unrelated to closure of KATP channels is active, the action of glibenclamide 
should be additive to KATP channel opening.  
To investigate this hypothesis, we used our isolated, working, erythrocyte perfused rat 
heart model, with a global ischemic insult of 12 min, leading to a situation of 
myocardial stunning. We tested the sulfonylurea derivative glibenclamide and two KATP 
channel openers: the aspecific opener pinacidil (sarcolemmal and mitochondrial) and 
the specific mitochondrial KATP channel opener diazoxide.  
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MATERIALS AND METHODS 
 
Reagent and experimental groups  
Glibenclamide and diazoxide were purchased from Sigma-Aldrich Chemie B.V., 
Zwijndrecht, The Netherlands. Pinacidil was kindly provided by Leo Pharmaceuticals, 
The Netherlands. In total 33 animals were used in nine experimental groups: vehicle 
(n=8); 4 µmol.L-1 glibenclamide (n=5), 1 µmol.L-1 pinacidil (n=5), 30 µmol.L-1 
diazoxide (n=5), and combinations of these drugs: pinacidil + glibenclamide (n=5) and 
diazoxide + glibenclamide (n=5).   
In a previous study from our department, 4 µmol.L-1 glibenclamide significantly 
improved post-ischemic cardiac function in our model 196. Concentrated drug solutions 
were infused into the system by a syringe with a computer-controlled pump (1:10). The 
vehicle composition in the syringe was as follows: 1 mmol.L-1 NaOH, 0.4% DMSO, 
0.8% NaCl and 1.5% bovine serum albumin (fraction V, ICN Biomedicals B.V., 
Zoetermeer, The Netherlands). The drug concentrations were free non-protein bound 
concentrations (measured by high-performance liquid chromatography (HPLC) analysis 
following equilibrium analysis 193. All drugs were highly bound to protein (sulfonylurea 
derivatives: 97.5 %, KATP channel openers: 40 %), and therefore we have quoted the 
free unbound concentrations. For example, a free concentration of 4 µmol.L-1 
glibenclamide was achieved using a total concentration of 160 µmol.L-1 
glibenclamide. 
 
Animal Model 
A more detailed description of the perfusion set-up has already been published 
elsewhere 174. Briefly, a male Wistar rat (400g nominal weight; 4-6 months old) was 
anesthetized with diethyl ether, the heart excised via thoractomy and placed in ice-cold 
buffer. The aorta was cannulated and Langendorff perfusion with buffer was started 
within 8-10 min after heart removal. Subsequently the left atrium was cannulated, 
pacing-wires were attached and the hearts were paced at around 360 bpm (pulse length 
= 1ms, voltage = 5 V). After checking for leaks, the system was switched to working 
configuration with erythrocyte suspension. Fluid columns were used to maintain the 
preload pressure at 2 kPa and the afterload pressure at  13 kPa. The buffer (95% O2 and 
5% CO2) and erythrocyte suspension (18% O2, 8% CO2 and the rest N2) were 
equilibrated using membrane oxygenators. The composition of the modified Krebs-
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Henseleit buffer solution was as follows: NaCl 118, CaCl2 3.0, KCl 4.7, NaHCO3 25, 
MgSO4 1.2, KH2PO4 1.2, Na2EDTA 0.5, Glucose 11.1 mmol.L-1 The erythrocyte 
suspension was prepared by washing heparinized bovine blood three times with 
physiological saline. For the erythrocyte suspension albumin was added to the same 
buffer solution to 1.5% by weight, followed by adding erythrocytes to a hematocrit of 
0.25. The free Ca2+ concentration in this composition was 1.6 mmol.L-1. The 
temperature of the heart and perfusate was maintained throughout the experiment at 
normothermia (38 ± 1 oC for rats).  
 
Experimental protocol & statistical analysis 
After an equilibrium period of approximately 15 min, baseline cardiac performance was 
assessed for 8 min by changing the preload pressure from 2.0 to 1.3 and 2.7 kPa, 
holding the afterload pressure constant at 13 kPa (baseline period). Secondly, 10 min 
infusion of drug was performed in Langendorff mode at a constant pressure of 13 kPa 
(pre-ischemic period), followed by 12 min of normothermic global ischemia by 
clamping the aortic line. Thereafter reperfusion was initiated in Langendorff mode for a 
period of 20 min, again with infusion of drug (post-ischemic period). Then the setup 
was switched back to working mode. Finally, cardiac performance was assessed for the 
second time in the same way as before (recovery period). In figure 4.1, a graphical 
representation of the coronary blood flow tracings during the whole protocol is shown, 
illustrating the protocol used. Cardiac performance was assessed by measuring cardiac 
output (aortic blood flow + coronary blood flow against constant pressure). All the data 
presented in the results section are based on the following data points in the different 
periods unless otherwise stated: baseline period  8th min, pre-ischemic period  10th 
min, post-ischemic period  20th min and recovery period  1st min. Aortic blood flow 
was measured using an ultrasound flow probe (Transonic Systems Inc., Ithaca, NY, 
USA) and coronary blood flow was measured by collecting and weighing the perfusate 
dripping off the heart. The coronary blood flow data collected during the pre-ischemic, 
post-ischemic and recovery periods were normalized to the baseline period coronary 
blood flow data. Functional loss was calculated by dividing the reduction in left 
ventricular output (aortic flow + coronary blood flow) in the recovery period by the left 
ventricular output in the baseline period. The results are presented as means ± standard 
error of the mean (SEM). Data were log transformed before statistical analysis. 
Differences in coronary blood flow, flow debt repayment and cardiac functional loss 
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were statistically tested using one-way ANOVA followed by a Bonferroni comparison 
test (correction for 12 tests). Statistical analysis was performed using Instat (version 
3.00, Graphpad Software Inc. San Diego, USA). Differences were considered to be 
statistically significant at P values lower than 0.05.  
Figure 4.1: Graph of the mean (± SEM) coronary blood flow throughout the whole experimental 
protocol (baseline, pre-ischemic, post-ischemic and recovery periods) of vehicle (open squares), 1 
µmol.L-1 pinacidil (open circles) and a combination of 1 µmol.L-1 pinacidil with 4 µmol.L-1 
glibenclamide (closed triangles). 
 
 
RESULTS 
 
Figure 4.1 shows a graphical representation of the baseline coronary blood flow, and of 
the effects of vehicle, 4 µmol.L-1 glibenclamide and 1 µmol.L-1 pinacidil on coronary 
blood flow before and after ischemia (baseline, pre-ischemic, post-ischemic and 
recovery periods). All the data presented below are based on the following data points 
in the different periods unless otherwise stated: baseline period  8th min, pre-ischemic 
period  10th min, post-ischemic period  20th min and recovery period  1st min.  
In table 4.1, the absolute baseline and recovery values are summarized for aortic blood 
flow and coronary blood flow.  
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Table 4.1: Effects of vehicle, 4 µmol.L-1 glibenclamide (Glib), 1 µmol.L-1 pinacidil (Pina), 30 µmol.L-1 
diazoxide (Dzx) and combinations of Glib with Pina/Dzx on cardiac hemodynamics at baseline and 
recovery periods. Absolute aortic blood flows and absolute coronary blood flows are shown. Data are 
presented as mean ± standard error of the mean (SEM).  
 Aortic blood flow 
(mL.min-1 ± SEM) 
Coronary blood flow 
(mL.min-1 ± SEM) 
 Baseline Recovery Baseline Recovery 
 
Vehicle (n=8) 
 
 
58.3 ± 3.1 
 
42.0 ± 2.7 
 
9.1 ± 0.4 
 
10.3 ± 0.7 
 
4 µmol.L-1 GLIB (n=5) 
 
1 µmol.L-1 PINA (n=5) 
62.8 ± 4.0 
 
68.8 ± 1.8 
61.4 ± 4.1 
 
61.0 ± 2.2 
8.7 ± 0.8 
 
8.2 ± 0.3 
7.1 ± 0.8 
 
12.8 ± 0.9 
30 µmol.L-1 DZX (n=5) 62.2 ± 1.8 51.0 ± 2.8 8.0 ± 0.9 17.2 ± 1.8 
     
GLIB + PINA (n=5) 66.4 ± 1.1 67.0 ± 1.1 6.5 ± 0.4 5.5 ± 0.4 
GLIB + DZX (n=5) 65.0 ± 1.5 61.6 ± 1.7 6.6 ± 0.8 6.3 ± 0.3 
     
 
In the following description, coronary blood flows are normalized to the baseline 
period. Opening the cardiovascular KATP channels by pinacidil or diazoxide resulted in 
a 2-3 fold increase in coronary blood flow during the pre-ischemic period (253.4 ± 23.8 
and 273.0 ± 24.8 % for pinacidil and diazoxide respectively versus 97.4 ± 3.1 % for 
vehicle, P<0.001). Post-ischemically similar increases were observed for both pinacidil 
and diazoxide (P<0.001). Treatment with glibenclamide resulted in a vasoconstrictive 
response, which was more pronounced during the post-ischemic period (38.3 ± 6.7 
versus 103.0 ± 6.6 %, P<0.001) compared with the pre-ischemic period (55.2 ± 4.5 
versus 97.4 ± 3.1 %, P<0.001). Glibenclamide completely abolished the pinacidil- and 
diazoxide-induced vasodilation (pre-ischemically: 93.7 ± 3.0 versus 253.4 ± 23.8 % 
(pinacidil, P<0.001) and 112.9 ± 14.3 versus 273.0 ± 24.8 % (diazoxide, p<0.001); 
post-ischemically: 91.9 ± 3.6 versus 235.6 ± 25.6 % (pinacidil, P<0.001) and 107.5 ± 
12.5 versus 269.3 ± 14.2 % (diazoxide, P<0.001)) (fig. 4.2).  
Pinacidil and diazoxide treatment both resulted in a decrease in cardiac function loss, 
which was similar in both groups, compared with vehicle (4.0 ± 1.5 (p<0.01) and 2.9 ± 
1.4 % (P<0.001) respectively versus 22.2 ± 2.9 % for vehicle).  
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Figure 4.2: Effect on coronary blood flow after drug treatment. The effects of vehicle,                         
4 µmol.L-1 glibenclamide (glib), 1 µmol.L-1 pinacidil (pina), 30 µmol.L-1 diazoxide (dzx)  and the 
combinations of pina/glib and dzx/glib are shown. White bars represent the pre-ischemic coronary 
blood flow (10th min pre-ischemic period) and gray bars represent the post-ischemic coronary blood 
flow (20th min post-ischemic period). Results are presented as mean ± standard error of the mean 
(SEM), ***=P<0.001 versus vehicle. =P<0.05 versus pina, =P<0.01 versus dzx. 
 
Glibenclamide treatment resulted in a similar decrease in cardiac functional loss as seen 
with pinacidil and diazoxide (4.3 ± 1.2 % versus 22.2 ± 2.9 % for vehicle, P<0.01). 
Interestingly, glibenclamide treatment in the combination with pinacidil resulted in 
additional protection compared with pinacidil treatment alone (0.6 ± 0.1 versus 4.0 ± 
1.5 %, P<0.05), while glibenclamide in the combination with diazoxide did not alter the 
observed protection of the individual components (fig. 4.3).  
 
 
DISCUSSION 
 
In the present study, coronary vasodilation after KATP channel openers was attenuated 
by glibenclamide indicating that the effect of glibenclamide on the coronary blood flow 
is mediated by closure of KATP channels. In contrast, openers of KATP channels as well 
as glibenclamide improved post-ischemic cardiac function. Therefore, the 
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glibenclamide-induced preservation of post-ischemic myocardial function in our model 
is not likely to occur through an effect on KATP channels.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: Percent of post-ischemic functional loss after drug treatment. The effects of vehicle (white 
bar), 4 µmol.L-1 glibenclamide (glib), 1 µmol.L-1 pinacidil (pina) and 30 µmol.L-1 diazoxide (dzx) 
(black bars) and combinations of pina/glib and dzx/glib (gray bars) are shown. Results are presented as 
mean ± standard error of the mean (SEM), *=P<0.05, **=P<0.01 and ***=P<0.001 versus vehicle. 
=P<0.001 versus pina.  
 
Model considerations & clinical relevance 
Effects of sulfonylurea derivatives on post-ischemic cardiac function are difficult to 
determine in a clinically relevant fashion. It is difficult to study these mechanisms in 
humans, so animal research facilitates exploration of the actions of glibenclamide. In 
the majority of these studies, isolated, perfused animal hearts were used. These models 
do have some avoidable limitations. These limitations have been discussed previously 
196. In short, first of all, most isolated hearts are perfused with crystalloid buffer, which 
may result in hypoxic areas in the heart 165. Furthermore, mostly protein is ommitted 
from the perfusate, which can lead to more edema in those hearts 166, and finally a 
Langendorff preparation is mostly used, which has been shown to be less sensitive to 
ischemic damage 166, 169, 170.  
Due to the reduced clinical relevance in the previous studies we performed the present 
study using an isolated working rat heart setup, which was perfused with a crystalloid 
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buffer, enriched with erythrocytes (improvement of oxygenation of the heart) and 
protein to improve interpretation of the coronary blood flow effects and functional 
recovery effects post-ischemically.  
 
Hemodynamic effects 
Coronary blood flow  
The increases in coronary blood flow during the pre-ischemic period (normoxia) 
observed after treatment with the KATP channel openers pinacidil and diazoxide are in 
close agreement with previous studies 46, 200-202. These increases can be explained by 
relaxation of the vascular smooth muscle cells due to hyperpolarization of the 
membrane. Glibenclamide at the supratherapeutic concentration of 4 µmol.L-1 
completely attenuated the vasodilator responses of pinacidil and diazoxide indicating a 
specific KATP channel mediated vasoactive effect. In addition to these results, treatment 
with glibenclamide alone resulted in a marked decrease of coronary blood flow, which 
has been shown by others 59, 60, 196, 203. Therefore, these observations show that KATP 
channels in the cardiovascular system are important in maintaining coronary blood flow 
during physiological situations. Post-ischemically the coronary blood flow showed 
similar effects to the treatment as pre-ischemically.  
 
Cardiac function 
The improvements of function seen with both pinacidil and diazoxide are similar to 
those found by others 81, 82, 200, 204, 205. For pinacidil, this can theoretically be explained (at 
least in part) by the opening of KATP channels, resulting in a K+ efflux and thus 
hyperpolarization of the myocardial membrane. This will subsequently lead to 
shortening of the action potential. This shortening of the action potential results in 
reduced contraction and thereby energy saving during ischemia. In this way, it will be 
protective for post-ischemic cardiac function 200. For diazoxide and also for pinacidil, 
this can be explained by the specific opening of mitochondrial KATP channels 69, 70, 81. 
Until now, no consensus has been reached on how exactly this opening of 
mitochondrial KATP channels results in protection of post-ischemic cardiac function. 
One possibility is that dissipation of mitochondrial membrane potential decreases the 
driving force for Ca2+ influx through the Ca2+ uniporter. This leads to prevention of 
mitochondrial Ca2+ overload protecting the hearts against ischemia and reperfusion 
injury 69, 70. Another possibility may be that the opening of mitochondrial KATP channels 
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results in increases in mitochondrial matrix volume and changed energetics, resulting in 
inhibition of ATP wastage 72.   
In addition, we found reduced cardiac functional loss after treatment with the 
sulfonylurea derivative glibenclamide. At the outset, we hypothesized that the 
improvement of post-ischemic cardiac function by glibenclamide in our model may be a 
result of a better inotropic state during reperfusion and a thereby improved cardiac 
output post-ischemically. If this hypothesis were true then treatment with the KATP 
channel openers pinacidil and diazoxide would result in a detrimental effect on cardiac 
function. The present study shows however, as described above, that treatment with 
pinacidil and diazoxide improves post-ischemic cardiac function and therefore, our 
hypothesis must be rejected.  
In addition to these findings, glibenclamide even further improved the post-ischemic 
cardiac function compared with pinacidil alone, definitely indicating that another 
mechanism than specific blockade of KATP channels is active. Several other 
mechanisms than blocking cardiac KATP channels may be involved in the 
glibenclamide-induced improvement of post-ischemic function. It has been shown that 
glibenclamide may attenuate the intracellular acidosis and deplete ATP faster during 
ischemia, indicating an inhibitory effect on glycolysis 82, 85. However, it has also been 
shown that intracellular ATP levels are preserved during ischemia by glibenclamide 
treatment 84.  
Another interesting possibility for the protective effects of glibenclamide in our model 
is that glibenclamide uncouples mitochondrial oxidative phosphorylation with a Kd of                     
4 µmol.L-1 197, 198. It has been reported that uncoupling of oxidative phosphorylation in 
cardiac mitochondria by the classical uncoupling agent dinitrophenol (DNP) also 
protects post-ischemic cardiac function, which supports the concept that stressful 
stimuli to the mitochondrion may result in cardioprotection, in the same way as 
ischemic preconditioning 199. Furthermore, both pinacidil and diazoxide have been 
shown to uncouple cardiac mitochondria 69, 70, 81, 206. The observed preservation of post-
ischemic cardiac function was similar for pinacidil and diazoxide in the present study. 
As stated above it is logically to ascribe the diazoxide-induced preservation to specific 
mitochondrial KATP channel opening, while for pinacidil also sarcolemmal KATP channel 
opening is involved. Glibenclamide had an additive effect on pinacidil-induced but not 
on diazoxide-induced preservation of post-ischemic cardiac function. This further 
indicates that the glibenclamide-induced preservation is possibly mediated at the 
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mitochondrial level. Therefore the observed improved post-ischemic cardiac function 
with both glibenclamide and KATP channel openers may be a result of the uncoupling of 
oxidative phosphorylation in mitochondria.  
 
Conclusion 
Opening of KATP channels as well as glibenclamide improves post-ischemic cardiac 
function in our model of mild global ischemia. This indicates that the glibenclamide-
induced improvement of post-ischemic cardiac function is not mediated specifically 
through closure of KATP channels. Therefore, other mechanisms for this improvement of 
post-ischemic function must be active, such as mitochondrial uncoupling. In contrast, 
the increases in coronary blood flow seen due to opening of vascular smooth muscle 
KATP channels, which can be attenuated by glibenclamide, indicate that the 
glibenclamide-induced reductions in coronary blood flow are indeed mediated through 
KATP channel blocking. 
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ABSTRACT 
 
This study determined the involvement of ATP-dependent K+ (KATP) channels in the 
adenosine- and dipyridamole-induced coronary vasodilation in rats. For this purpose, 
we used our isolated, erythrocyte perfused, working rat heart model.  
The effects of the following drugs were investigated in separate groups: 50 µmol.L-1 
adenosine, 5 µmol.L-1 dipyridamole, 4 µmol.L-1 glibenclamide (KATP channel blocker), 
adenosine+glibenclamide, dipyridamole+glibenclamide or vehicle alone (all n=5). 
Coronary blood flow and cardiac output were assessed before and after induction of 
ischemia. 
Pre-ischemically, coronary blood flow was 97.4 ± 3.1, 365.5 ± 42.4 and 340 ± 59.1 % 
for vehicle, adenosine and dipyridamole respectively (P<0.01 for adenosine and 
dipyridamole versus vehicle). Post-ischemically, coronary blood flow was 103.0 ± 6.6, 
340 ± 59.1 and 209.4 ± 26.8 % for vehicle, adenosine and dipyridamole respectively 
(P<0.001 for adenosine and dipyridamole versus vehicle). The adenosine-induced 
vasodilation was significantly attenuated in the presence of glibenclamide (pre-
ischemic: 192.1 ± 7.1 % versus 365.5 ± 42.4 %, P<0.01 and post-ischemic: 179.5 ± 
17.5 % versus 340.0 ± 59.1 %, P<0.05). In contrast, glibenclamide did not attenuate 
dipyridamole-induced vasodilation. Both adenosine, dipyridamole and glibenclamide 
reduced the functional loss. In contrast to adenosine, dipyridamole-induced protection 
against stunning was increased in the presence of glibenclamide. 
It can be concluded that KATP channels are involved in adenosine- but not in 
dipyridamole-induced vasodilation. KATP do not seem to be involved in adenosine and 
dipyridamole-induced protection against stunning. 
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INTRODUCTION 
 
Dipyridamole, a potent inhibitor of human equilibrative nucleoside transport 207, 208, is 
frequently used as a pharmacological tool to increase endogenous extracellular 
adenosine levels 209-211. Recently, we have shown that local infusion of dipyridamole 
into the human forearm vascular bed induced vasodilation, which is inhibited by the 
KATP channel blocker glibenclamide (unpublished observations). In contrast, the 
vasodilator response to local infusion of adenosine was not inhibited by KATP blockade. 
Using the same perfused forearm technique, both adenosine and dipyridamole-
induced vasodilation was inhibited by the adenosine receptor antagonist theophylline. 
We explained the differences in interaction with glibenclamide between adenosine and 
dipyridamole by postulating stimulation of adenosine receptors at different cell types: 
endothelial cells for adenosine and vascular smooth muscle cells for dipyridamole.  
However, dipyridamole may have opened KATP channels by actions that are not related 
to inhibition of nucleoside transport and subsequent stimulation of adenosine receptors 
by endogenous adenosine. Among these non-specific actions of dipyridamole are 
stimulation of prostacycline release 212, 213 and inhibition of phosphodiesterase 214-216.  
Therefore, we investigated the importance of these non-specific actions of dipyridamole 
in opening KATP channels. For this purpose, we studied the interaction between 
dipyridamole-induced coronary vasodilation and glibenclamide in isolated erythrocyte-
perfused working rat hearts 174, 196, a species in which the nucleoside transporter is not 
sensitive to dipyridamole (IC50 values 190 nmol.L-1 in humans and more than 10 
µmol.L-1 in rats respectively) 207. We used adenosine as a control vasodilator at a high 
concentration to overcome rapid uptake and metabolism of adenosine by the 
endothelium and to ensure stimulation of adenosine receptors on vascular smooth mucle 
cells 217-219. 
 
 
MATERIALS AND METHODS 
 
Reagent and experimental groups 
Glibenclamide, adenosine and dipyridamole were purchased from Sigma-Aldrich 
Chemie B.V., Zwijndrecht, The Netherlands. In total 33 animals were used in 6 
experimental groups: vehicle (n=8); 4 µmol.L-1 glibenclamide (n=5), 50 µmol.L-1 
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adenosine (n=5), 5 µmol.L-1 dipyridamole (n=5) and the combinations 
glibenclamide+adenosine (n=5) and dipyridamole+adenosine (n=5). Concentrated drug 
solutions were infused into the system by a syringe with a computer-controlled pump 
(1:10). The vehicle composition in the syringe was as follows: 1 mmol.L-1 NaOH, 0.4% 
DMSO, 0.8% NaCl and 1.5% bovine serum albumin (fraction V, ICN Biomedicals 
B.V., Zoetermeer, The Netherlands). The glibenclamide concentrations were free non-
protein bound concentrations (measured by HPLC analysis following equilibrium 
analysis) 193. 
 
Animal Model 
A more detailed description of the perfusion set-up has already been published              
elsewhere 174, 196. Briefly, a male Wistar rat was anesthetized with diethyl ether, the 
heart excised via thoracotomy and placed in ice-cold buffer. The aorta was cannulated 
and Langendorff perfusion with buffer was started within 8-10 min after heart removal. 
Subsequently the left atrium was cannulated, pacing-wires were attached and after 
checking for leaks, the system was switched to working configuration with erythrocyte 
suspension. Fluid columns were used to maintain the preload pressure at 2 kPa and the 
afterload pressure at 13 kPa. The buffer (95% O2 and 5% CO2) and erythrocyte 
suspension (18% O2, 8% CO2 and the rest N2) were equilibrated using membrane 
oxygenators. The composition of the modified Krebs-Henseleit buffer solution was as 
follows: NaCl 118, CaCl2 3.0, KCl 4.7, NaHCO3 25, MgSO4 1.2, KH2PO4 1.2, 
NaEDTA 0.5, Glucose 11.1 mmol.L-1 For the erythrocyte suspension albumin was 
added to the same buffer solution to 1.5% followed by adding erythrocytes to a 
hematocrit of 0.25. The free Ca2+ concentration in this composition was 1.6 mmol.L-1. 
The temperature of the heart and perfusate was maintained throughout the experiment at 
normothermia of a rat (38 oC).  
 
Experimental protocol & Statistical analysis 
All experiments started after an equilibrium period of approximately 15 min. Baseline 
cardiac performance was assessed for 8 min by changing the preload pressure from 2.0 
to 1.3 and 2.7 kPa, holding the afterload pressure constant at 13 kPa (baseline period). 
Secondly, 10 min infusion of drug was performed in Langendorff mode (non-working) 
with erythrocyte suspension (pre-ischemic period), followed by 12 min of 
normothermic global ischemia by clamping the aortic line. Thereafter reperfusion was 
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initiated in Langendorff mode for a period of 20 min, again with infusion of drug (post-
ischemic period). Then the setup was switched again to working mode. Finally, cardiac 
performance was assessed for the second time in the same way as before (recovery 
period). To illustrate the protocol used, figure 5.1 shows the relative coronary blood 
flow levels throughout the whole experimental protocol (baseline, pre-ischemic, post-
ischemic and recovery periods) for vehicle, 50 µmol.L-1 adenosine, and 50 µmol.L-1 
adenosine in combination with 4 µmol.L-1 glibenclamide. Coronary blood flow was 
measured by collecting and weighting the perfusate dripping off the heart. Aortic blood 
flow was measured using an ultrasound flow probe (Transonic Systems Inc., Ithaca, 
NY, USA). Cardiac performance was assessed by measuring cardiac output (aortic 
blood flow + coronary blood flow). The coronary blood flow data collected during the 
pre-ischemic, post-ischemic and recovery periods were normalized to the baseline 
period coronary blood flow data. Functional loss was calculated by dividing the 
reduction in left ventricular output (aortic flow + coronary blood flow) in the recovery 
period by the left ventricular output in the baseline period. 
Figure 5.1: Graphical representation of the coronary blood flow throughout the whole experimental 
protocol (baseline, pre-ischemic, post-ischemic and recovery periods) of vehicle (open circles), 50 
µmol.L-1 adenosine (closed squares), and 50 µmol.L-1 adenosine+ 4 µmol.L-1 glibenclamide (closed 
triangles). 
 
The results are presented as means ± standard error of the mean (SEM). All the data 
presented below are based on the following data points in the different periods unless 
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otherwise stated: baseline period  8th min, pre-ischemic period  10th min, post-
ischemic period  20th min and recovery period  1st min. Differences in coronary blood 
flow were tested by logarithmic transformation followed by an analysis of variance 
(ANOVA) with a post-hoc Bonferroni multiple comparison test. Differences in cardiac 
functional loss were statistically tested using an ANOVA followed by a Bonferroni 
multiple comparison test. Statistical analysis was performed using Instat (version 3.00, 
Graphpad Software Inc. San Diego, USA). Differences were considered to be 
statistically significant at P values (Bonferroni corrected) lower than 0.05 (two-sided). 
 
 
RESULTS 
 
Table 5.1 summarizes the absolute data on coronary blood flow as well as the data on 
aortic blood flow after administration of vehicle or drugs during the baseline and 
recovery periods. There were no significant differences in baseline values between the 
groups in either aortic blood flow or coronary blood flow values.  
 
Table 5.1: Effects of vehicle, adenosine (ADO), dipyridamole (DIPY), glibenclamide (GLIB) and the 
combinations ADO+GLIB, DIPY+GLIB on cardiac hemodynamics at baseline during recovery periods. 
Absolute aortic blood flows and absolute coronary blood flows are shown. Data are presented as mean 
± standard error of the mean (SEM). 
 Aortic blood flow 
(mL.min-1 ± SEM) 
Coronary blood flow 
(mL.min-1 ± SEM) 
 Baseline Recovery Baseline Recovery 
 
Vehicle (n=8) 
 
 
58.3 ± 3.1 
 
42.0 ± 2.7 
 
9.1 ± 0.4 
 
10.3 ± 0.7 
 
50 µmol.L-1 ADO (n=5) 67.4 ± 1.3 55.0 ± 1.6 7.1 ± 0.8 17.3 ± 1.3 
5 µmol.L-1 DIPY (n=5) 67.4 ± 0.8 48.8± 0.9 8.1 ± 0.7 16.2 ± 1.1 
 
4 µmol.L-1 GLIB (n=5) 
 
62.8 ± 4.0 
 
61.4 ± 4.1 
 
8.7 ± 0.8 
 
 
7.1 ± 0.8 
ADO + GLIB (n=5) 65.0 ± 1.3 59.0 ± 2.3 9.1 ± 1.5 11.2 ± 1.2 
DIPY + GLIB (n=5) 66.8 ± 1.2 57.6 ± 2.8 6.4 ± 0.6 12.1 ± 1.5 
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Figure 5.2 shows the normalized (to baseline period) maximal coronary blood flow 
effects at the end of the pre-ischemic and the post-ischemic periods. Adenosine 
administration resulted in a 3-4 fold increase in coronary blood flow both pre- and 
postischemically to 365.5 ± 42.4 % (p<0.001) and 340.0 ± 59.1 % (P<0.01) respectively 
compared with vehicle.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2: Coronary blood flow relative to baseline levels (% ± standard error of the mean (SEM) of 
all groups pre-ischemically (gray bars) and post-ischemically (black bars). ***=P<0.001, **=P<0.01, 
*=P<0.05 versus vehicle. ADO versus ADO+GLIB: P<0.01 pre-ischemically, P<0.05 post-
ischemically. 
0
100
200
300
400
500
***
***
*** ******
0
100
200
300
400
500
***
**
***
* *
Relative coronary blood flow (%) 
Vehicle    50 µmol.L-1   50 µmol.L-1    4 µmol.L-1           ADO/           DIPY/ 
                      ADO            DIPY          GLIB           GLIB            GLIB 
Chapter 5 
78 
Glibenclamide significantly attenuated the adenosine-induced vasodilation from 365.5 
± 42.4 % to 192.1 ± 7.1 % (P<0.01 pre-ischemically) and from 340.0 ± 59.1 to 179.5 ± 
17.5 % (P<0.05) post-ischemically). Dipyridamole also increased coronary blood flow, 
although to a lesser extent than adenosine, to 169.1 ±19.0 % (P<0.001) and 209.4 ± 
26.8 % (P<0.01) pre- and postischemically, respectively compared with vehicle. 
Glibenclamide did not have any effect on the dipyridamole-induced vasodilation. 
Glibenclamide treatment alone lowered coronary blood flow significantly both pre- and 
postischemically to 55.2 ± 4.5 % and 38.3 ± 6.7 % respectively (P<0.001).  
Figure 5.3 shows the cardiac functional loss calculated for all groups. Twelve minutes 
of normothermic global ischemia resulted in the vehicle group in a significant loss of 
cardiac function (22.2 ± 2.9 %). Adenosine reduced the cardiac functional loss 
significantly (to 3.0 ± 1.4 %, P<0.001), compared with vehicle. Dipyridamole also 
lowered cardiac functional loss (13.9 ± 0.6 % versus 22.2 ± 2.9 %, P<0.05).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3: Percentage of post-ischemic functional loss after vehicle, adenosine (ADO), dipyridamole 
(DIPY), glibenclamide (GLIB) and combinations (ADO+GLIB and DIPY+GLIB) treatment. Results 
are presented as mean ± standard error of the mean (SEM), **=P<0.01, *=P<0.05 versus vehicle. DIPY 
versus DIPY+GLIB: P<0.01. 
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% versus 13.9 ± 0.6 %, P<0.01). Glibenclamide alone also resulted in a reduced cardiac 
functional loss (4.3 ± 1.2 % versus 22.2 ± 2.9 %, P<0.001) compared with vehicle. 
 
 
DISCUSSION 
 
The present study shows that the adenosine-induced increases in coronary blood flow 
can be attenuated by glibenclamide, indicating that vascular smooth muscle KATP 
channels are involved in the adenosine-induced vasodilation. On the other hand, the 
dipyridamole-induced increases in coronary blood flow could not be attenuated by 
glibenclamide, indicating that in rats the mechanism of dipyridamole-induced 
vasodilation does not involve KATP channels.  
 
Vasodilation 
Adenosine is a very potent vasodilating agent acting via adenosine A2 receptors. This 
has been reported in several species 220-225. In the present study we found that 
administration of adenosine resulted in a three to four fold increase in coronary blood 
flow both at the end of the pre-ischemic period as well as at the end of the post-
ischemic period.  
The apparent contrast with our previous human study, in which we did not observe an 
interaction between adenosine and glibenclamide, is explained by differences in used 
concentration of adenosine. The relatively low concentration of adenosine in the human 
study are not sufficient to reach vascular smooth muscle cells in the presence of the 
metabolically active endothelium 217-219. In the current study, a 100 fold higher 
adenosine concentration was used, which probably resulted in sufficient amounts of 
adenosine at the vascular smooth muscle cell.  
Dipyridamole infusion also resulted in an increase of coronary blood flow, however to a 
lesser extent than adenosine both pre- and post-ischemically (two fold). In contrast, the 
dipyridamole-induced vasodilation was not inhibited by glibenclamide. It is known that 
dipyridamole inhibits nucleoside transport in humans but not in rats 207, 208. Therefore, 
this observation supports our hypothesis that dipyridamole-induced opening of KATP 
channels in the human forearm is related to its property to inhibit nucleoside transport. 
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Cardiac function loss 
The present study confirms that adenosine treatment is beneficial for the ischemic                 
heart 210, 211, 226-231. The exact mechanisms by which adenosine acts are still not 
completely understood. It has been clearly described that adenosine activates adenosine 
A1 receptors inducing a cascade of reactions leading to cardioprotection 227, 232-234. One 
of the proposed mechanisms is that the activation of adenosine A1 receptors results in 
activation of KATP channels on the myocardial membrane and thereby prevents Ca2+ 
overload during ischemia/reperfusion. The reports on this proposed mechanism are 
however not conclusive 232, 234-239. In the present study, adenosine was highly protective 
against the 12 min ischemic insult, which was not attenuated at all by glibenclamide. 
Treatment with glibenclamide alone also resulted in cardioprotection, which cannot be 
explained by the electrophysiological effects of KATP channel blockade 80. 
Glibenclamide might have certain metabolic effects 196, 240. These effects may be 
attenuation of lactate accumulation during ischemia 82 or preservation of intracellular 
ATP levels during ischemia 84. Therefore, no definite conclusions can be drawn about 
the involvement of KATP channels in the adenosine-mediated cardioprotection. 
Dipyridamole infusion also resulted in a significant protection against the ischemic 
insult. Because nucleoside transport inhibition by dipyridamole is not present in rats, 
another mechanism must be active. Dipyridamole increases cAMP levels by inhibition 
of PDEs 214, 216. It has been shown that the contractile dysfunction in cardiac stunning 
might be mediated in part by decreased levels of cAMP 241. Increases in cAMP levels 
protect and preserve the heart against post-ischemic dysfunction 242, 243. Therefore, the 
preservation of post-ischemic cardiac function in the presence of dipyridamole may be 
explained by inhibition of PDE and subsequent increases in cAMP. Glibenclamide 
further increased the dipyridamole-induced protection against stunning. This 
observation excludes a role for KATP channels in the protection of dipyridamole against 
stunning. 
 
Conclusion 
This study shows that the adenosine-induced vasodilation in the coronary circulation of 
the rat can be attenuated by glibenclamide, indicating that activation of vascular smooth 
muscle KATP channels are involved. In rats, as opposed to humans, the dipyridamole-
induced vasodilation cannot be attenuated by glibenclamide. This supports that 
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dipyridamole-induced opening of KATP channels in humans is related to its property to 
inhibit nucleoside transport.  
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ABSTRACT 
 
 
Previous research has shown that the sulfonylurea derivative glibenclamide may 
improve post-ischemic cardiac functional recovery. Although KATP channel blockade is 
a possible explanation for this observation, alternative mechanisms exist. Therefore, we 
simultaneously recorded cardiac function and the intracellular concentration of ATP, 
PCr, Pi and pH before and after ischemia in the presence of glibenclamide or vehicle.   
31P magnetic resonance spectroscopy on erythrocyte-perfused, isolated working rat 
hearts was performed. Glibenclamide 4 µmol.L-1 or vehicle alone was tested (both n=5). 
The following protocol was used: 8 min performance assessment, 10 min drug 
treatment, 12 min global ischemia, 20 min reperfusion with drug treatment and 8 min 
functional recovery assessment. 
Compared with vehicle, glibenclamide significantly decreased coronary blood flow             
(59.5 ± 7.0 % versus 94.3 ± 1.3 %, P=0.008), ischemia-induced cardiac functional loss        
(7.4 ± 1.3 % versus 18.8 ± 3.3 %; P=0.019) as well as the ichemia-induced intracellular 
acidosis (6.75 ± 0.01 v 6.43 ± 0.03 for vehicle, P=0.03).  
In conclusion, glibenclamide is able to reduce the myocardial functional loss after 
ischemia while preserving pH but not ATP levels during ischemia. This suggests that 
the beneficial response to glibenclamide is probably not the result of myocardial KATP 
channel blockade, but may be explained by inhibition of glycolysis.  
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INTRODUCTION 
 
Sulfonylurea derivatives, e.g. glibenclamide, are still the corner stone in the treatment 
of type 2 diabetes mellitus. The blood glucose lowering effect of these drugs is 
achieved by closing the so-called ATP-sensitive K+ (KATP) channels in the pancreatic β 
cells. This subsequently results in depolarization of the membrane and opening of 
voltage-gated Ca2+ channels. The resulting Ca2+ influx ultimately leads to insulin 
secretion by the pancreatic β cells 37, 38.  
Interestingly, KATP channels have also been discovered in the myocardium, and it has 
been shown that sulfonylurea derivatives are able to interact with these KATP channels 
45. During ischemia, myocardial KATP channels open due to a decrease of the ATP/ADP 
ratio, resulting in K+ efflux which in turn results in hyperpolarization of the myocardial 
membrane. The subsequent shortening of the action potential preserves energy 
utilization and in this way, the opening of myocardial KATP channels acts as an 
endogenous protective mechanism of the heart 45, 67, 68.  
Based on this endogenous role of myocardial KATP channels during ischemia, it is 
logical that blocking these channels with sulfonylurea derivatives does have an 
influence on the outcome of an ischemic insult, which has also been shown in several 
experimental models of ischemia. Glibenclamide may increase the post-ischemic infarct 
size and abolish the ischemic preconditioning-induced reduction in post-ischemic 
infarct size 74-78. This may be explained by counteracting of the above-described 
endogenous protective mechanism by glibenclamide, resulting in increased energy 
usage and therefore increased necrotic tissue. On the other hand, it has been shown that 
glibenclamide improves post-ischemic cardiac function 82-85, 196. This improvement of 
post-ischemic cardiac function may be explained by the positive inotropic effects of the 
higher intracellular Ca2+ levels due to blockade of the KATP channel. 
However, other mechanisms for glibenclamide-induced improvements of post-ischemic 
cardiac function can also be active. It has been shown that glibenclamide accelerates 
depletion of ATP levels and attenuates intracellular acidosis during ischemia, indicating 
an inhibitory effect on glycolysis 82, 85. Another possibility may be that the uncoupling 
effect of glibenclamide on mitochondrial oxidative phosphorylation is responsible for 
the effects of glibenclamide on post-ischemic cardiac function 197, 199. 
The goal of the present study was to investigate whether the effects of glibenclamide on 
post-ischemic cardiac function can be related to intracellular ATP measurements, and 
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so determine whether glibenclamide has an effect on the ischemia-induced ATP 
depletion. 
To study this, we used our isolated, perfused working rat heart model. We perfused the 
hearts using an erythrocyte-enriched perfusate to ensure adequate oxygen supply to the 
heart 165, 166 and to adequately interpret possible vasoactive effects of glibenclamide. A 
mild global ischemic insult was chosen to simulate a situation of myocardial stunning 
post-ischemically. The effects of glibenclamide on intracellular ATP, phosphocreatine 
(PCr), inorganic phosphate (Pi) and pH levels were monitored throughout the whole 
experimental protocol using 31P-magnetic resonance (MR) spectroscopy. 
 
 
MATERIALS AND METHODS 
 
Reagent and experimental groups 
Glibenclamide was purchased from Sigma-Aldrich Chemie, Zwijndrecht, The 
Netherlands. In total 10 animals were used in two experimental groups; vehicle (n=5) 
and 4 µmol.L-1 (n=5). In a previous study, 4 µmol.L-1 glibenclamide was shown to be 
cardioprotective in our model 196. Concentrated drug solutions were infused into the 
system by a syringe with a computer-controlled pump (1:10). The vehicle composition 
in the syringe was as follows: 1 mmol.L-1 NaOH, 0.4% dimethylsulfoxide (DMSO), 
0.8% NaCl and 1.5% bovine serum albumin (fraction V, ICN Biomedicals, Zoetermeer, 
The Netherlands). The drug concentration was the free non-protein bound concentration 
(measured by high-performance liquid chromatography (HPLC) analysis following 
equilibrium analysis 193). Glibenclamide is highly bound to protein (97.5%), and 
therefore we used the free unbound concentrations. So, the free concentration of 4 
µmol.L-1 glibenclamide was achieved using a total concentration of 160 µmol.L-1. 
 
Animal model 
A detailed description of the perfusion set-up has been published elsewhere 174, also 
using magnetic resonance spectroscopy 176. Briefly, a male Wistar rat (400g nominal 
weight, 4-6 months old) was anesthetized with diethyl ether, the heart excised via 
thoracotomy and placed in ice-cold buffer. The aorta was cannulated and Langendorff 
perfusion with buffer was started within 8-10 min after heart removal. Subsequently the 
left atrium was cannulated, and after checking for leaks the system was switched to 
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working configuration with erythrocyte suspension. Fluid columns were used to 
maintain the preload pressure at 2 kPa and the afterload pressure at 13 kPa.  
The buffer (95% O2 and 5% CO2) and erythrocyte suspension (18% O2, 8% CO2 and the 
rest N2) were equilibrated using membrane oxygenators. The composition of the buffer 
solution was as follows: NaCl 118, CaCl2 3.0, KCl 4.7, Na2HCO3 25, MgSO4 1.2, 
KH2PO4 1.2, Na2EDTA 0.5, Glucose 11.1 mmol.L-1. The erythrocyte suspension was 
prepared by washing heparinized bovine blood three times with physiological saline. 
For the erythrocyte suspension albumin was added to the same buffer solution to 1.5% 
followed by adding washed bovine erythrocytes to a hematocrit of 0.25. The free Ca2+ 
concentration in this composition was 1.6 mmol.L-1 as determined by blood gas 
analysis. The temperature of the heart and perfusate were maintained throughout the 
experiment at normothermia of a rat (38 ± 1 oC). In the magnet the temperature of the 
heart (in air) was maintained using a humidified system and temperature was measured 
inside the heart with Luxtron® fiber-optic probes 177.  
 
Experimental protocol  
After an initial 15  30 min stabilization period, which included the time required for 
tuning the magnetic resonance probe and shimming of the magnet, baseline cardiac 
performance was assessed for 8 min with a preload pressure of 2 kPa, holding the 
afterload pressure constant at 13 kPa (baseline period). Next, drug was infused for 10 
min in Langendorff mode at a constant pressure of 13 kPa (pre-ischemic period), 
followed by 12 min of normothermic global ischemia, achieved by clamping the aorta 
line. Thereafter, reperfusion was initiated in Langendorff mode for 20 min, again with 
infusion of drug (post-ischemic period). Then the set-up was switched back to working 
mode. Finally, cardiac performance was assessed for the second time in the same way 
as before (recovery period). Erythrocyte suspension perfusate was used throughout. In 
Fig. 6.1, a graphical representation of the coronary blood flow during the whole 
protocol is shown, illustrating the protocol used. Cardiac performance was assessed by 
measuring cardiac output (aortic blood flow + coronary blood flow against constant 
pressure). All the hemodynamic data presented in the Results Section are based on the 
following data points in the different periods unless otherwise stated: baseline period        
8th min, pre-ischemic period  10th min, post-ischemic period  20th min, and recovery            
period  1st min. Aortic blood flow was measured using an ultrasound flow probe 
(Transonic Systems Inc., Ithaca, NY, USA) and coronary blood flow was measured by 
Chapter 6 
88 
collecting and weighing the perfusate dripping off the heart. The coronary blood flow 
data collected during the pre-ischemic, post-ischemic and recovery periods were 
normalized to the baseline coronary blood flow data. Functional loss was calculated by 
dividing the reduction in left ventricular output (aortic flow + coronary blood flow) in 
the recovery period by the left ventricular output in the baseline period. 
Figure 6.1: Graphical representation of the relative coronary blood flow throughout the whole 
experimental protocol (baseline, pre-ischemic, post-ischemic and recovery periods) and the 
effects of vehicle (open circles) and 4 µmol.L-1 glibenclamide (closed triangles) on this. 
Results are presented as mean ± standard error of the mean (SEM). 
 
Magnetic Resonance (MR) spectroscopy 
MR spectroscopy experiments were performed using a 7.0 T magnet (Magnex 
Scientific, Abingdon, England) interfaced to a S.M.I.S. spectrometer (Surrey Medical 
Imaging Systems, Surrey, England) operating at 300.22 MHz for 1H and at 121.53 MHz 
for 31P. The horizontal magnet is equipped with a 150 mT/m shielded gradient set and 
has a free bore size of 120 mm. A solenoid coil was used with a diameter of 20 mm. 
Field inhomogeneity was adjusted by shimming on the water (1H) signal from the 
sample yielding line widths of 50-70 Hz. 31P MR spectra were acquired using a simple 
pulse and acquire sequence with a conventional hard 90 o RF pulse (=60 µs) with a 
repetition time of 4 s. The pulse sequence also generated trigger pulses to slightly over-
pace the heart (360 bpm) such that acquisition immediately preceded a pacing pulse to 
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minimize movement artifacts. 32 free induction decays (FIDs) were acquired and 
averaged resulting in a time resolution of 2 min, which gave an adequate signal-to-noise 
ratio for frequency domain analysis. The sweep width was 10 kHz and 512 data points 
were collected. The spectra obtained during the 8 min baseline and recovery periods (4 
time points per period, 128 FIDs total) were averaged. Also the 10 min pre-ischemic 
period spectra (5 time points, 160 FIDs total), and the last 14 min of the post-ischemic 
period (7 time points, 224 FIDs total) were averaged. During ischemia and the first 6 
min of reperfusion, 2 min spectra (32 FIDs) were used. 
Signals in 31P MR spectra were quantitated by iterative fitting of the time-domain signal 
with the variable projection method (VARPRO) and with appropriate prior knowledge 
for the ATP-multiplets 178, 179 using MRUI software (version 99.7). All the peak areas 
were obtained by fitting the spectral lines to Gaussian line shapes. All peaks were 
analyzed relatively to an external reference of methylene diphosphonic acid (resonating 
at 16 ppm), which is positioned adjacent to the heart in the coil. The ATP content was 
determined from the β-ATP intensity. Its baseline value was used as a reference for the 
phosphocreatine (PCr) and Pi levels. The chemical shift of the PCr-peak was set to 0 
ppm and the pH was calculated from the shift between PCr and inorganic phosphate 
(Pi) as described previously 180. 
 
Statistical analysis 
The hemodynamic results are presented as mean ± standard error of the mean (SEM). 
Differences in coronary blood flow and cardiac functional loss were statistically tested 
using Students t test. Differences in metabolic profiles were tested in different sections 
during the experiment. These sections are: baseline period (8 min  1 time point), pre-
ischemic period (10 min  1 time point), ischemic period (12 min  6 time points), post-
ischemic period (20 min  4 time points) and recovery period (8 min  1 time point). 
The baseline, pre-ischemic and recovery period differences were statistically tested for 
intergroup differences using Students t test. The ischemic and reperfusion periods were 
statistically tested using repeated measures analysis of variance, followed by a 
Students t test with Bonferroni correction for intergroup differences. Statistical 
analysis was performed using SPSS (version 8.0.0, SPSS inc., USA). Differences were 
considered to be statistically significant at P values lower than 0.05.  
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RESULTS 
 
Hemodynamic readings 
Fig. 6.1 shows a graphical representation of the coronary blood flow before and after 
ischemia (baseline, pre-ischemic, post-ischemic and recovery periods) for 4 µmol.L-1 
glibenclamide or vehicle. As shown in table 6.1, there are no differences in baseline 
aorta flow or coronary blood flow between groups.  
 
Table 6.1: Hemodynamic effects of vehicle and glibenclamide at baseline and recovery periods. 
Absolute aortic blood flow and absolute coronary blood flow are shown. Data are presented as mean ± 
standard error of the mean (SEM). 
 Vehicle  
(n=5) 
4 µmol.L-1 glibenclamide  
(n=5) 
 
Aortic blood flow (mL.min-1) 
  
Baseline 38.6 ± 1.3 40.8 ± 2.3 
Recovery 27.6 ± 1.6 40.2 ± 2.4 
 
Coronary blood flow (mL.min-1) 
  
Baseline 7.3 ± 1.3 10.1 ± 1.0 
Recovery 9.8 ± 1.4 6.9 ± 0.9 
   
 
 
The 10-min pre-ischemic infusion of 4 µmol.L-1 glibenclamide decreased the coronary 
blood flow to 59.5 ± 7.0 % of control versus 94.3 ± 1.3 % for vehicle (P=0.008). During 
the post-ischemic period, the glibenclamide-induced reduction in coronary blood flow 
is even more pronounced (45.6 ± 5.4 % versus 104.4 ± 5.9 % for vehicle, P<0.0001) 
(Fig 6.2A). During the recovery period the coronary blood flow increases seen with 
vehicle (due to the higher metabolic demand) are significantly lower in the 
glibenclamide group (68.9 ± 7.8 % versus  137.4 ± 10.2 %, P=0.0007) (Fig 6.2A).  
The 12-min global ischemic insult resulted in a significant amount of cardiac functional 
loss (18.8 ± 3.3 %), which was significantly reduced by glibenclamide (7.4 ± 1.3 %, 
P=0.019) (Fig 6.2B).  
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Figure 6.2: Hemodynamic changes induced by vehicle (gray bars) and 4 µmol.L-1 glibenclamide (black 
bars). Effects on coronary blood flow in the pre-ischemic, post-ischemic and recovery period relative to 
baseline values are shown in panel A. Effects on post-ischemic cardiac functional loss are shown in 
panel B. Cardiac functional loss is expressed as post-ischemic cardiac function (aorta flow + coronary 
blood flow) relative to pre-ischemic cardiac function. Data are represented as mean ± standard error of 
the mean (SEM). * = P<0.05, ** = P<0.01 and *** = P<0.001 compared with vehicle. 
 
Metabolic readings 
Fig. 6.3 shows representative spectra of one experiment in presence of 4 µmol.L-1 
glibenclamide. During the baseline period, no significant differences in relative Pi, PCr 
and ATP levels were observed between vehicle and 4 µmol.L-1 glibenclamide (Fig. 
6.4A,B&C). The calculated ATP:PCr ratios were also comparable (vehicle: 0.66 ± 0.07 
versus 0.59 ± 0.04 for glibenclamide). The Pi level was significantly higher during pre-
ischemic period in the vehicle group compared with the glibenclamide group           
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(0.97 ± 0.27 versus 0.31 ± 0.10, P=0.05) (Fig. 6.4A), while for PCr and ATP there were 
no differences during the pre-ischemic period (Fig 6.4B&C). The calculated 
intracellular pH was not significantly different between groups during either baseline or 
pre-ischemic periods (Fig. 6.4D).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
During the ischemic period, the rise in relative Pi levels and the drop in relative PCr and 
ATP levels were not significantly different between vehicle and glibenclamide (Fig 
6.4A&B). The ischemia-induced drop in intracellular pH was significantly attenuated in 
ATP 
PCr 
Pi 
PPM 
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C 
Figure 6.3: Representative 31P-magnetic
resonance spectra of A) baseline, B) ischemia
and C) recovery periods after 4 µmol.L-1
glibenclamide treatment. Peaks of inorganic
phosphate (Pi), phosphocreatine (PCr) and
ATP are shown.  
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the glibenclamide group compared with the vehicle group (P=0.03), with a final pH 
after 12 min ischemia of  6.75 ± 0.05 versus 6.43 ± 0.06 (P=0.03) (Fig. 6.4D).  
During the post-ischemic and recovery periods the relative PCr and ATP levels were 
similar in both groups (Fig. 6.4B&C). Relative Pi levels were significantly higher post-
ischemically in the vehicle group compared with the glibenclamide group (P=0.01), 
although during the recovery period the Pi levels were similar again (Fig. 6.4A). No 
significantly different intracellular pH levels were observed during the post-ischemic 
and recovery periods between in either group. (Fig 6.4D).  
 
  
DISCUSSION 
 
Glibenclamide reduces coronary blood flow, which may be completely attributed to 
vascular KATP channel blockade. Furthermore, glibenclamide improves post-ischemic 
cardiac function preserving intracellular pH but not intracellular ATP levels during 
ischemia. This suggests that the beneficial response to glibenclamide is probably not the 
result of myocardial KATP channel blockade, but may be explained by inhibition of 
glycolysis. 
 
Model considerations & clinical relevance 
Effects of sulfonylurea derivatives on post-ischemic cardiac function are difficult to 
determine in a clinically relevant fashion. It is difficult to study these mechanisms in 
humans, so animal research facilitates exploration of the actions of glibenclamide. In 
the majority of these studies, isolated, perfused animal hearts were used. These models 
do have some avoidable limitations. These limitations have been discussed previously 
196. First of all, most isolated hearts are perfused with crystalloid buffer, to provide 
oxygen and metabolic supplies to the heart. However it has been shown previously that 
perfusing hearts with crystalloid buffer, without the presence of an oxygen carrier (e.g. 
hemoglobin) results in higher coronary blood flow levels (near maximal vasodilation); 
in fact, hearts are at the brink of being hypoxic during normal baseline situations 165. 
This is illustrated by the 3-fold decline in coronary blood flow levels after switching 
from crystalloid perfused buffer to erythrocyte-enriched crystalloid buffer in our setup 
165. Therefore interpretation of ischemia-induced and vasoactive effects is much more 
difficult because baseline registrations are not completely free of ischemia. A second 
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point of importance is the lack of protein in crystalloid perfused hearts. The presence of 
protein is needed to avoid edema 166, and also reflects the in vivo condition of patients 
treated by sulfonylurea derivatives more precisely than protein free perfusion fluid. 
Sulfonylureas are highly protein bound drugs (>98%) and the dynamic equilibrium 
between the bound and the active non-bound fraction of the drugs is also applying to 
our model. Also the isolated heart model mostly used is the so called Langendorff heart 
setup instead of the preferable working heart setup. Because the working heart setup 
actually performs external work, this model is one step further in the direction of 
clinical relevance than the Langendorff heart setup. In addition it has been shown that 
the working heart is more sensitive to ischemic damage than the Langendorff heart 
setup 166, 169, 170.  
Due to the limited clinical relevance, conclusions from studies in the Langendorff 
model are restricted. Therefore, we performed the present study  using an isolated 
working rat heart setup, which was perfused with a crystalloid buffer, enriched with 
erythrocytes and protein to improve the clinical relevance of observations on coronary 
blood flow, functional recovery and metabolic effects post-ischemically.  
 
Hemodynamic effects 
Coronary blood flow 
The observed decrease in coronary blood flow after glibenclamide treatment during 
normoxia is consistent with previous observations in open-chest dogs 59, 60, and in 
isolated rat hearts 196. These observations suggest that the ion flux across KATP channels 
in vascular smooth muscle cells of coronary arteries contributes to baseline coronary 
vascular tone. Interestingly, the vasoconstrictor effect of the drug seemed to be more 
pronounced in the post-ischemic period. This agrees with the view that the open-state 
probability of KATP channels is higher during and after ischemia than under resting 
conditions 45, 67.  
Interpretation of the clinical relevance of the vasoconstrictor response to glibenclamide 
is difficult, because in the present study healthy rats were used instead of diabetic rats. 
Since diabetes impairs regional blood flow and many of these patients have coronary 
artery disease, the importance of the vasoconstrictor effect of the sulfonylurea 
derivatives may actually be underestimated in the present study.  
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Figure 6.4: Metabolic readings 
throughout the whole 
experimental protocol 
(baseline, pre-ischemic, post-
ischemic and recovery periods) 
of vehicle (open triangles) and 
4 µmol.L-1 glibenclamide 
(closed squares). In fig 6.4A 
the Pi levels are shown relative 
to the baseline ATP level. In 
fig 6.4B the phosphocreatine 
(PCr) levels are shown relative 
to the baseline ATP level. In 
fig 6.4C the relative ATP 
levels (β-ATP peak) are shown 
as a ratio to baseline level. In 
fig 6.4D the calculated 
intracellular pH is shown. 
Results are presented as mean 
± standard error of the mean 
(SEM). The rectangled areas 
represent the 12 min global 
ischemic interval and the 
discontinued lines discriminate 
between baseline/pre-ischemic 
and post-ischemic / recovery 
periods, respectively. 
 *=P<0.03 versus vehicle.  
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Furthermore, in this study, we used a concentration that is slightly higher than 
therapeutic, but we previously showed that with therapeutic concentrations of 
glibenclamide a vasoconstrictor response is also present, although to a lesser extent 196. 
 
Cardiac function 
Glibenclamide reduced the ischemia-induced loss of cardiac function in the present 
study. This was consistent with previous observations in isolated hearts 82-84, 196. 
Consistent with this, intracellular Pi levels were significantly lower post-ischemically 
due to glibenclamide treatment, also indicating an improved energetic status post-
ischemically. On the other hand, it has been found that glibenclamide increases the 
infarct size developing after ischemia and it can abolish the beneficial effect on infarct 
size due to ischemic preconditioning 74-78. The detrimental effect of glibenclamide on 
infarct size can be explained by the depolarization of the myocardial membrane. This 
results in an increase of Ca2+ influx, thereby prolonging the ischemia-induced 
shortening of the action potential and increasing energy utilization. In a situation of 
infarct development, this increased energy utilization is damaging to the heart.  
In the present study, intracellular pH was preserved by glibenclamide during ischemia, 
which is consistent with previous observations 82. In the study of Docherty et al. ATP 
levels were also depleted at a faster rate during ischemia by glibenclamide, and they 
concluded that inhibition of glycolysis during ischemia contributes to the protective 
mechanism of glibenclamide in their model, which was consistent with a previous 
observation 85. In addition, it has been shown that the involvement of lactate may be 
important in the observed reduction in functional loss in ventricular myocytes 195. In the 
present study ATP levels were not depleted at a significantly faster rate, but ATP levels 
were also not preserved during ischemia. Therefore, the present result may indicate that 
inhibition of glycolysis contributes to the observed protective mechanism of 
glibenclamide.  
Glibenclamide has been shown to uncouple mitochondrial oxidative phosphorylation 
with a Kd of 4 µmol.L-1 197. Furthermore, it has been shown that uncoupling of 
mitochondrial oxidative phosphorylation with the classical uncoupling agent 
dinitrophenol (DNP) also protects post-ischemic cardiac function, which supports the 
concept that stressful stimuli to the mitochondrion may result in cardioprotection, in the 
same way as ischemic preconditioning 199. In addition, it is believed that the protective 
effect of opening mitochondrial KATP channels is potentiated by uncoupling of the 
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oxidative phosphorylation 69, 70, 81, 206. When uncoupling of mitochondrial oxidative 
phosphorylation is an important contributor to the preservation of post-ischemic cardiac 
function in the present study, PCr or ATP levels should decline at a much faster rate 
during ischemia and recovery, which was not observed in this study. This therefore 
does not support a significant role for uncoupling of mitochondrial oxidative 
phosphorylation in our model. 
It has been proposed that glibenclamide preserves ATP levels during ischemia 84. By 
preserving intracellular ATP levels, hearts would be less energy depleted after 
ischemia, and therefore they might recover better. However, in the present study 
glibenclamide did not preserve intracellular ATP levels during ischemia, indicating that 
this does not play a role in the cardioprotection observed.   
Interestingly, the vasoconstrictor response to glibenclamide did not impair post-
ischemic cardiac function. Apparently, the resulting reduced coronary blood flow is 
high enough to support the improved myocardial function after ischemia. Our data 
suggest that the vasoconstrictive effect of glibenclamide is probably due to direct 
blockade of vascular smooth muscle KATP channels, while the improvement of post-
ischemic function is probably due to other mechanisms. Therefore, a possible 
detrimental effect of the reduction in coronary blood flow may be masked by other 
mechanisms triggered by glibenclamide. 
 
Future considerations 
Future experiments are needed to know whether the effects by glibenclamide reported 
in this study are specific to glibenclamide only. It would be very interesting to know 
what the effects of glimepiride, a newer sulfonylurea derivative, are on intracellular 
ATP levels. In a previous study of our department we showed that glimepiride also 
improved post-ischemic cardiac function as does glibenclamide 196. Furthermore is it of 
interest to compare the present results with data from 5-hydroxydecanoate, a specific 
mitochondrial KATP channel blocker. Differences would be expected because the 
effects of glibenclamide on intracellular pH in this study are likely to occur not through 
direct KATP channel blockade, while 5-hydroxydecanoate directly inhibits 
mitochondrial KATP channels.  
 
 
 
Chapter 6 
98 
Conclusion 
Glibenclamide reduces coronary blood flow both during normoxic and post-ischemic 
tissue perfusion, indicating that the coronary vasomotor action of glibenclamide is 
mediated by blockade of vascular KATP channels. Furthermore, glibenclamide improves 
post-ischemic cardiac function preserving intracellular pH but not intracellular ATP 
levels during ischemia. This suggests that the beneficial response to glibenclamide is 
probably not the result of myocardial KATP channel blockade, but may be explained, at 
least in part, by inhibition of glycolysis. 
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ABSTRACT 
 
The biguanide metformin is widely used for the treatment of type 2 diabetes mellitus. In 
the recently published United Kingdom Prospective Diabetes Study (UKPDS), it was 
shown that the use of metformin was associated with a reduction of macrovascular 
complications, this in contrast to other blood glucose lowering strategies. The present 
study determined whether metformin has direct beneficial effects on the heart. We 
tested the effects of metformin on cardiac functional recovery after a mild ischemic 
incident (stunning) in our isolated, erythrocyte perfused, working rat heart model.  
Three groups were tested: vehicle, 50 and 500 µmol.L-1 metformin (all n=6). In rats, a 
concentration of 50 µM has been shown to induce blood glucose lowering.  
Small metformin-induced increases in coronary blood flow during normoxia (pre-
ischemically) and during reperfusion (post-ischemically) were observed as compared 
with vehicle (P<0.05).  Both metformin concentrations significantly reduced cardiac 
functional loss induced by the 12 min global ischemic incident compared with vehicle 
(3.4 ± 1.0 % and 3.5 ± 0.6 % loss during metformin versus 10.7 ± 0.8 % during vehicle, 
P<0.001).  
This study clearly shows that metformin acutely improves cardiac function after a mild 
ischemic incident (stunning) in rats. 
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INTRODUCTION 
 
The biguanide metformin is widely used for the treatment of type 2 diabetes mellitus. 
Its mode of action remains not completely resolved. Major effects of metformin in 
humans are to decrease hepatic glucose output and to increase insulin-dependent 
peripheral glucose utilization 119.  Some recent studies provided evidence that 
metformin exerts its anti-diabetic effects through inhibition of complex 1 of the 
mitochondrial respiratory chain, resulting in restraining of hepatic gluconeogenesis, 
while increasing glucose utilization in peripheral tissues 126, 127. 
In the recent United Kingdom Prospective Diabetes Study (UKPDS) trial the use of 
metformin was associated with a reduction of macrovascular complications, while this 
was not the case with other blood glucose lowering strategies 244. Because diabetes 
mellitus type 2 patients have a 2-4 fold increased risk in developing cardiovascular 
disease and due to the promising results from the UKPDS trial, the effects of metformin 
on post-ischemic cardiac function are of particular importance.  
Therefore, the objective of the present study was to determine whether metformin has 
direct beneficial effects on the heart. We tested whether metformin was able to reduce 
the post-ischemic functional loss in our clinically relevant isolated working heart 
model. We used an erythrocyte-enriched perfusate to assure adequate oxygen supply to 
the tissue 166 and used a working configuration, because it is more sensitive to ischemic 
damage than a Langendorff configuration 170. We have chosen a mild ischemic incident 
resulting in a condition of myocardial stunning.  
 
 
MATERIALS AND METHODS 
 
Reagents 
The Principles of laboratory animal care (NIH publication no. 85-23, revised 1985) 
were followed, as well as the current version of the Dutch Law on the Protection of 
Animals. Metformin (dimethylbiguanide) was purchased from Sigma-Aldrich  B.V., 
Zwijndrecht, The Netherlands. In total 18 animals were used in 3 experimental groups 
(all n=6): vehicle; 50 and 100 µmol.L-1 metformin. In rats, the 50 µmol.L-1 metformin 
dose was shown to be therapeutic 134.  Concentrated drug solutions were infused into the 
system by a syringe with a computer-controlled pump (1:10). The vehicle composition 
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in the syringe was as follows: 1 mmol.L-1 NaOH, 0.4% DMSO, 0.8% NaCl and 1.5% 
bovine serum albumin (fraction V, ICN Biomedicals B.V., Zoetermeer, The 
Netherlands).  
 
Experimental setup 
A more detailed description of the perfusion set-up has already been published 
elsewhere 240. Briefly, a male Wistar rat (400 g nominal weight; 4-6 months old) was 
anesthetized with diethyl ether, the heart excised via thoracotomy and placed in ice-cold 
buffer. Then the heart is quickly attached to the aortic cannula and Langendorff 
perfusion (retrograde perfusion) with buffer was started within 8-10 min after heart 
removal. It has been shown that this time interval between heart removal and buffer 
perfusion does not induce metabolic compromise 245. Subsequently the left atrium was 
cannulated, pacing-wires were attached and the hearts were paced at around 360 bpm 
(delay time = 1 ms, voltage = 5 V). After checking for leaks, the system was switched 
to working configuration with erythrocyte suspension. After opening of the atrial line, 
the heart starts to eject and the retrograde line is closed. Fluid columns were used to 
maintain the preload pressure at 2 kPa and the afterload pressure at 13 kPa. The buffer 
(95% O2 and 5% CO2) and erythrocyte suspension (18% O2, 8% CO2 and the rest N2) 
were equilibrated using membrane oxygenators. The composition of the modified 
Krebs-Henseleit buffer solution was as follows: NaCl 118, CaCl2 3.0, KCl 4.7, 
NaHCO3 25, MgSO4 1.2, KH2PO4 1.2, NaEDTA 0.5, glucose 11.1 mmol.L-1. The 
erythrocyte suspension was prepared by washing heparinized bovine blood three times 
with physiological saline. For the erythrocyte suspension albumin was added to the 
same buffer solution to 1.5% followed by adding erythrocytes to a hematocrit of 0.25. 
The free Ca2+ concentration in this composition was 1.6 mmol.L-1 as determined by 
blood gas analysis. The temperature of the heart and perfusate was maintained 
throughout the experiment at normothermia of a rat (38 oC).  
 
Experimental protocol & Statistical analysis 
After an equilibrium period of approximately 15 min, baseline cardiac performance was 
assessed for 8 min with a preload pressure of 2 kPa, holding the afterload pressure 
constant at 13 kPa (baseline period). Next, 10 min infusion of drug was performed in 
Langendorff mode at a constant pressure of 13 kPa (pre-ischemic period), followed by 
12 min of normothermic global ischemia by clamping the aortic line. Thereafter 
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reperfusion was initiated in Langendorff mode for a period of 20 min, again with 
infusion of drug (post-ischemic period). Then the setup was switched again to working 
mode. Finally, cardiac performance was assessed for the second time in the same way 
as before (recovery period). In Fig. 7.1 a graphical representation of the coronary blood 
flow during the whole protocol is shown, illustrating the protocol used. Cardiac 
performance was assessed by measuring cardiac output (aortic blood flow + coronary 
blood flow against constant pressure). All the data presented in the results section are 
based on the following data points in the different periods unless otherwise stated: 
baseline period  8th min, pre-ischemic period  10th min, post-ischemic period  20th 
min and recovery period  1st min. These endpoints are chosen based on the fact that 
relative steady states are achieved. During switching from Langendorff mode in the 
post-ischemic period to working mode in the recovery period, a short period was 
present in order to achieve a steady-state situation at the 1st min in the recovery period.  
Figure 7.1: Graphical representation of the coronary blood flow effects throughout the whole 
experimental protocol (baseline, pre-ischemic, post-ischemic and recovery periods) of vehicle (open 
circles), 50 (open squares) and 500 µmol.L-1 metformin (closed triangles). The hearts were in working 
mode during the baseline and recovery periods, while they were in Langendorff mode (non-
working) during the pre- and postischemic periods. The endpoints of the several periods used are also 
indicated in the figure.  
 
Aortic blood flow was measured using an ultrasound flow probe (Transonic Systems 
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Inc., Ithaca, NY, USA) and coronary blood flow was measured by collecting and 
weighing the perfusate dripping off the heart. The coronary blood flow data collected 
during the pre-ischemic, post-ischemic and recovery periods were normalized to the 
baseline period coronary blood flow data. Functional loss was calculated by dividing 
the reduction in left ventricular output (aortic flow + coronary blood flow) in the 
recovery period by the left ventricular output in the baseline period.  
The results are presented as means ± standard error of the mean (SEM). Differences in 
coronary blood flow and cardiac functional loss were statistically tested using one-way 
analysis of variance (ANOVA) followed by a Bonferroni comparison test. The 
Bonferroni comparison test was only performed when the one-way ANOVA was 
significant. Statistical analysis was performed using Instat (version 3.00, Graphpad 
Software Inc. San Diego, USA). Differences were considered to be statistically 
significant at P values lower than 0.05.  
 
 
RESULTS 
 
Fig. 7.1 shows a graphical representation of the baseline coronary blood flow, and of 
the effects of vehicle, 50 and 500 µmol.L-1 metformin on coronary blood flow before 
and after ischemia (baseline, pre-ischemic, post-ischemic and recovery periods). The 
absolute data on coronary blood flow as well as the data on aortic blood flow after 
administration of vehicle or drugs during the baseline and recovery periods are 
summarized in table 7.1.  
 
Table 7.1: Effects of vehicle, 50 and 500 µmol.L-1 metformin on cardiac hemodynamics at baseline and 
recovery periods. Absolute aortic blood flows and absolute coronary blood flows are shown. Data are 
presented as mean ± standard error of the mean (SEM).  
 Aortic blood flow 
(mL.min-1 ± SEM) 
Coronary blood flow 
(mL.min-1 ± SEM) 
 Baseline Recovery Baseline Recovery 
 
Vehicle (n=6) 
 
69.2 ± 1.2 
 
59.8 ± 1.5 
 
5.9 ± 0.8 
 
7.2 ± 0.5 
50 µmol.L-1 Metformin (n=6)  66.2 ± 1.3 60.3 ± 1.7 5.3 ± 0.2 8.6 ± 0.5 
500 µmol.L-1 Metformin (n=6)  66.8 ± 1.2 60.8 ± 1.1 5.1 ± 0.5 8.6 ± 0.5 
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Figure 7.2: Hemodynamic changes induced by vehicle, 50 and 500 µmol.L-1 metformin. Effects on 
coronary blood flow relative to baseline values are shown in panel A. Effects on post-ischemic cardiac 
functional loss are shown in panel B. Cardiac functional loss is expressed as post-ischemic cardiac 
function (aorta flow + coronary blood flow) relative to pre-ischemic cardiac function. Data are 
represented as mean ± standard error of the mean (SEM). * = P<0.05, ** = P<0.01 and *** = P<0.001 
compared with vehicle. 
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The highest metformin concentration (500 µmol.L-1) significantly increased the pre-
ischemic coronary blood flow compared with vehicle (121.5 ± 6.6 % versus 103.4 ± 4.9 
%, P<0.05). Post-ischemically, both metformin concentrations significantly increased 
the coronary blood flow compared with vehicle (50 µmol.L-1 : 133.7 ± 1.8 % (P<0.05) 
and 500 µmol.L-1 : 142.7 ± 8.3 % (P<0.01) versus 108.9 ± 4.8 % for vehicle) (Fig 
7.2A).  
Interestingly, the peak post-ischemic vasodilation was significantly higher after 50 
µmol.L-1 metformin as compared with 500 µmol.L-1 metformin (465.0 ± 14.8 % versus 
329.2 ± 46.0 %, P<0.05). 
In the vehicle group, 12 min global ischemia induced a calculated loss of cardiac 
function of 10.7  ± 0.8 %. Both metformin concentrations reduced this loss of cardiac 
function to 3.4 ± 1.0 % and 3.5 ± 0.6 % as compared with vehicle (P<0.001). (Fig 
7.2B). 
 
 
DISCUSSION 
 
This study clearly shows that metformin in rats acutely reduces the ischemia-induced 
loss of cardiac function in rats. This already occurred in a concentration that has shown 
to be therapeutic in the diabetic rat. Additionally, metformin treatment results in a slight              
post-ischemic vasodilator effect. 
In the recent UKPDS, metformin was shown to be the only blood glucose lowering 
drug which was associated with a reduction in macrovascular complications 244. Two 
meta-analyses of five and eleven randomized studies, respectively, confirm this 
beneficial effect on macrovascular complications 137, 138. In the present study, acute 
administration of metformin reduced the cardiac functional loss induced by a short 
ischemic incident (stunning). To our knowledge, no other studies are available studying 
acute effects of metformin on post-ischemic cardiac function. Interestingly,  Verma et 
al. showed that metformin improves cardiac function in isolated streptozocin-diabetic 
rat hearts under conditions of increasing preload, however in control hearts no response 
to metformin was found 134. Nevertheless, the responses of the heart to increased stress 
and to ischemia are different in several aspects, and therefore our results are difficult to 
compare with those of Verma et al.  
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Recently two studies were performed showing that metformin induces its anti-diabetic 
effect by inhibiting complex 1 of the mitochondrial respiratory chain in isolated 
hepatocytes 126, 127. It was found that inhibition was already present after 5 min 
incubation of isolated hepatocytes with 50 µmol.L-1 metformin. We speculate therefore 
that the acute post-ischemic cardioprotection is also based on a similar effect in the 
myocytes. By mild inhibition of complex 1 of the mitochondrial respiratory chain in 
myocytes, free radical production during ischemia/reperfusion by the respiratory chain 
may also be inhibited, possibly resulting in less membrane damage and less impairment 
of the contractile mechanism, thereby improving post-ischemic cardiac function. On the 
contrary, inhibition of the mitochondrial respiratory chain can also be detrimental 
because of the slower rate of ATP repletion during reperfusion, and thereby worsening 
the energetic state during the recovery period. A slight vasodilator effect of metformin 
was also observed, therefore the improved post-ischemic cardiac function may also be a 
result of increases in flow, thereby restoring the metabolic status of the heart more 
rapidly. Because no insulin was present in the perfusate, it is unlikely that the protective 
effect was caused by an insulin-enhancing effect, like enhancement of glucose-uptake. 
Interestingly, the peak post-ischemic vasodilation was higher after 50 µmol.L-1 
metformin as compared with 500 µmol.L-1 metformin. A possible explanation for this 
could be that the post-ischemic vasodilation is at least partly due to shear stress-induced 
production of endothelial NO 246-248. Metformin could lower ATP repletion after 
ischemia in endothelial cells due to the inhibition of complex 1 of the mitochondrial 
respiratory chain and thus impairing intracellular signalling the shear stress is causing 
NO synthesis through 126, 127. Therefore the higher metformin dose, which is more able 
to inhibit the mitochondrial respiratory chain results in less peak post-ischemic 
vasodilation as compared with the low dose of metformin. However, it cannot be 
excluded that metformin has a direct effect on the vascular smooth muscle cells.  
In conclusion, metformin appears to have direct beneficial effects on the heart in rats. If 
this also holds for the human setting such an effect may contribute to the observed 
cardiovascular effects in clinical trials, although caution must be taken in transfering 
experimental results in animals to results observed in clinical trials.  
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ABSTRACT 
 
This study determined whether insulin at pre- (fasting) and postprandial concentrations 
increases coronary blood flow and improves cardiac function after acute ischemia 
during a situation of myocardial stunning. The experiments were performed using an 
isolated, erythrocyte perfused, working rat heart model. To the perfusate we added 
erythrocytes and 1.5% bovine serum albumin to improve clinical relevance. The 
following protocol was used: 8 min baseline performance assessment, 10 min pre-
ischemic treatment, 12 min global ischemia, 20 min post-ischemic treatment and 8 min 
recovery assessment. Vehicle, 10 mIU.L-1 and 100 mIU.L-1 human insulin were tested 
(all n=6). No significant vasodilator response to insulin was observed either pre- or 
postischemically. After the 12 min ischemic insult, cardiac function returned dose-
dependently to pre-ischemic values (function loss with 100 mIU.L-1 insulin: -0.2 ± 
0.4% versus vehicle: 10.7 ± 0.8%, P<0.001). This study clearly shows that in our 
clinically relevant model of moderate ischemia (stunning), insulin is highly 
cardioprotective at physiological concentrations. This may be explained primarily by 
higher glucose uptake, improving the myocardial energetic state during ischemia. 
Therefore, insulin should be considered for use when the myocardium is at acute risk 
for ischemic incidents. 
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INTRODUCTION 
 
The ischemic myocardium has several endogenous mechanisms to protect itself against 
damage. One of these metabolic defenses against ischemia-induced injury is myocardial 
stunning. Ischemia is basically a metabolic problem, usually caused by coronary artery 
disease (CAD), by lack of oxygen and blood flow. Revascularization is of course very 
important as therapy in this patient group, however metabolic therapy should also be 
considered 249, 250.  
In recent years, it has been shown that insulin may have important cardiovascular 
effects as well as metabolic actions. Some of these effects are peripheral vasodilation, 
stimulation of the sympathetic nervous system and antinatriuresis 251. Since their 
introduction in 1965 by Sodi-Pollares, glucose-insulin-potassium (GIK) solutions have 
been used to protect against ischemia-induced damage 156. Recently, GIK solutions 
underwent a resurgence of interest, partly due to promising results in a large 
Argentinean trial with CAD patients 158. The hypothesis for this protective effect is that 
the myocardium prefers glucose as a substrate instead of fatty acids during a period of 
ischemia. In the beneficial effect of GIK, insulin itself has several effects; which are 
promotion of glycolysis and inhibition of circulating fatty acids and hence fatty acid 
oxidation 249. There is also accumulating evidence that insulin acts as a vasoactive 
peptide in the coronary circulation.  Several groups have found increases in myocardial 
blood flow following euglycemic insulin infusion, both in animals 146, 150 and in    
humans 151, 152.  
Usually GIK solutions have supraphysiological insulin (and glucose/potassium) 
concentrations but the effects of physiological (pre- and postprandial) insulin 
concentrations have been studied less frequently. Furthermore, it should be emphasized 
that the majority of studies focus on infarct size, while it is also of particular interest 
whether cardiac functional recovery after a mild ischemic incident (resulting in 
reversible damage, e.g. stunning) is also improved after insulin treatment. Therefore, we 
used our isolated working rat heart model to assess the effects of physiological insulin 
concentrations on post-ischemic cardiac functional recovery. We perfused the hearts 
using an erythrocyte-enriched perfusate to ensure adequate oxygen supply to the heart 
165, 166 and to adequately interpret possible vasodilatory effects of insulin. A mild global 
ischemic insult was chosen to simulate a situation of myocardial stunning post-
ischemically.   
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We hypothesize that physiological insulin treatment leads to small increases in coronary 
blood flow both during normoxic and post-ischemic (reactive hyperemic) myocardial 
perfusion, and also that it will lead to acute improvements in cardiac functional 
recovery.  
 
 
MATERIALS AND METHODS 
 
Reagent and experimental groups  
Insulin (Actrapid) was purchased from NOVO Nordisk Pharma B.V., Alphen a/d Rijn, 
The Netherlands. In total 18 animals were used in 3 experimental groups (all n=6): 
vehicle; 10 mIU.L-1 (70 pmol.L-1) and 100 mIU.L-1 (700 pmol.L-1) insulin. 
Concentrated drug solutions were infused into the system by a syringe with a computer-
controlled pump (1:10). The vehicle composition in the syringe was as follows: 1 
mmol.L-1 NaOH, 0.4% DMSO, 0.8% NaCl and 1.5% bovine serum albumin (fraction V, 
ICN Biomedicals B.V., Zoetermeer, The Netherlands) containing 1-2 mg per g protein. 
This results in a concentration of 50  100 µmol.L-1 fatty acids in the perfusate.  
 
Animal Model 
A more detailed description of the perfusion set-up has already been published           
elsewhere 174, 176. Briefly, a male Wistar rat (400g nominal weight, 4-6 months old  
normally fed prior to study) was anesthetized with diethyl ether, the heart excised via 
thoractomy and placed in ice-cold buffer. The aorta was cannulated and non-circulating 
Langendorff perfusion with buffer was started within 8-10 min after heart removal. 
Subsequently the left atrium was cannulated, pacing-wires were attached and after 
checking for leaks the system was switched to circulating working configuration with 
erythrocyte suspension. Fluid columns were used to maintain the preload pressure at 2 
kPa and the afterload pressure at 13 kPa. The buffer (95% O2 and 5% CO2) and 
erythrocyte suspension (18% O2, 8% CO2 and the rest N2) were equilibrated using 
membrane oxygenators. The composition of the modified Krebs-Henseleit buffer 
solution was as follows: NaCl 118, CaCl2 3.0, KCl 4.7, NaHCO3 25, MgSO4 1.2, 
KH2PO4 1.2, NaEDTA 0.5, Glucose 11.1 mmol.L-1 For the erythrocyte suspension 
albumin was added to the same buffer solution to 1.5% followed by adding erythrocytes 
to a hematocrit of 0.25. The free Ca2+ concentration in this composition was 1.6 
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mmol.L-1. The temperature of the heart and perfusate was maintained throughout the 
experiment at normothermia of a rat (38 oC).  
 
Experimental protocol & statistical analysis 
After an equilibrium period of approximately 15 min, baseline cardiac performance was 
assessed for 8 min by changing the preload pressure from 2.0 to 1.3 and 2.7 kPa, 
holding the afterload pressure constant at 13 kPa (baseline period). Secondly, 10 min 
infusion of drug was performed in Langendorff mode (pre-ischemic period), followed 
by 12 min of normothermic global ischemia by clamping the aortic line. Thereafter 
reperfusion was initiated in Langendorff mode for a period of 20 min, again with 
infusion of drug (post-ischemic period). Then the setup was switched again to working 
mode. Finally, cardiac performance was assessed for the second time in the same way 
as before (recovery period). Erythrocyte suspension perfusate was used throughout the 
whole experimental protocol. In Figure 8.1 coronary blood flow tracings during the 
whole protocol are shown for different drugs, illustrating the protocol used. Cardiac 
performance was assessed by measuring cardiac output (aortic blood flow + coronary 
blood flow).  
Figure 8.1: Coronary blood flow tracings throughout the whole experimental protocol (baseline,            
pre-ischemic, post-ischemic and recovery periods) of vehicle (open circles), 10 mIU.L-1 insulin (closed 
triangles), and 100 mIU.L-1  insulin (open squares). Data are represented as mean ± standard error of the 
mean (SEM). 
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Aortic blood flow was measured using an ultrasound flow probe (Transonic Systems 
Inc., Ithaca, NY, USA) and coronary blood flow was measured by collecting and 
weighting the perfusate dripping off the heart. The coronary blood flow data collected 
during the pre-ischemic, post-ischemic and recovery periods were normalized to the 
baseline period coronary blood flow data. Functional loss was calculated by dividing 
the reduction in left ventricular output (aortic flow + coronary blood flow) in the 
recovery period by the left ventricular output in the baseline period.  
The results are presented as mean ± standard error of the mean (SEM). Differences in 
coronary blood flow and cardiac functional loss were statistically tested using one-way 
ANOVA followed by a Bonferroni comparison test. Statistical analysis was performed 
using Instat (version 3.00, Graphpad Software Inc. San Diego, USA). Differences were 
considered to be statistically significant at P values lower than 0.05.  
 
 
RESULTS 
 
Figure 8.1 shows the time course of the mean coronary blood flow throughout the 
whole experimental protocol (baseline, pre-ischemic, post-ischemic and recovery 
periods) for vehicle, 10 and 100 mIU.L-1 insulin. All the data presented below are based 
on the following data points in the different periods unless otherwise stated: baseline 
period  8th min, pre-ischemic period  10th min, post-ischemic period  20th min and 
recovery period  1st min. 
Table 8.1 summarizes the absolute data on hemodynamic performance during baseline 
and recovery periods of all three groups. There were no significant differences in 
baseline values between the groups in either aortic blood flow or coronary blood flow 
values.  
Figure 8.2 shows the coronary blood flow during the pre- and postischemic period for 
vehicle, 10 and 100 mIU.L-1 insulin, normalized against coronary blood flow during the 
baseline period. No significant vasodilation properties were observed after insulin 
treatment pre- and postischemically. Notice that the glucose concentrations were 
constant throughout the insulin treatment (11 mmol.L-1).  
 
 
 
Chapter 8 
115 
Table 8.1: Effects of vehicle, 10 and 100 mIU.L-1 insulin on cardiac hemodynamics at baseline and 
recovery periods. Absolute aortic blood flows and absolute coronary blood flows are shown. Data are 
presented as mean ± standard error of the mean (SEM).  
 Aortic blood flow 
(mL.min-1 ± SEM) 
Coronary blood flow 
(mL.min-1 ± SEM) 
 Baseline Recovery Baseline Recovery 
 
Vehicle (n=6) 
 
69.2 ± 1.2 
 
59.8 ± 1.5 
 
5.9 ± 0.8 
 
7.2 ± 0.5 
10 mIU.L-1 insulin (n=6)  67.8 ± 1.7 61.7 ± 2.0 6.6 ± 0.5 9.5 ± 0.7 
100 mIU.L-1 insulin (n=6) 67.3 ± 1.4 65.5 ± 1.4 6.5 ± 0.4 8.5 ± 0.7 
     
     
Figure 8.3 shows the cardiac functional loss data, expressed in percentage of pre-
ischemic values. The 12 min global ischemic insult resulted in a moderate amount of 
damage of 10.7 ± 0.8%. The physiological pre-prandial (fasting) insulin concentration 
(10 mIU.L-1) reduced this to 4.3 ± 0.8% (P<0.001 compared with vehicle). The 
protective effect of the post-prandial insulin concentration (100 mIU.L-1) was even 
more pronounced, it completely returned post-ischemic function to pre-ischemic levels 
(-0.2 ± 0.4%, P<0.001 both compared with vehicle and with 10 mIU.L-1 insulin).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.2: Effects of vehicle, 10 and 100 mIU.L-1 insulin pre- (white bars) and post-ischemically         
(black bars) on coronary blood flow relative to baseline values. Data are represented as mean ± standard 
error of the mean (SEM). 
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DISCUSSION 
 
In the present study, insulin at physiological pre- and postprandial concentrations was 
able to preserve cardiac function dose-dependently after a moderate global ischemic 
insult. Furthermore, insulin did not induce increases in myocardial blood flow during 
the normoxic pre-ischemic period or during the reactive hyperemia postischemically at 
these physiological concentrations.  
Figure 8.3: Effects of vehicle, 10 and 100 mIU.L-1 insulin on post-ischemic cardiac functional loss. 
Cardiac functional loss is expressed as post-ischemic cardiac function (aorta flow + coronary blood 
flow) relative to pre-ischemic cardiac function. Data are represented as mean ± standard error of the 
mean (SEM). *** = P<0.001 compared with vehicle. 
 
Clinical relevance 
The isolated heart model is a very suitable model to study effects of metabolic 
interventions to preserve cardiac function during and after an ischemic incident, 
although it is very important to notice that the mostly used form of this model has some 
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normal baseline situations. This is illustrated by the 3-fold decline in coronary blood 
flow levels after switching from crystalloid perfused buffer to erythrocyte-enriched 
crystalloid buffer in our setup 165. Therefore, interpretation of ischemia-induced and 
vasoactive effects is much more difficult because baseline registrations are not 
completely free of ischemia. A second point of importance is the lack of protein in 
crystalloid perfused hearts. Protein is needed to avoid possible edema. Also the isolated 
heart model mostly used is the so-called Langendorff heart setup instead of the 
preferable working heart setup. Because the working heart setup actually performs 
external work, this model is one step further in the direction of clinical relevance than 
the Langendorff heart setup 169, 170. 
 
Hemodynamic insulin actions 
Although the action of insulin on the peripheral vasculature has been well documented 
141-144, it is not known whether insulin plays an important role in the regulation of 
myocardial blood flow both in health and disease. The absence of increases in 
myocardial blood flow induced by insulin in the present study is consistent with 
observations by Barrett et al. 146. In that study, insulin was also administrated using 
physiological concentrations. In neonatal lambs insulin treatment at supraphysiological 
concentrations induced increases in myocardial blood flow, however blood glucose 
levels were allowed to fall 147-149. Inducing euglycemic hyperinsulinemia Liang et al. 
were able to show that increases in myocardial blood flow were less pronounced than 
during a blood glucose lowering hyperinsulinemic period 150. Therefore, it is very 
important to discriminate between effects of insulin itself on myocardial blood flow or 
possible effects induced by insulin, like hypoglycemia.  
In humans, also contradictory results were found. In CAD patients and healthy subjects, 
both increases in myocardial blood flow due to insulin 151, 152 as well as no changes in 
myocardial blood flow were reported 153, 154. 
The present study clearly showed that insulin protected hearts against the moderate 
global ischemic insult after administration prior to the insult and continued during 
reperfusion. Interestingly, already at the baseline insulin concentration (fasting), insulin 
treatment resulted in a significant decrement in cardiac functional loss. This 
improvement in post-ischemic cardiac function is in close agreement with a study by 
Doenst et al. which showed that insulin at a post-prandial concentration was able to 
improve post-ischemic cardiac function in working rat hearts 159. In that study, 
Chapter 8 
118 
however, hearts were perfused with crystalloid buffer and insulin was only given post-
ischemically. Similar results to ours were also found in several other studies using GIK 
solutions to preserve hearts against ischemic dysfunction 156-158. However, these GIK 
solutions used insulin concentrations far higher than the physiological pre- and 
postprandial concentrations used in this study. Secondly, the effects of GIK solutions 
on post-ischemic cardiac function were mostly studied after a longer ischemic incident 
leading to infarct, rather than after a mild ischemic incident leading to a situation of 
myocardial stunning.  
It has been shown that physiological increases in insulin levels significantly increase 
myocardial glucose uptake in vivo 252, 253, however it is uncertain whether this can be 
fully attributed to a direct insulin action on the heart, as it can be partly explained by a 
reduction in circulating free fatty acids. Recently, McNulty showed that the insulin-
induced increases in myocardial glucose extraction in stable CAD patients were equally 
mediated by a reduction in free fatty acids and by direct insulin action on the heart itself 
254. Therefore, the cardioprotective effect of physiological fasting and post-prandial 
insulin concentrations in the present study is most likely explained by insulin-induced 
increases in myocardial glucose uptake, directly by insulin itself on the heart, thereby 
promoting glycolysis by translocating the glucose transporters GLUT4 and to a lesser 
extent GLUT1, increasing intracellular ATP levels 252, 253. Because the hearts were 
perfused in the present study without addition of fatty acids to the perfusate, the afore 
mentioned indirect effect of insulin cannot play an important role in the 
cardioprotection observed in this study. 
 
Limitations of this study 
In the present study, fatty acids were not added to the perfusate. However, as a result of 
the addition of albumin, which almost always contains bound free fatty acids, the final 
concentration of fatty acids in our perfusate was 50  100 µmol.L-1. As compared to 
experimental models where free fatty acids were added, the concentration of 100 
µmol.L-1 is negligible. In the in vivo setting, insulin lowers free fatty acids due to 
inhibition of lypolysis. Since this does not occur in vitro, addition of free fatty acids 
may result in an overestimation of its effect.  
In the present study, insulin was administered both prior and after the ischemic event. 
To determine whether the beneficial effect of insulin occurs during ischemia, after 
ischemia or both, further studies are necessary. However, the present study may still be 
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of relevance to clinical practice. In a number of cases insulin therapy can be given prior 
to an ischemic event, e.g. in patients with unstable angina pectoris, patients undergoing 
coronary artery bypass grafting (CABG) and in patients with an ongoing infarction and 
subsequent trombolytic therapy. 
 
Conclusion 
The present study clearly showed that physiological insulin concentrations were able to 
improve cardiac function in our clinically relevant model of myocardial stunning, 
without the presence of insulin-induced increases in myocardial blood flow. Therefore, 
preservation of hearts by insulin during open-heart surgery already at physiological 
post-prandial insulin concentrations must be considered. Furthermore, these results 
indicate that insulin may be an important contributing factor concerning the outcome of 
harmful cardiovascular events in the early morning (fasting insulin levels) as compared 
to daytime events (post-prandial insulin levels).  
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SUMMARY 
 
Coronary heart disease is a major complication of diabetes mellitus type 2. It represents 
the cause of death in more than half of the patients with this disease. The prevalence of 
type 2 diabetes is at least 2% in most countries, and its incidence is increasing due to 
aging population, to increasing prevalence of obesity and decreasing physical activity. 
The management of type 2 diabetes consists mainly of three treatment steps. In the first 
place diet and exercise, secondly, oral blood glucose lowering agents (e.g. sulfonylurea 
derivatives, biguanides, α-glycosidase inhibitors and thiazolidinediones derivatives) are 
prescribed for these patients and finally subcutaneous insulin treatment takes place 
possibly combined with oral blood glucose lowering agents. In this thesis, special 
emphasis is given to the cardiovascular effects of sulfonylurea (SU) derivatives. 
The mechanism of action of the SU derivatives (e.g. glibenclamide) consists of 
blocking the ATP-sensitive K+ (KATP) channels in the pancreatic β-cells, thereby 
depolarizing the plasma membrane. This results in an influx of Ca2+ through voltage-
gated Ca2+ channels, subsequently leading to excretion of insulin. Similar KATP 
channels also exist in the myocardium and in vascular smooth muscle cells, both 
located at the sarcolemmal and the mitochondrial membrane. During a period of 
myocardial ischemia, it has been clearly shown that both sarcolemmal and 
mitochondrial KATP channels open due to a fall in intracellular ATP levels. For 
sarcolemmal KATP channels this subsequently results in less Ca2+ influx and thereby 
energy saving. For mitochondrial KATP channels, no consensus has been reached yet on 
how exactly this opening of mitochondrial KATP channels results in protection of post-
ischemic cardiac function. One possibility is that dissipation of mitochondrial 
membrane potential decreases the driving force for Ca2+ influx, thereby preventing 
mitochondrial Ca2+ overload. Another possibility may be that increases in mitochondrial 
matrix volume and changed energetics by opening of mitochondrial KATP channels is 
involved, thereby inhibiting ATP wastage. So both the sarcolemmal and mitochondrial 
KATP channel opening due to myocardial ischemia results in endogenous preservation of 
post-ischemic cardiac function.  
It has been proposed that blocking these myocardial KATP channels during a period of 
ischemia counteracts this endogenous protective mechanism of the heart. Therefore, 
much research has been focusing on this topic in recent years, but there are still some 
controversies. Concerning epidemiological studies, it was shown in the 1970s in a 
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large-scale clinical trial, the UGDP, that type 2 diabetes patients allocated the SU 
derivative tolbutamide had a higher cardiovascular mortality. However, recently, the 
second large-scaled clinical trial, the UKPDS, showed no increased cardiovascular 
mortality in patients allocated SU derivatives. Compared with patients allocated 
metformin the UKPDS reported an increased cardiovascular mortality. 
Concerning experimental studies, it has been shown in several animal models that the           
SU derivative glibenclamide can increase infarct size following an ischemic insult, 
however concerning post-ischemic cardiac function the results are much less 
conclusive, both beneficial and detrimental effects on post-ischemic cardiac function 
having been described. Recently, it has been shown that the newly developed SU 
derivative glimepiride is more specific for the pancreatic β-cell and therefore less 
cardiovascular effects have been reported. In these animal studies (mostly isolated heart 
models), some avoidable limitations were present. Firstly, the isolated hearts used in 
these studies were usually perfused using a crystalloid buffer without the presence of 
erythrocytes or protein. It has been shown that perfusing hearts without erythrocytes 
may lead to hypoxic areas in these hearts due to the lower oxygen capacity of the 
buffer. By adding protein to the buffer, the amount of edema developing in the 
experiment can be minimized. Secondly, the isolated hearts were often perfused using 
the Langendorff preparation. It has been shown that the working heart preparation is 
much more physiological and more sensitive to ischemic damage than the Langendorff 
preparation. Because the working heart preparation actually performs work, its clinical 
relevance is much higher than the Langendorff preparation. Finally, a major point of 
importance is the use of unrealistically high concentrations of SU derivatives in these 
animal models, making interpretation of the results of these studies for clinical practice 
much more difficult.  
In the studies presented in this thesis, we assessed whether SU derivatives do have 
beneficial or harmful cardiovascular effects in our specific heart model. As described in 
the introduction this model has certain specific advantages for the topic of this thesis. 
Furthermore, we compared these effects with those of two other blood glucose lowering 
agents: metformin, a biguanide, and insulin. In these studies, we used an isolated, 
erythrocyte and protein perfused, working rat heart model and we chose an ischemic 
insult which resulted in reversible myocardial injury.  
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In Chapter 2, the vulnerability to ischemia of both the Langendorff and the working 
heart preparation was investigated using both hemodynamic and metabolic variables. 
Although it has been shown that the working heart preparation is more vulnerable than 
the Langendorff preparation, this has been investigated solely in crystalloid perfused 
hearts. Therefore, the present study was performed. The working heart preparation 
suffered more functional damage as compared with the Langendorff preparation, after a 
12 min global ischemic insult as would be expected due to the higher workload in these 
hearts. Interestingly, no differences in coronary blood flow characteristics either during 
baseline or during the reactive hyperemia was observed. The ischemia-induced acidosis 
was more severe in the working heart preparation compared with the Langendorff 
preparation. However, the recovery of high-energy phosphate levels was similar in both 
groups. From this study, therefore, it can be confirmed that the working heart 
preparation is more vulnerable to ischemic damage than the Langendorff preparation. 
This was however not accompanied by differences in high-energy phosphate levels 
between these groups.  
 
In Chapter 3, dose-response relationships of two SU derivatives were determined for 
their effect on coronary blood flow and on cardiac functional loss after 12 min global 
ischemia. The classical sulfonylurea derivative glibenclamide and the newer 
glimepiride were used. The results showed that both drugs dose-dependently decreased 
pre-ischemic (normoxic) coronary blood flow, already starting at concentrations that are 
slightly higher than therapeutic ones. Post-ischemically these decreases in coronary 
blood flow were even more pronounced than pre-ischemically. Glibenclamide 
decreased the cardiac functional loss at the supratherapeutic concentration of                  
4 µmol.L-1, while glimepiride decreased cardiac functional loss already at the 
therapeutic concentrations of 0.005 and 0.05 µmol.L-1.  
These results suggest that sulfonylurea derivatives do not harm the myocardium during 
or after ischemia. However, the vasoconstrictor properties of these drugs may have 
negative consequences for patients with a compromised coronary circulation. 
In Chapter 4, we hypothesized that the improved post-ischemic function observed with          
4 µmol.L-1 glibenclamide is due to higher intracellular Ca2+ levels because of blocking 
myocardial KATP channels. Blockade of myocardial KATP channels results in 
depolarization of the membrane, resulting in an increased Ca2+ influx. If this hypothesis 
were true, opening of these channels would result in a deleterious effect on post-
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ischemic cardiac function. To investigate this, we performed a series of experiments 
with 4 µmol.L-1 glibenclamide, two KATP channel openers: the specific mitochondrial 
KATP channel opener diazoxide and the aspecific KATP channel opener pinacidil, and 
with combinations of these. The results showed that the increases in coronary blood 
flow by both KATP channel openers were attenuated by glibenclamide. Both KATP 
channel openers improved post-ischemic cardiac function, as did glibenclamide. 
Interestingly, the combination of glibenclamide and pinacidil even further improved 
post-ischemic cardiac function as compared with the improvements seen with the 
individual components. These results therefore suggest that the effects of glibenclamide 
on the coronary vasculature are mediated primarily by KATP channel blockade, while 
contrary to our hypothesis the improvements in post-ischemic function by 
glibenclamide cannot be ascribed to KATP channel blockade.  
In Chapter 5, it was determined whether cardiovascular KATP channels are involved in 
the adenosine- and dipyridamole-induced cardiac hemodynamic changes prior to and 
after myocardial ischemia. It has been shown in several studies that adenosine receptors 
are linked to KATP channels and therefore the present study was performed. We tested 
adenosine, dipyridamole (not an adenosine uptake-inhibitor in rats) solely or in 
combination with glibenclamide. Both adenosine and dipyridamole significantly 
increased the coronary blood flow both during baseline conditions as during the post-
ischemic reactive hyperemia. Interestingly, the vasodilation response of adenosine 
could be attenuated by glibenclamide, while the dipyridamole-induced vasodilation 
remained similar in the presence of glibenclamide. Adenosine, dipyridamole and 
glibenclamide all reduced post-ischemic cardiac functional loss. In contrast to 
adenosine, dipyridamole-induced protection against ischemia was increased in the 
presence of glibenclamide. From these results, it can be concluded that KATP channels 
are involved in adenosine- but not in dipyridamole-induced vasodilation. Furthermore, 
KATP channels do not seem to be involved in adenosine- and dipyridamole-induced 
protection against ischemia. 
In Chapter 6, we determined whether the improved post-ischemic cardiac function by 
glibenclamide could be related to changes in high-energy phosphate metabolism. 
Therefore, we used 31phosphorus Magnetic Resonance Spectroscopy in combination 
with our isolated heart model. Both the hemodynamic effects and the effects of 
glibenclamide on intracellular ATP, phosphocreatine (PCr), inorganic phosphate (Pi) 
and pH were investigated. Glibenclamide at a concentration of 4 µmol.L-1, again 
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improved post-ischemic cardiac function, which was accompanied by a significant 
decrease in coronary blood flow pre- and postischemically. Glibenclamide attenuated 
the ischemia-induced acidosis, while showing no effects on intracellular ATP levels. 
The recovery of high-energy phosphates after ischemia was also similar with 
glibenclamide and vehicle. From these results, it can be suggested that the 
glibenclamide-induced improvements of post-ischemic cardiac function can be at least 
partly ascribed to inhibition of anaerobic glycolysis during ischemia.  
In Chapter 7, the hemodynamic effects of the biguanide metformin were determined 
prior to and after ischemia. In the large UKPDS trial, metformin was the only blood 
glucose lowering agent that reduced the number of macrovascular complications in 
patients suffering from type 2 diabetes. Therefore, we hypothesized that metformin 
would improve post-ischemic function. Both 50 and 500 µmol.L-1 metformin were 
tested. The concentration of 50 µmol.L-1  has been shown to be therapeutic in rats (5-
10× higher than in humans). The results showed that after ischemia the coronary blood 
flow remained slightly higher after treatment with metformin (both doses). The post-
ischemic cardiac functional loss was significantly decreased with both metformin 
concentrations. Therefore, metformin has beneficial effects on cardiac function after an 
ischemic insult. We speculated that inhibition of complex I of the mitochondrial 
respiratory chain might be involved in the protective mechanism of metformin. By 
inhibition of this complex, less free radical production during reperfusion may occur, 
resulting in improved post-ischemic cardiac function. It can be concluded that the 
protective effect of metformin in this study may contribute to the observed positive 
effects in clinical trials.  
In Chapter 8, the hemodynamic effects of pre- and postprandial insulin concentrations 
were determined using a 12 min global ischemic insult. The effects of physiological 
insulin concentrations on the heart itself were still poorly described. It was 
hypothesized that insulin would increase coronary blood flow, based on vasodilating 
properties of insulin in the peripheral circulation. Furthermore, it was hypothesized that 
post-ischemic cardiac function would be improved after insulin treatment. Insulin, 
surprisingly, did not have any effect on coronary blood flow either pre- or 
postischemically. However, post-ischemic cardiac function was improved after insulin 
treatment. Although insulin did not act as a vasoactive peptide in the coronary 
circulation, post-ischemic cardiac function was improved and therefore it can be 
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concluded that physiological concentrations of insulin protect the heart against an 
ischemic insult. 
 
General discussion 
From the studies described in this thesis, several general points can be addressed. First, 
concerning cardiovascular effects of SU derivatives, this group of drugs cannot be 
considered as one class, in contrast, effects of individual drugs must be considered. This 
argument has been shown in several studies. These studies (including ours, see        
Chapter 3) show differences in effects on the cardiovascular system between SU 
derivatives. However, in this thesis only two sulfonylurea derivatives were investigated. 
Regarding the specificity for the KATP channel in the pancreatic β-cell it has been 
shown that the first-generation SU derivative tolbutamide is less specific than the 
second-generation SU derivative glibenclamide, while glimepiride, a newer second-
generation SU derivative has been shown to be most specific for the pancreatic β-cell 52, 
53. Recently, however, it has been shown that the specificity for the pancreatic β-cell in 
recombinant KATP channels is similar for glibenclamide and glimepiride 54. Therefore, 
besides the methodological problems, the alarming results from the first large-scaled 
randomized trial of type 2 diabetes patients, the UGDP, in which patients allocated 
tolbutamide had a higher cardiovascular mortality rate cannot be generalized to possible 
alarming effects of SU derivatives on the cardiovascular system 110. The results in        
Chapter 3 confirm the idea that SU derivatives must be seen as separate drugs with 
different effects on the cardiovascular system.  
The vasoconstrictive effects of glibenclamide and glimepiride on the coronary 
circulation were shown to be similar, indicating similar blocking activity in the vascular 
smooth muscle KATP channels. On the other hand, glimepiride, at therapeutic 
concentrations, and glibenclamide, at supratherapeutic concentrations preserved post-
ischemic function. This suggests that this preserving action on post-ischemic cardiac 
function cannot be ascribed to myocardial KATP channel blockade. This was shown in 
Chapter 4. Recent literature shows that the mitochondrial oxidative phosphorylation is 
uncoupled by glibenclamide. Therefore, we speculated that this may result in a stressful 
stimulus to the mitochondria, and in this way preconditioning the hearts against the 
ischemic insult 197, 199. Interestingly, metformin also preserved post-ischemic cardiac 
function (Chapter 7). We speculated that the mechanism for this concerns inhibition of 
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complex I of the mitochondrial respiratory chain. Therefore, metformin may preserve 
post-ischemic cardiac function in a similar way as glibenclamide does.  
However, in Chapter 6 it was found that the ischemia-induced acidosis was 
significantly attenuated by glibenclamide. If uncoupling of oxidative phosphorylation 
were responsible for the protective effect of glibenclamide, the intracellular acidosis 
during ischemia would not be expected to be attenuated, because anaerobic glycolysis 
would be upregulated, resulting in higher lactate levels. Therefore, from the studies 
described in this thesis it seems to be most likely to ascribe the glibenclamide-induced 
improvements of post-ischemic cardiac function to inhibition of anaerobic glycolysis 
during ischemia.  
An additional interesting observation in the studies presented in this thesis was that the 
vasoconstrictive effect of the SU derivatives apparently does not impair post-ischemic 
cardiac function. One would expect the decreases in coronary blood flow to be 
deleterious to the post-ischemic myocardium. It could be however, that potentially 
deleterious effects of the lower coronary blood flows are masked by the beneficial 
effect of glibenclamide on the ischemia-induced acidosis.  
Comparing the effects of the SU derivatives glibenclamide and glimepiride with the 
other blood glucose lowering agents metformin and insulin itself, it can be seen that all 
treatments improved post-ischemic cardiac function. However, only the SU derivatives 
showed vasoconstriction, while insulin did not have any effect on the vasculature and 
metformin even showed a slight vasodilation. These results suggest that SU derivatives 
do not harm the myocardium during or after ischemia. However, the vasoconstrictor 
properties of these drugs may have negative consequences for patients with a 
compromised coronary circulation.  
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CONCLUSIONS 
 
1. The isolated working rat heart preparation is more vulnerable to myocardial 
ischemia than the Langendorff preparation. This difference however is not 
reflected in differences in high-energy phosphate levels between preparations. 
2. Both the classical sulfonylurea derivative glibenclamide and the newly 
developed sulfonylurea derivative glimepiride decrease the coronary blood flow 
both during baseline-conditions and after a 12 min global ischemic insult. These 
decreases were observed at concentrations slightly higher than therapeutic. Both 
sulfonylurea derivatives were able to reduce the myocardial functional loss after 
ischemia, but this effect only occurred at high (supratherapeutic) concentrations 
for glibenclamide, whereas this occurred at therapeutic concentrations for 
glimepiride.  
3. While the vasoconstrictive effect of glibenclamide can be ascribed to vascular 
smooth muscle KATP channel blockade, its preserving effect on post-ischemic 
cardiac function cannot be ascribed to blockade of myocardial KATP channels, 
but can probably be attributed to an inhibition of anaerobic glycolysis during 
ischemia by glibenclamide. 
4. Short-term administered insulin at physiologically pre- and postprandial 
concentrations does not induce vasodilation in the coronary circulation, while 
metformin increases coronary blood flow. On the other hand, both insulin and 
metformin preserve post-ischemic cardiac function after the 12 min global 
ischemic insult. 
5. All drugs tested (SU derivatives, metformin and insulin) preserve post-ischemic 
cardiac function, so no alarming effect on the myocardial function has been 
shown. However, because the SU derivatives acted as vasoconstrictors in the 
coronary circulation, while metformin and insulin did not, SU derivatives may 
have negative consequences for patients with a compromised coronary 
circulation. 
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SAMENVATTING 
 
Coronaire hartziekte (kransslagadervernauwing) is een belangrijke complicatie die 
optreedt bij diabetes mellitus type 2. Het representeert de doodsoorzaak in meer dan de 
helft van patiënten met diabetes mellitus type 2. De prevalentie (vóórkomen) van type 2 
diabetes is op zijn minst 2% in de meeste landen, en de incidentie (aantal nieuwe 
gevallen) is stijgende door vergrijzing van de populatie, een verhoogde prevalentie van 
obesitas (overgewicht) en een verminderde fysieke activiteit. De behandeling van type 2 
diabetes bestaat in grote lijnen uit drie behandelingsstrategieën: a) een dieet en het 
verhogen van de fysieke activiteit door sport en/of beweging, b) het voorschrijven van 
orale bloedsuikerverlagende geneesmiddelen (bijv. sulfonylureumderivativen, 
biguanides, α-glucosidase-remmers en thiozolidinedione-derivaten), en c) subcutane 
behandeling met insuline. In deze dissertatie wordt met name aandacht besteed aan 
sulfonylureum (SU) derivaten. 
Het werkingsmechanisme van de SU derivaten (bijv. glibenclamide) bestaat uit het 
blokkeren van ATP-afhankelijke K+ (KATP) kanalen in de pancreatische β-cellen. 
Hierdoor wordt de plasmamembraan gedepolariseerd. Dit resulteert in een influx van 
Ca2+ (calcium) door voltage-afhankelijke Ca2+- kanalen, leidend tot uitscheiding van 
insuline. Vergelijkbare KATP- kanalen bevinden zich ook in het hart- en vaatstelsel 
(cardiovasculaire systeem), gelokaliseerd op beide de sarcolemmale en mitochondriële 
membranen. Het is duidelijk aangetoond dat sarcolemmale en mitochondriële KATP- 
kanalen open gaan gedurende een periode van myocardischemia (zuurstoftekort in het 
hart) door de afbraak van intracellulaire ATP niveaus (brandstof voor de cel). Voor 
sarcolemmale KATP- kanalen leidt dit hieropvolgend tot minder Ca2+- influx en hierdoor 
het behoud van energie. Voor mitochondriële KATP- kanalen is er tot nu toe geen 
consensus bereikt over hoe het openen van mitochondriële KATP- kanalen leidt tot 
bescherming van de hartfunctie na ischemie (post-ischemische hartfunctie). Een 
mogelijkheid is dat het uiteenvallen van de mitochondriële membraanpotentiaal de 
drijvende kracht van Ca2+- influx verminderd, en dat hierdoor mitochondriële Ca2+- 
overload wordt voorkomen. Een andere mogelijkheid kan zijn dat stijgingen in het 
volume van de mitochondriële matrix en veranderde energetica door het opengaan van 
mitochondriële KATP- kanalen belangrijk is. Dit resulteerd in een vermindering van het 
ATP verbruik. Dus, sarcolemmale en mitochondrieële KATP- kanaal opening door 
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myocardischemie leidt tot endogene (lichaamseigen) bescherming van myocardfunctie 
na ischemie.  
Men heeft voorgesteld dat het blokkeren van deze myocardiale KATP- kanalen 
gedurende een periode van ischemie het endogene beschermingsmechanisme van het 
hart tegengaat, en daarom is gedurende de laatste jaren veel onderzoek verricht naar dit 
onderwerp. Desondanks zijn er nog steeds controversies betreffende dit onderwerp. Wat 
betreft epidimiologische studies, is in de jaren zeventig in een groots opgezette 
klinische studie, de UGDP, aangetoond dat type 2 diabetes patienten die het SU 
derivaat tolbutamide gebruikten een hogere cardiovasculaire mortaliteit (doodsoorzaak) 
hadden. Recentelijk werd in een tweede groots opgezette klinische studie, de UKPDS, 
aangetoond dat er geen verhoogde cardiovasculaire mortaliteit in patiënten was die SU 
derivaten gebruikten vergeleken met patiënten die insuline gebruikten. Vergeleken met 
patiënten die metformin gebruikten was er wel een hogere cardiovasculaire mortaliteit 
aangetoond.  
Wat betreft experimentele studies, is in vele diermodellen aangetoond dat het SU 
derivaat glibenclamide de grootte van een geïnduceerd infarct kan vergroten. Wat 
betreft de effecten op de post-ischemische hartfunctie, zijn de resultaten minder 
eenduidig. Beide beschermende- alswel beschadigende effecten op de post-ischemische 
hartfunctie zijn beschreven. Recentelijk is aangetoond dat het nieuw-ontwikkelde SU 
derivaat glimepiride meer specifiek is voor de pancreatische β-cel en daardoor minder 
cardiovasculaire effecten hebben. In deze dierstudies (meestal geïsoleerde 
hartmodellen), zijn een aantal vermijdbare beperkingen aanwezig. Ten eerste, de 
geïsoleerde harten die gebruikt werden in deze studies werden vaak geperfundeerd 
(doorstroomt) met een crystalloide bufferoplossing zonder de aanwezigheid van 
erytrocyten (rode bloedlichamen) en eiwitten. Het is aangetoond dat het perfunderen 
van harten zonder de aanwezigheid van erytrocyten kan leiden tot gebieden met 
hypoxie (zuurstoftekort) door de lagere zuurstofcapaciteit van de buffer. Door het 
toevoegen van eiwitten aan de buffer, kan de hoeveelheid oedeem (vochtuittreding) die 
gevormd wordt gedurende een experiment worden geminimaliseerd. In de tweede plaats 
werden de geïsoleerde harten vaak geperfundeerd, gebruik makend van het zogenaamde           
Langendorff-model. Dit is een techniek waarbij de richting van perfusie tegengesteld is 
aan de normale, fysiologische richting (retrograde perfusie). Het is aangetoond dat het 
werkend hart meer fysiologisch is en gevoeliger is voor ischemische schade dan de 
Langendorff-model. Omdat het werkend hart echt werkt, is de klinische relevantie van 
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dit model veel hoger dan die van de Langendorff-model. Als laatste is een belangrijk 
aandachtspunt het gebruik van onrealistisch hoge concentraties van SU derivaten in 
deze diermodellen. Hierdoor kunnen resultaten moeilijker worden geïnterpreteerd in de 
klinische praktijk.  
In de studies die in deze dissertatie worden beschreven, is bestudeerd of SU derivaten 
beschermende- of beschadigende cardiovasculaire effecten hebben in ons specifieke 
model. Zoals beschreven in de inleiding, heeft dit model bepaalde voordelen 
betreffende het onderzoeksgebied in deze dissertatie. Vervolgens hebben we deze 
effecten vergeleken met twee andere bloedsuikerverlagende geneesmiddelen: 
metformin, een biguanide, en insuline. In deze studies hebben we gebruik gemaakt van 
een geïsoleerde, erytrocyten en eiwit geperfundeerde, werkend rattenhart model, 
waarbij gekozen is voor een ischemische periode resulterend in reversibele 
myocardschade. 
  
In Hoofdstuk 2, is de kwetsbaarheid voor ischemie van de Langendorff en de werkend 
hart model onderzocht wat betreft hemodynamische (coronaire bloeddoorstroming en 
myocardfunctie) en metabole (energiehuishouding van de cel) variabelen. Het is 
aangetoond dat de werkende hartpreparatie meer gevoelig is voor ischemische schade 
dan de Langendorff. Dit is echter alleen onderzocht in crystalloide geperfundeerde 
harten, zonder de aanwezigheid van erytrocyten en eiwitten. Het werkende hart had 
meer functionele schade dan de Langendorff na een 12 minuten durende globale 
ischemische periode. Dit komt zoals verwacht door de hogere werkbelasting in deze 
harten. Een interessante bevinding is dat er geen verschillen in de coronaire 
bloeddoorstroming gedurende basale condities (normale zuurstofvoorziening) en 
gedurende de reactive hyperemie (verhoogde bloeddoorstroming) werden 
waargenomen. De ischemie-geïnduceerde acidose (verzuring) was sterker in het 
werkend hartmodel in vergelijking tot het Langendorff-model. Echter, het herstel van 
de hoog-energieke fosfaatniveaus (bijv. ATP) was vergelijkbaar tussen beide groepen. 
Uit deze studie kan worden geconcludeerd dat het werkend hartmodel meer kwetsbaar 
is voor ischemische schade dan de Langendorff-preparatie. Dit gaat echter niet 
vergezeld met veranderingen in hoog-energieke fosfaatniveaus tussen beiden groepen. 
 
In Hoofdstuk 3 werden dosis-reponsrelaties bepaald van twee SU derivaten wat betreft 
hun effect op de coronaire bloeddoorstroming en op het functieverlies van het hart na 
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een ischemisch incident van 12 minuten. Het klassieke SU derivaat glibenclamide en 
het nieuwere glimepiride werden gebruikt. De resultaten laten zien dat beide 
geneesmiddelen dosis-afhankelijk de coronaire bloeddoorstroming voor de ischemische 
periode verminderen, beginnend bij concentraties die iets hoger zijn dan de 
therapeutische range. Post-ischemisch waren deze verlagingen in coronaire 
bloeddoorstroming meer uitgesproken dan pré-ischemisch. Glibenclamide verlaagde het 
functieverlies van het hart bij een concentratie van 4 µmol.L-1 (supratherapeutisch), 
terwijl glimepiride het al bij therapeutische concentraties van 0.005 en 0.05 µmol.L-1 
verminderde. Het kan daarom worden geconcludeerd dat deze SU derivaten veilig 
gebruikt kunnen worden in patiënten met type 2 diabetes, echter enige voorzichtheid 
moet worden betracht bij patiënten met een al aangedane coronaire circulatie.  
In Hoofdstuk 4 onderzochten we de hypothese dat de verbeterde post-ischemische 
functie na behandeling met 4 µmol.L-1 glibenclamide samenhangt met de hogere 
intracellulaire Ca2+ concentratie ten gevolge van myocardiale KATP- kanaalblokkade. 
Het blokkeren van deze kanalen leidt tot depolarisatie van de membraan, resulterend in 
een verhoogde Ca2+- influx. Als deze hypothese juist is, zal het openen van deze 
kanalen resulteren in beschadigende effecten op de post-ischemische hartfunctie. Om 
dit te onderzoeken, hebben we een serie van experimenten uitgevoerd met 4 µmol.L-1 
glibenclamide, twee KATP- kanaalopeners: het specifieke mitochondriële KATP- 
kanaalopener diazoxide en de aspecifieke KATP- kanaalopener pinacidil, en combinaties 
van deze stoffen. De resultaten laten zien dat de coronaire vasodilatatie onder invloed 
van beide KATP- kanaalopeners werd verminderd door glibenclamide. Beide KATP- 
kanaalopeners verbeterden de post-ischemische hartfunctie, terwijl glibenclamide alleen 
eenzelfde effect had. De combinatie van glibenclamide met pinacidil resulteerde zelfs in 
een verbeterde post-ischemische hartfunctie in vergelijking tot de verbeteringen 
verkregen door de afzonderlijke componenten. Deze resultaten suggeren daarom dat de 
effecten van glibenclamide op het coronaire vaatbed primair zijn gemedieërd door 
KATP- kanaalblokkade, terwijl de verbetering van post-ischemische hartfunctie door 
glibenclamide niet louter toegeschreven kan worden aan KATP- kanaalblokkade. 
In Hoofdstuk 5 is onderzocht of cardiovasculaire KATP- kanalen betrokken zijn bij de 
adenosine-en dipyridamol-geïnduceerde cardiovasculaire veranderingen vóór en na een 
periode van myocard ischemie. Het is aangetoond in diverse studies dat 
adenosinereceptoren gekoppeld zijn aan KATP- kanalen. Adenosine en dipyridamol (niet 
een adenosine-uptake remmer in ratten in tegenstelling tot in mensen) alleen of in 
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combinatie met glibenclamide, werden getest. Adenosine en dipyridamole verhoogden 
significant de coronaire bloeddoorstroming gedurende de basis condities enerzijds en 
gedurende de post-ischemische reactive hyperemie anderzijds. De vasodilatoire 
(vaatverwijdende) respons van adenosine kon worden verminderd door glibenclamide, 
terwijl de dipyridamol-geïnduceerde vaatverwijding vergelijkbaar bleef in de 
aanwezigheid van glibenclamide. Adenosine en dipyridamol, en eveneens 
glibenclamide, verminderden het post-ischemische functieverlies van het hart. In 
tegenstelling tot adenosine, was de bescherming door dipyridamol tegen ischemie 
verhoogd in de aanwezigheid van glibenclamide. Hieruit kan worden geconcludeerd dat 
KATP- kanalen betrokken zijn bij de adenosine-geïnduceerde-, maar niet de dipyridamol-
geïnduceerde vaatverwijding. Verder, lijkt het zo te zijn dat KATP- kanalen niet 
betrokken zijn bij de adenosine- en dipyridamol-geïnduceerde bescherming tegen 
ischemie.  
In Hoofdstuk 6 werd onderzocht of het beschermende effect op de post-ischemische 
hartfunctie door glibenclamide kan worden gerelateerd aan veranderingen in het                
hoog-energieke fosfaatmetabolisme. Daarvoor werd 31P (fosfor) magnetische 
resonantiespectroscopie gebruikt in combinatie met het eerder beschreven geïsoleerde 
hartmodel. Zowel de hemodynamische effecten als de effecten van glibenclamide op 
het intracellulaire ATP, fosfocreatine (PCr), inorganisch fosfaat (Pi) en pH werden 
onderzocht. Glibenclamide bij een concentratie van 4 µmol.L-1, verbeterde wederom de 
post-ischemische hartfunctie na de 12 minuten durende ischemische periode, met 
opnieuw een significante vermindering in de coronaire bloeddoorstroming zowel voor 
als na de ischemische periode. Glibenclamide verminderde de ischemie-geïnduceerde 
acidose, terwijl geen effect zichtbaar was op intracellulaire ATP niveaus. Het herstel 
van hoog-energieke fosfaten na ischemie was ook vergelijkbaar tussen glibenclamide en 
het oplosmiddel. Deze resultaten suggereren dat de glibenclamide-geïnduceerde 
verbeteringen in post-ischemische hartfunctie op zijn minst gedeeltelijk te verklaren 
zijn door remming van de anaerobe glycolyse gedurende ischemie.  
In Hoofdstuk 7 werden de hemodynamische effecten van metformin bepaald voor en 
na een 12 minuten durende ischemische periode. In de grote UKPDS studie, was 
metformin het enige bloedsuikerverlagende geneesmiddel dat het aantal 
macrovasculaire complicaties in patiënten met type 2 diabetes verminderde. Als gevolg 
daarvan was de hypothese dat metformin de post-ischemische hartfunctie zou 
verbeteren. Metformin in de concentraties van 50 en 500 µmol.L-1 werden getest. De 
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concentratie van 50 µmol.L-1 is therapeutisch in ratten (5  10x hoger dan in mensen). 
De resultaten laten zien dat na een periode van ischemie de coronaire 
bloeddoorstroming enigszins verhoogd blijft na behandeling met metformin (beide 
doseringen). Het post-ischemisch functieverlies was significant verlaagd bij beide 
metformin-concentraties. Dit betekend dat metformin beschermende effecten op de 
post-ischemische hartfunctie heeft. We speculeerden dat remming van complex I van de 
mitochondriële respiratieketen betrokken kan zijn bij het beschermende mechanisme 
van metformin. Door remming van dit complex, zou minder vrije radicaalproductie 
kunnen optreden gedurende reperfusie (vlak na de ischemische periode), resulterend in 
een verbetering van de post-ischemische hartfunctie. Het kan worden geconcludeerd dat 
het beschermende effect van metformin in deze studie bij kan dragen aan de 
waargenomen postitieve effecten in klinische studies, zoals in de UKPDS.  
In Hoofdstuk 8 zijn de hemodynamische effecten van pre- en postprandiale (voor en na 
het eten) insulineconcentraties bepaald voor en na een 12 minuten durende ischemische 
periode. De effecten die beschreven zijn van fysiologische insulineconcentraties op het 
hart zijn schaars. De hypothese werd gesteld dat de post-ischemische hartfunctie 
verbeterd is na insuline behandeling. Insuline had geen effect op de coronaire 
bloeddoorstroming gedurende het gehele experiment. Echter, de post-ischemische 
hartfunctie was verbeterd na insuline behandeling. Ondanks dat insuline niet als een 
vasoactief peptide werkte in de coronaire circulatie, was de post-ischemische 
hartfunctie verbeterd en daarom kan worden geconcludeerd dat fysiologische 
insulineconcentraties het hart beschermen tegen ischemische schade.  
 
Algemene beschouwing van dit proefschrift 
Uit de studies, beschreven in deze dissertatie, kunnen verschillende algemene punten 
worden bediscussieërd. Allereerst, met betrekking tot de cardiovasculaire effecten van 
SU derivaten, kan deze groep van geneesmiddelen niet worden beschouwd als één 
klasse. Daarentegen moeten de effecten van individuele representanten van de groep 
worden onderzocht. Dit argument is in verschillende studies aangetoond. Deze studies 
(inclusief onze studie, zie Hoofdstuk 3) laten verschillen zien in effecten op het 
cardiovasculaire systeem tussen verschillende SU derivaten. Onze studie heeft echter 
maar twee SU derivaten onderzocht. Met betrekking tot de specificiteit voor KATP- 
kanalen in de pancreatische β-cel, is het aangetoond dat het eerste generatie SU 
derivaat tolbutamide minder specifiek is dan het tweede generatie SU derivaat 
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glibenclamide, terwijl glimepiride, een nieuwer tweede-generatie SU derivaat het 
meest specifiek is voor de pancreatische β-cel 52, 53. Recentelijk is echter aangetoond in 
recombinante KATP kanalen dat glimepiride een vergelijkbare specificiteit heeft als 
glibenclamide in de pancreatische β-cel 54. Daarom kunnen, naast mogelijke 
methodologische problemen, de alarmerende resultaten van de eerste grootschalige 
gerandomiseerde trial van type 2 diabetes patiënten, de UGDP, waarin patiënten die 
tolbutamide gebruikten een hogere cardiovasculaire mortaliteit hadden, niet worden 
gegeneraliseerd tot mogelijke alarmerende effecten van SU derivaten op het 
cardiovasculaire systeem in algemene zin 110. De resultaten in Hoofdstuk 3 bevestigen 
het idee, dat de verschillende SU derivaten gezien moeten worden als afzonderlijke 
geneesmiddelen met verschillende effecten op het cardiovasculaire systeem.  
Zoals aangetoond, waren de vasoconstrictieve (vaatvernauwende) effecten van 
glibenclamide en glimepiride op de coronaire circulatie vergelijkbaar. Dit wijst op een 
vergelijkbare blokkerende activiteit van de gladde spiercel KATP- kanalen (KATP kanalen 
in de vaatwand). Anderzijds verbeterde glimepiride de post-ischemische hartfunctie bij 
therapeutische concentraties, terwijl glibenclamide dit bij supratherapeutische 
concentraties deed. Dit suggereert dat het beschermende effect op de post-ischemische 
hartfunctie niet aan blokkade van myocardiale KATP- kanaalblokkade kan worden 
toegeschreven. Dit was aangetoond in Hoofdstuk 4. Recente literatuur laat zien dat de 
mitochondriële oxidatieve fosforylering (ATP aanmaak) wordt ontkoppeld door 
glibenclamide. Het is bekend dat wanneer een hart korstondig wordt blootgesteld aan 
ischemie (stress-achtige stimulus), het een daaropvolgend langdurige periode van 
ischemie beter doorstaat. Derhalve, speculeerden wij dat de mogelijke ontkoppeling 
door glibenclamide resulteerd in een stress-achtige stimulus op de mitochondria, en op 
deze manier zouden de harten tegen een ischemische periode worden beschermd 197, 199. 
Metformin had ook een beschermend effect op de postischemische hartfunctie 
(Hoofdstuk 7). Dit beschermend effect zou mogelijkerwijs verklaard kunnen worden 
door het remmen van complex I van de mitochondriële oxidatieve fosforylering. 
Derhalve zou het beschermingsmechanisme van metformin overeen kunnen komen met 
dat van glibenclamide. 
Echter, in Hoofdstuk 6 is gevonden dat de ischemie-geïnduceerde acidose significant 
was verminderd door glibenclamide. Wanneer het ontkoppelen van de oxidatieve 
fosforylering verantwoordelijk zou zijn voor het beschermend effect van glibenclamide, 
dan is het niet te verwachten dat de ischemie-geïnduceerde acidose verminderd is. Dit 
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omdat de anaerobe glycolyse extra wordt geactiveerd, resulterend in hogere 
lactaatconcentraties. Uit onze studies, lijkt het zo te zijn dat de glibenclamide-
geïnduceerde verbeteringen van post-ischemische hartfunctie toe te schrijven zijn aan 
remming van de anearobe glycolyse gedurende een periode van myocard ischemie.  
Een interessante bevinding in onze studies is dat het vasoconstrictieve effect van de               
SU derivaten schijnbaar niet zorgt voor een verslechtering van de post-ischemische 
hartfunctie. Het zou te verwachten zijn dat een vermindering in de coronaire 
bloeddoorstroming een nadelig effect op het post-ischemische myocard heeft. Het zou 
echter zo kunnen zijn dat de mogelijk nadelige effecten als gevolg van de lagere 
coronaire bloeddoorstroming gemaskeerd worden door beschermende effecten van 
glibenclamide op de ischemie-geïnduceerde acidose.  
Wanneer de effecten van de SU derivaten glibenclamide en glimepiride worden 
vergeleken met de andere bloedsuikerverlagende geneesmiddelen, metformin en 
insulin, dan resulteren alle behandelingen in een verbeterde post-ischemische 
hartfunctie. Echter, alleen de SU derivaten waren vasoconstrictief, terwijl insuline geen 
effect had op het coronaire vaatbed en metformin zelfs enigszins een vasodilatoir effect 
liet zien. De studies in deze dissertatie laten geen alarmerende cardiovasculaire effecten 
van SU derivaten zien, vergeleken met andere behandelingen. Echter, enige 
voorzichtheid moet worden betracht in patiënten met een al aangedane coronaire 
circulatie.  
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CONCLUSIES 
 
1. Het geïsoleerde werkend rattenhart model is gevoeliger voor myocard ischemie 
dan het Langendorff-model. Deze verschillen in kwetsbaarheid worden echter 
niet gereflecteerd in verschillen in hoog-energieke fosfaatniveaus (bijv. ATP) bij 
beide modellen. 
2. Het klassieke sulfonylureumderivaat glibenclamide alswel het nieuw 
ontwikkelde glimepiride verlagen de coronaire bloeddoorstroming zowel onder 
basale condities als na ischemie. Deze vasoconstrictie wordt al waargenomen bij 
concentraties die iets hoger zijn dan therapeutisch. De hartfunctie na de 
ischemische periode was verminderd na een supratherapeutische 
glibenclamideconcentratie, terwijl het bij therapeutische glimepiride-
concentraties was verlaagd. 
3. Terwijl het vasoconstrictieve effect van glibenclamide kan worden 
toegeschreven aan een gladde spiercel KATP- kanaalblokkade, is het 
beschermende effect van glibenclamide op de post-ischemische hartfunctie niet 
toe te schrijven aan myocardiale KATP- kanaalblokkade. Dit kan mogelijkerwijs 
worden toegeschreven aan remming van de anaerobe glycolyse gedurende 
ischemie door glibenclamide. 
4. Kortdurende insuline toediening bij fysiologische pre- en postprandiale 
concentraties veroorzaakt geen coronaire vasodilatatie, terwijl metformin de 
coronaire bloeddoorstroming laat stijgen. Anderzijds, beschermen insuline en 
metformin de post-ischemische hartfunctie na ischemie.  
5. Alle geneesmiddelen die zijn getest (SU derivaten, metformin en insuline) 
beschermen de post-ischemische hartfunctie. Er zijn dus geen ongunstige 
effecten op hartfunctie aangetoond. Echter, omdat de SU derivaten werken als 
vasoconstrictoren in de coronaire circulatie, terwijl metformin en insuline dit niet 
deden, moet enige voorzichtigheid worden betracht bij type 2 diabetes patiënten, 
indien bij deze patiënten sprake is van een reeds aangedane coronaire circulatie.  
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en helpende hand gedurende de afgelopen vier jaar. Hierbij wil ik in het bijzonder een 
aantal mensen noemen:  
 
Prof. Dr. P. Smits (afdeling Farmacologie-Toxicologie), Beste Paul. Je eeuwige 
enthousiasme, je inventiviteit, en de bekende woorden, Kun je dat stofje ook nog even 
testen, hebben er in belangrijke mate toe geleidt dat het onderzoek beschreven in dit 
proefschrift tot een goed einde is gekomen. Zonder jou, zou het project nooit tot dit 
resultaat hebben geleidt. 
 
Prof. Dr. B. Oeseburg, Beste Berend. Helaas ben je veel te vroeg overleden                 
(30 december 2000), maar ik wil je graag bedanken voor het feit dat jij me altijd het 
vetrouwen en de vrijheid hebt gegeven die ik graag wilde gedurende de eerste drie jaar. 
En als ik t eens niet zag zitten was er altijd wel een opbeurend woord bij jou te krijgen. 
Mede door jou heb ik heel wat van de wereld mogen zien.   
 
Dr. R.J.F. Houston (afdeling Anesthesiologie, UMC Utrecht), Beste Ralph. Ondanks 
dat je na ruim twee jaar wegging van de afdeling naar het UMC in Utrecht, was je 
inbreng en begeleiding in dit project van onschatbare waarde. Ook als kamergenoot 
hebben we vele gesprekken gevoerd over het werk, en andere zaken. Als prettige 
bijkomstigheid heb ik de engelse taal ook nog iets beter leren beheersen (met een schots 
accent weliswaar!). 
 
J.A.M. Evers & M.D. de Jong, Beste Jos en Maarten. Zonder jullie inzet, hulp en 
kennis was het onderzoek nooit tot een goed einde gekomen. Ik heb veel gezellige, 
brommerige en zweterige uurtjes met jullie meegemaakt de afgelopen vier jaar. Jullie 
waren ook nooit te beroerd een avondje danwel zaterdagje door te werken. Bedankt 
jullie beiden !!!   
 
Dr. L.J.C. Hoofd, Beste Louis. We hebben menig uurtje met elkaar gediscussieërd. 
Was het niet over een artikel danwel een onderzoeksopzet dan was het wel over 
badminton. Bedankt voor je vele nuttige adviezen. 
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Prof. Dr. A. Heerschap (afdeling Radiologie), Beste Arend. Uiteindelijk is er veel 
minder MR spectroscopie dan oorspronkelijk gepland in het proefschrift verschenen, 
maar gelukkig is het in het laatste anderhalf jaar toch nog gelukt enige spectra te 
verkrijgen. Bedankt voor je ondersteuning hierbij en je vele adviezen.  
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Dr. JPWM Lamers-Lemmers, Beste Jolanda. Bedankt voor alle gezellige uurtjes die 
we samen hebben beleefd ..... lange discussies over hoe erg wij t wel niet hadden als 
AIOs. Maar alles is uiteindelijk wel op zn pootjes terecht gekomen. 
 
Afdeling Fysiologie. Bedankt allemaal voor de vele gezellige uurtjes in de koffiekamer 
en voor de vele discussies die daar werden gevoerd, over werk danwel andere 
interessante zaken. 
 
Dierverzorging CDL. Diegene die betrokken zijn geweest bij de verzorging en 
huisvesting van de dieren, bedankt! Jullie zijn onmisbaar.  
 
NMR-faciliteit CDL, Beste Dennis, Jeroen, Gert-Jan en Erik. Bedankt voor de 
onmisbare ondersteuning voor het opzetten van sequenties, protocollen en problemen 
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En verder ieder die ik vergeten ben: Bedankt !!! 
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Lieve Ouders, Jullie hebben me altijd door dik en dun gesteund. Zonder jullie was het 
gewoonweg niet mogelijk geweest om dit proefschrift af te ronden. Bedankt voor alles! 
 
Lieve Joan, Michelle en Mark, Door jullie heb ik de laatste anderhalf jaar met 
motivatie het onderzoek tot een goed einde kunnen brengen. Joan, je stond en staat 
altijd voor me klaar. Michelle en Mark, ik heb vele leuke uren met jullie samen 
meegemaakt en er zullen er vast en zeker nog vele volgen .... dat weet ik zeker. 
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